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Abstract
A promising approach for the development of novel therapeutics with fewer side
effects in healthy tissues is the targeted delivery of bioactive molecules directly
to the site of disease. The prerequisite is the identification of a robust, disease-
specific biomarker, targetable either with monoclonal antibodies interfering with the
target’s biological function or with antibody-drug conjugates delivering a therapeutic
payload such as a cytotoxic drug. Hence, the target molecules of interest have to
be vascular-accessible and are therefore located on the surface of diseased cells, on
newly formed blood vessels or in the perivascular extracellular matrix. Proteomic
approaches for the identification of novel biomarkers have to deal with (i) the high
dynamic range of the proteome over at least seven orders of magnitude, (ii) the low
abundance of the highly diverse plasma membrane proteome fraction, as well as with
(iii) the hydrophobic character of membrane proteins. The proteins of interest are
therefore often under-represented in mass spectrometric datasets of full proteome
samples and cannot be stably quantified. One avenue towards the enrichment of the
vascular-accessible surface proteome fraction prior to mass spectrometric analysis
is the covalent modification of the target proteins with a membrane-impermeable
ester-derivative of biotin, followed by streptavidin-based affinity capturing. The
biotinylation of potential biomarkers is fast and efficient and can be performed by
in vitro labelling of cells, via in vivo perfusion of mice or ex vivo using surgically
resected tissue material.
The work in this thesis focused on the synthesis and multi-step validation of
two novel, multiply-charged peptide-based as well as of two novel heparin-based
biotinylation reagents. Furthermore, two alkyne-tagged reagents for bioorthogonal
click-chemistry based enrichment were designed. The reagents’ reactivity was as-
sessed by coupling to BSA in different ratios and analysis with linear MALDI mass
spectrometry. Subsequent validation was performed in vitro on HeLa cells and in
vivo via perfusion of healthy NSG mice. Biotinylation efficacy was examined using
FACS analysis, ELISA and Western Blot of cell and tissue samples. Cell surface
or perivascular biotinylation was visualized by confocal laser scanning microscopy.
Mass spectrometric analyses of the accessible proteome fractions were performed in
comparison to the commercial reagents Sulfo-NHS-LC-biotin and NHS-PEG12-biotin
and PBS- or non-treated negative controls on biotinylated HeLa cells and kidney
or liver tissue using a MALDI TOF/TOF™ 5800 system (AB SCIEX). Mass spec-
trometric data were analysed in terms of identified protein and proteotypic peptide
numbers as well as of protein localization. Relative quantification based on MS1
signal intensities was performed using the in-house developed software MSQBAT.
SRM-analysis of some medium- and low-abundant cell surface and extracellular ma-
trix proteins was performed in comparison to full proteome samples on a QTRAP®
6500 system (AB SCIEX).
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The properties of any biotinylation reagent are determined by the linker between
the biotin residue for affinity purification and the reactive group for protein cou-
pling. Increase in size and polarity influences the reagents’ selectivity and reactiv-
ity. Site-specific activation of the novel peptide-based biotinylation reagents could
significantly improve the reactivity in comparison to non-specifically activated NHS-
β-Ala-(L-Asp)3-biotin published by Strassberger et al. in 2010. Alkyne-tagged re-
agents revealed comparable reactivity to the biotinylation reagents resulting from
the similarity of the peptide-based linkers. Due to their enormous size and the in-
creased steric hindrance, heparin-based reagents are less reactive than the smaller
peptide-based and commercial reagents. The reactivity difference is also mirrored in
the mass spectrometric datasets. A total of 1574 proteins could be identified within
the in vitro analysis. The proof-of-principle study could demonstrate the stable
identification of a 38-49% fraction of plasma membrane or extracellular matrix an-
notated proteins with the peptide-based reagents. 1965 proteins were found in the
kidney dataset with a comparable fraction of 40-45% surface annotated proteins.
Within the liver dataset, 1531 proteins could be identified with a slightly increased
intracellular protein fraction (27-34% surface proteome fraction). Reasons for the
typical background proteome identification in all samples were further assessed by
different sample preparation strategies within this thesis. In short, it can be stated,
that the success of biomarker studies with biotinylation reagents are dependent of
the vascularisation of the target tissue to enable high biotinylation rates as well of
elaborated sample preparation protocols: For example, delipidation is crucial for the
work with tissue samples. A slight reactivity decrease of the novel peptide-based
reagents compared to commercial Sulfo-NHS-LC-biotin was detected due to the ster-
ically more hindered peptide linker. Nevertheless, the enrichment of the targeted
surface proteome is very stable: 40% of the quantified proteins are more than 2-fold
up- or down-regulated in comparable fractions between the peptide-based and the
commercial reagent (kidney dataset). The number of identified proteotypic peptides
per plasma membrane or extracellular matrix annotated protein is significantly in-
creased compared to the negative controls and to the intracellular proteome fraction,
which is the basis for enabling a stable protein quantification.
The mass spectrometric studies revealed that the novel peptide-based reagents
provide a reliable technology platform for the enrichment of vascular accessible pro-
teins: Plasma membrane or extracellular matrix annotated biomarker candidates
can be stably identified and quantified based on high numbers of proteotypic pep-
tides. Furthermore, stable SRM-based quantification of medium- and low-abundant
targets is enabled.
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Zusammenfassung
Ein vielversprechender Ansatz zur Entwicklung von neuen Medikamenten mit
weniger Nebenwirkungen in gesundem Gewebe besteht im zielgerichteten Transport
von bioaktiven Molekülen direkt an den Krankheitsherd. Die Entwicklung solcher
innovativer Medikamente setzt zunächst die Identifizierung eines robusten und spe-
zifischen Biomarkers als Zielstruktur im erkrankten Gewebe voraus. Diese kann im
Folgenden mit monoklonalen Antikörpern, die die biologische Funktion des Bio-
markers beeinträchtigen, oder mit an Antikörpern gekoppelten Medikamenten ange-
griffen werden. Dabei ist die Analyse des vaskulär erreichbaren Oberflächenproteoms
aufgrund der leichten Zugänglichkeit durch den Blutstrom von großem Interesse:
Potentielle Zielstrukturen sind auf den Zelloberflächen im erkrankten Gewebe, auf
der Oberfläche neugebildeter Blutgefäße sowie in der umgebenden extrazellulären
Matrix zu suchen. Die Identifizierung neuer Protein-Biomarker durch massenspek-
trometrische Analyse wird zum einen durch die hohe Komplexität des Proteoms
mit einer Abundanz-Spanne von mindestens sieben Größenordnungen erschwert.
Oberflächenproteine sind hochdivers in Struktur und Funktion, aber oftmals nur in
niedriger Kopienzahl exprimiert. Des weiteren erschwert der hydrophobe Charakter
der Membranproteine die Analyse. Aus diesen Gründen sind potentielle Biomarker
in Vollproteom-Datensätzen meist unterrepräsentiert und können daher auch nicht
stabil quantifiziert werden. Eine Möglichkeit zur Anreicherung der vaskulär erreich-
baren Zielstrukturen vor der massenspektrometrischen Analyse ist deren kovalen-
te Modifizierung mit einem Membran-impermeablen Biotin-Ester-Derivat, welches
mit Hilfe von Streptavidin-Sepharose affinitätsbasiert angereichert werden kann. Die
Biotinylierungsreaktion verläuft schnell und quantitativ, was neben dem Markieren
von Zellen in vitro auch die in vivo Perfusion von Mäusen sowie die ex vivo Perfusion
von humanem, operativ entferntem Gewebe ermöglicht.
Die Entwicklung und Validierung zweier mehrfach geladener Peptid- und zweier
Heparin-basierter Biotinylierungsreagenzien zur selektiven Anreicherung von vasku-
lär erreichbaren Zelloberflächenproteinen steht im Fokus dieser Doktorarbeit. Dar-
überhinaus wurden zwei Alkin-modifizierte Reagenzien für bioorthogonale Anreiche-
rung über eine Click-Reaktion synthetisiert. Die Reaktivität der Reagenzien wurde
durch Reaktion mit BSA in verschiedenen molaren Verhältnissen und Analyse des
modifizierten Proteins durch lineare MALDI Massenspektrometrie untersucht. Wei-
tere Validierungsexperimente wurden mit der Zelllinie HeLa sowie mit in vivo per-
fundierten, gesunden NSG-Mäusen durchgeführt. Die Effizienz der Biotinylierung
von Zell- und Gewebeproben wurde hierbei durch Durchflusszytometrie (FACS),
ELISA und Western Blot Analyse bestimmt. Die Biotinylierung der Zelloberflächen
bzw. die perivaskuläre Markierung mit den Reagenzien wurde mittels konfokaler
Laser-Scanning Mikroskopie untersucht. Die massenspektrometrische Analyse der
angereicherten Proteinfraktion wurde im Vergleich zu den kommerziellen Reagenzi-
en Sulfo-NHS-LC-biotin und NHS-PEG12-biotin sowie zu PBS- oder unbehandelten
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Negativkontrollen durchgeführt. Die angereicherten Proteinlysate von biotinylierten
HeLa-Zellen sowie von Nieren- und Lebergewebe von perfundierten Mäusen wurden
dabei auf einem MALDI TOF/TOF™ 5800 System (AB SCIEX) analysiert. Die
anschließende Datenanalyse konzentrierte sich auf die vergleichende Untersuchung
der Anzahl der identifizierten Proteine und proteotypischen Peptide, sowie deren
subzelluläre Lokalisierung. Eine relative Quantifizierung wurde basierend auf den
MS1 Signalintensitäten mit Hilfe der Labor-eigenen Software MSQBAT durchge-
führt. Mittels SRM-Analyse wurden darüber hinaus einige Oberflächenproteine mit
niedriger oder mittlerer Abundanz im Vergleich zu nicht angereicherten Vollproteom-
Proben auf einem QTRAP® 6500 System (AB SCIEX) quantifiziert.
Die Eigenschaften von Biotinylierungsreagenzien werden durch den Linker zwi-
schen dem Biotinrest und der reaktiven Gruppe zur Modifizierung der Zielproteine
bestimmt. Eine Vergrößerung des Reagenz oder eine Veränderung der Polarität be-
einflussen die Reaktivität und die Selektivität. Die regioselektive Aktivierung der
neuen Peptid-basierten Reagenzien erhöht die Reaktivität im Vergleich zum unspe-
zifisch aktivierten NHS-β-Ala-(L-Asp)3-biotin (Strassberger et al., 2010) signifikant.
Die alkinmodifierten Peptid-Reagenzien weisen eine ähnliche Reaktivität wie die
strukturell verwandten Biotinylierungsreagenzien auf. Aufgrund ihrer enormen Grö-
ße und der daraus resultierenden sterischen Hinderung sind die Heparin-basierten
Reagenzien weniger reaktiv als die wesentlich kleineren Peptid-basierten oder die
kommerziell erhältlichen Reagenzien. Diese Reaktivitätsdifferenz spiegelt sich auch
in der massenspektrometrischen Analyse wider. Im Gesamten konnten in der in
vitro Analyse 1574 Proteine identifiziert werden. Das Pilotexperiment konnte bele-
gen, dass die Peptid-basierten Biotinylierungsreagenzien die stabile Identifizierung
einer 38-49% großen Fraktion von Proteinen ermöglicht, die in der Plasmamem-
bran oder der extrazellulären Matrix lokalisiert sind. Im Nieren-Datensatz wurden
1965 Proteine mit einer vergleichbaren Fraktion an Oberflächenproteinen von 40-
45% gefunden. Die Identifizierung intrazellulärer Proteine war im Leber-Datensatz
leicht erhöht: 1531 Proteine mit einem Oberflächenproteomanteil von 27-34%. Die
für solche Datensätze typische Identifizierung eines intrazellulären Hintergrundpro-
teoms wurde in dieser Arbeit mittels verschiedener Probenaufarbeitungs-Strategien
ebenfalls untersucht. Zusammenfassend lässt sich feststellen, dass der Erfolg von
Biomarker-Identifizierungsstudien zum einen von der Vaskularisierung des Zielgewe-
bes abhängig ist, um hohe Biotinylierungsraten zu ermöglichen, und zum anderen
von verfeinerten Protokollen zur Probenpräparation: Beispielsweise erwies sich die
Delipidierung als wesentlich für die Arbeit mit Gewebeproben. Trotz der vermin-
derten Reaktivität der Peptid-basierten Reagenzien gegenüber des kommerziellen
Sulfo-NHS-LC-biotin durch den sterisch anspruchsvolleren Peptidlinker verläuft die
Anreicherung des Zielproteoms sehr stabil: 40% der quantifizierten Proteine sind
mehr als 2-fach reguliert, und zwar zu gleichen Teilen zwischen Peptid- und kommer-
ziellem Reagenz (Nieren Datensatz). Die Anzahl der identifizierten proteotypischen
Peptide von Plasmamembran oder extrazellulärer Matrix-annotieren Proteinen ist
im Vergleich zu den Negativkontrollen und der intrazellulären Proteinfraktion signi-
fikant erhöht - die Basis für jede erfolgreiche Quantifizierung.
24
Die massenspektrometrischen Validierungsstudien konnten zeigen, dass die neuen
Peptid-basierten Biotinylierungsreagenzien eine verlässliche Technologie zur Anrei-
cherung vaskulär erreichbarer Proteine darstellen: Plasmamembran- oder extrazel-
luläre Matrix-Proteine konnten basierend auf einer Vielzahl von proteotypischen
Peptiden stabil identifiziert und quantifiziert werden. Darüber hinaus ermöglichen
die neuen Reagenzien auch eine robuste SRM-basierte Quantifizierung von Zielpro-
teinen mit mittlerer bis niedriger Abundanz.
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1. Introduction
In this chapter, an introduction to the field of biomarker discovery is given, in which
this thesis is embedded. The introduction covers the entire range from basic princi-
ples in biomarker discovery to the application of biomarkers in targeted therapies.
Hereby, the focus is on vascular accessible biomarkers and mass spectrometry based
proteomics, reflecting the focus of this thesis.
1.1. Biomarker Discovery
1.1.1. Biomarker – Definition, Importance and Requirements
According to the Biomarker Definitions Working Group from the National Institutes
of Health, USA (NIH) a biomarker or biological marker is “a characteristic that is
objectively measured and evaluated as an indicator of normal biological processes,
pathogenic processes, or pharmacologic responses to a therapeutic intervention”.[1]
Biomarkers serve as diagnostic tool for the detection of a disease, to evaluate the
stage of the disease and disease survival (prognostic biomarker), to classify subtypes
or to identify patients, that benefit from a specific therapy (predictive biomarker),
and to monitor disease progression or a therapeutic response.[1],[2] Hereby, according
to the World Health Organisation (WHO), “a biomarker is any substance, structure
or process that can be measured in the body or its products and influence or predict
the incidence of outcome or disease”.[3] Examples span from simple measurement
of blood pressure or imaging of tumour size or blood vessel growth, to molecular
biomarkers such as the glucose level in blood or antigens specifically expressed in a
diseased tissue.[1],[4],[5]
Molecular differences between healthy and diseased tissue or across different sub-
groups of a disease are assessed to gain mechanistic insights in disease development
and progression or to exploit the detected changes for diagnostic or therapeutic pur-
poses. Changes include alterations in expression or molecular modifications, hereby
DNA, RNA, proteins, lipids, carbohydrates or a metabolites can serve as biomark-
ers.[6],[7],[8] A promising biomarker candidate needs to meet specific sensitivity and
specificity criteria: Sensitivity quantifies the probability for correct detection of the
disease (true positive rate), specificity measures the likelihood for correct identifica-
tion of negatives (true negative rate).[9] For clinical relevance, a 90%/90% standard
is recommended.[10]
Besides the prognostic, predicitve and monitoring power of a biomarker, molecules
specifically expressed on the diseased tissue can also be exploited for targeted thera-
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pies.[2] According to the National Institutes of Health, a targeted therapy is “a type
of treatment that uses drugs or other substances to identify and attack specific types
of [...] cells with less harm to normal cells”.[11] For vascular targeting of a diseased
tissue with a diagnostic or a drug, both a disease biomarker and a binding molecule
to that biomarker, e.g. an antibody, have to be identified, and, depending on the
mode of action, a bioactive moiety has to be coupled to the binder.[12] Require-
ments for a high-quality biomarker include up-regulation in the diseased tissue, and
ideally absence in healthy tissue, a stable and reasonably abundant expression as
well as accessibility for the drug.[12],[13] Also differentially regulated splice isoforms
can serve as biomarkers.[14],[15] Furthermore, protein translocation can be detected
under specific disease conditions, which might not result in deregulation of protein
abundance, but in differential accessibility for drugs.[16],[17],[18],[19],[20]
1.1.2. Strategies in Biomarker Discovery
1.1.2.1. Disease Modelling
Model systems to recapitulate human disease are of crucial importance in biomarker
research. Human material is not accessible in the required quantities.[9] Furthermore
samples can be highly heterogeneous among different populations and individuals,
e.g in terms of the molecules’ abundances, structural variants or modifications.[21]
Despite the genetic background, also other factors such as environment, lifestyle, age
or sex affect a clinical sample.[8],[9] Further diversity in diseased cohorts might occur
due to different stages of disease, treatments obtained or molecular subtypes.[9] For
those reasons, most biomarker investigations begin with a model system.
Cell lines represent a valuable in vitro model: As the culture system can be
well-defined, differences and changes upon manipulation can be detected reliably.
Many commonly used cell lines are immortalised to obtain unlimited proliferation
capacity. Immortalisation is associated with tumourigenesis, therefore the cell phe-
notype might slightly change. Long-term passaging of the cell lines additionally
leads to genetic alterations and clonal selection.[22] As it is questionable whether
the phenotype of immortalized cells still reliably recapitulates the disease situation,
primary cell lines directly derived from resected patient material might be the bet-
ter in vitro model. However, successful culture conditions for those cells are more
difficult to establish.[23] To examine diseases in an in vivo situation, genetically engi-
neered mouse models are commonly used. Hereby, the gene of interest might either
undergo knockdown or knockout (loss of function), or being overexpressed or intro-
duced (so-called transgenesis) (gain of function).[24] Whereas genetically engineered
animal models are very useful to examine the effect of a mutation in a specific gene,
xenograft models are favoured to mimic human disease. Human tissue material (e.g.
primary tumour material) is transferred into immunocompromised animals such as
NOD/SCID mice.[25] Within xenograft models, the heterogeneity of the patient ma-
terial as well as the interaction with the microenvironment are more realistically
reproduced or mimicked. Furthermore, many molecular features of the diseased
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tissue are conserved.[26] Finally, ex vivo biomarker studies of patient material are
performed, either in surrogates such as blood (secreted biomarkers) or with surgi-
cally resected tissue material.[27] In the following, biomarker discovery approaches
on different molecular levels (see Figure 1.1) are further elucidated.
DNA 
Genomics 
Epigenomics 
RNA 
Transcriptomics 
Protein 
Proteomics 
Metabolite 
Lipidomics 
Glycomics 
Metabonomics 
Figure 1.1.: Biomarker discovery on different molecular levels.
1.1.2.2. Genomics and Epigenomics
Many human diseases are characterized by alterations of the genome including mu-
tation of the DNA, copy number variations, chromosomal aberrations or epige-
netic changes.[28],[29] Since Sanger developed the first DNA sequencing method in
the 1970s, considerable efforts have been undertaken to determine the whole DNA
sequence of organisms.[30],[31] Next-generation sequencing technologies perform the
analysis of genomes in a heavily parallelized way and are about 200 times faster
and cheaper than the conventional Sanger method. In the course of next-generation
sequencing, single-stranded DNA molecules are immobilised on a solid support such
as a glass slide or beads and the sequencing is performed with modified pyrosequenc-
ing protocols.[32],[33] Sequencing machines are meanwhile commercially available from
many companies.[32]
Epigenetic regulations such as DNA methylation or histone modification do not
affect the DNA sequence but influence the chromatin structure and gene transcrip-
tion.[29] For example, CpG island methylation in promotor regions occurs in normal
cells to down-regulate gene expression by prevention of transcription factor or RNA
polymerase binding. In early tumour development, the DNA methylation pattern
often changes, e.g. resulting in the prevention of tumour suppressor gene expression
by hypermethylation of the promotor regions.[29],[34] Common chemical histone mod-
ifications are methylation/demethylation or acetylation/deacetylation, resulting in
changes of the chromatin structure and differential gene regulation.[34] Analysis tech-
niques include bisulfite sequencing to examine the methylation status of cysteines
or chromatin immunoprecipitation DNA sequencing (ChIP-seq) to study histone
modification and nucleosome positioning.[35]
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1.1.2.3. Transcriptomics
Transcriptomics decribes the analysis of the RNA molecules transcribed from the
genome, including mRNA, small RNAs and non-coding RNAs, whose expression
indirectly influences most processes within a cell in health and disase.[36] Analysis
techniques are either relying on hybridisation or on sequencing.[36] Microarray-based
gene expression profiling is conducted by hybridisation between single-stranded DNA
probes of defined sequences immobilised on a solid support and differentially fluo-
rescently labelled cDNA derived from the samples’ RNA by reverse transcription.[37]
Hybridisation techniques are high-throughput and relatively cheap, but limited by
the prior selection of the detectable sequences and experimental challenges such as
non-specific cross-hybridisation or the accessible dynamic range.[36] The serial anal-
ysis of gene expression (SAGE) technology, developed for the large-scale quantifi-
cation of transcripts, is a tag-based sequencing approach. In brief, short nucleotide
sequence tags, able to clearly identify the corresponding transcripts, are generated
and ligated to so-called concatemers, amplified by PCR and sequenced.[38],[39] The
development of high-throughput DNA sequencing methods provided the platform
for the development of high-throughput RNA-Seq for whole transcriptome profiling.
Hereby, a library of cDNA fragments is generated and subsequently sequenced.[36]
Whereas some circulating miRNAs either derived from miRNA containing mi-
crovesicles or from cell debris were found to be potent blood-based biomarkers for
several cancer types, it is questionable if the whole transcriptomic profile can directly
mirror the biological phenotype.[40],[41] Whereas RNA-Seq can detect the expressed
genes, splicing isoforms and novel or rare transcripts, the data cannot provide in-
formation about translational regulation, protein degradation or posttranslational
modifications, e.g. phosphorylation or glycosylation.[41] The median half-life of pro-
teins is reported to be around five times as long as for mRNA (46 h vs. 9 h, re-
spectively).[42] The dynamic range of the transcriptome covers about three to four
orders of magnitude, whereas the proteome of a cell spans a range of about seven
orders of magnitude.[42] Translational regulation of protein expression was found as
main cause for differences in protein abundance.[42] A large-scale study of the human
proteome supports this fact by showing that the ratio of mRNA and protein level for
one specific protein is well-conserved across different tissue types, whereas absolute
abundance levels and ratios might heavily vary.[43]
1.1.2.4. Proteomics
The analysis of the proteome, which includes protein abundance, structure, modifica-
tion, interaction and function, is crucial for the understanding of health and disease
and the development of novel diagnostics or therapeutics.[44] In general, two method-
ologies are applied to study the proteome: Affinity- or antibody-based techniques
and mass spectrometric approaches.[45] Despite the clinically applied antibody-based
methods immunohistochemistry (IHC) of paraffin embedded tissue samples or en-
zyme-linked immunosorbent assay (ELISA) using body fluids or tissue lysates to de-
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tect or quantify single proteins, many attempts have been undertaken to multiplex
this type of analysis. Tissue microarrays are commonly applied to screen hundreds
of tissue specimens simultaneously.[46] Cytometric bead arrays are based on different
antibody coated beads with diverse fluorescent properties mixed with cell or tissue
lysates and analysed all at once via FACS. Microtitre plate-based arrays or slide-
based systems with robotically deposited antibodies (more than 2000 features per
cm2) exploit and multiplex the classical sandwich ELISA principle with fluorescent
detection.[47] Antibody-based technologies suffer from the cross-reactivity of anti-
bodies and the limited sensitivity and specificity of immunoassays.[45] Importantly,
even the standards in commercial antibody kits are not necessarily reproducible.[47]
Therefore, reliable comparisons are difficult to perform.[47] Mass spectrometric ap-
proaches are currently the method of choice for large-scale proteomic studies. As
the focus of this thesis is on mass spectrometry-based proteomics, methods and
technologies are further described in a distinct section (see chapter 1.3).
1.1.2.5. Lipidomics
Since the mid-2000s, the molecular profiling of whole lipidomes from organisms, cells
or cell organelles and the deciphering of cellular lipid networks developed into the
rapidly growing research field of lipidomics.[48],[49] Lipid formation is in most cases
based on condensation of esters or isoprene units.[49] The high structural diversity
of lipids is generated by combination of fatty acids, headgroups and backbones,
e.g. glycerol.[50] The character of lipids hereby reaches from high hydrophobicity
to amphiphilicity. The main lipid classes include fatty acycls, glycerolipids, glyc-
erophospholipids, polyketides, sterol lipids, prenol lipids, sphingolipids and saccha-
rolipids.[49],[50] Lipid function does not only consist in dynamic barrier formation
in form of membranes. Lipids are also involved in energy homeostasis and sig-
nalling.[50],[51] Changes in the lipid profiles have been reported for different nutrition
conditions, e.g. dietary fat consumption, as well as for many diseases, such as cancer,
diabetes or neurodegenerative diseases.[52],[53],[54],[55],[56] For analysis, the hydropho-
bic lipids have to be firstly extracted from the source (cells/tissue), most often
by phase separation, e.g. via lipid extraction in organic solvents, a method that
can be also adapted to isolate highly hydrophobic lipid modified peptides.[57],[50],[58]
Chromatographic separation methods, such as high-performance liquid chromatog-
raphy (HPLC), gas chromatography (GC) or thin-layer chromatography are well
established for all different kinds of lipids.[50] Analyses in lipidomics usually rely
on mass spectrometry, mostly via electrospray ionisation (ESI).[57],[59] Furthermore,
mass spectrometric imaging of lipids on intact tissue specimens is reported via ma-
trix-assisted laser desorption/ionization (MALDI).[60] Non-destructive 1H- or 31P-
NMR measurements can be used for structural analyses of single compounds.[50]
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1.1.2.6. Glycomics
Glycomics is the study of the glycan profile of an organism. Glycans are found
as dense coating of the cell surface in the form of glycoproteins or glycolipids.[61]
About half of the proteome of a cell is estimated to be glycosylated.[62] The glycan
signature of a cell plays an important role in the immune system, e.g. for pathogen
recognition, in cell-cell contacts, in the mediation of cell adhesion and migration
or in signalling.[61],[63] Modified glycosylation patterns are found under pathogenic
conditions. For example, in the majority of cancers especially fucosylation and sialy-
lation are reported to be deregulated.[64],[65] The high diversity of the sugar residues
arises from the enormous combinatorial possibilities: The human glycome is mainly
constructed out of nine monosaccharide building blocks, which can be differentially
linked, both at different positions and under different stereochemistry, to form lin-
ear or branched structures.[61] Attachment to proteins occurs via N- or O-glycosidic
linkages to different amino acid side chains.[61] As about 75% of protein linkages
are reported to be exclusively N-glycosidic, and further 10% of the proteins contain
both type of linkages, N-glycan release with PNGaseF is a commonly used step in
sample preparation.[62],[64] For structural analysis via mass spectrometry, different
enzymatic depolymerization methods for the glysosyl chains are reported.[66] In gen-
eral, analysis methods include chromatographic separation, ESI- or MALDI-based
mass spectrometry as well as structural analysis (monosaccharide composition and
linkage information) via NMR.[63] Furthermore, carbohydrate microarrays have been
developed to screen for binding specificity to proteins.[67] Methods for glycoproteome
enrichment and analysis are further described in chapter 1.2.3.1.
1.1.2.7. Metabolomics and Metabonomics
Metabolomics describes the measurement of the concentrations of intermediates
and products of the metabolism. Metabonomics can be understood as a sub-
set of metabolomics and deals with quantitative profiling of metabolite changes
upon pathological stimuli, genetic effects, changes in diet, environment or phar-
maceutical intervention.[68],[69] The assessed metabolites are mostly small molecules
(M < 1000 g/mol) such as amino acids, vitamins, nucleotides or organic acids.[69],[70]
The studied material reaches from a wide range of biofluids (e.g. urine, blood, cere-
brospinal fluid) to extracts from tissue biopsies.[68] One common analysis technique
is nuclear magnetic resonance (NMR), a non-destructive and rapid measurement
used for metabolite fingerprinting.[70] Further analysis methods are based on mass
spectrometry, either coupled to liquid or gas chromatography or to capillary elec-
trophoresis.[70],[71]
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1.2. Vascular Accessible Biomarkers
1.2.1. Importance of Vascular Accessible Biomarkers
A monoclonal antibody or an antibody coupled to a diagnostic or a therapeutic
payload cannot access all possible biomarkers identified by comparative analysis of
a whole tissue samples. The diffusion characteristics of a vascular administered an-
tibody are mainly determined by its size and charge characteristics and the affinity
for the target. Small antibodies with low affinity and a low target number in the
surrounding tissue are able to reach a larger penetration depth around blood vessels,
however for the price of reduced retention in circulation and faster clearance.[72],[73]
Additionally, in tumour tissue, the elevated interstitial pressure as well as prolifer-
ating cancer cells compressing the tumour vessels further reduce the extravasation
rates of monoclonal antibodies.[74],[75],[76] Moreover, the vascular density in tumours
expressed as capillary surface area-to-tumour volume ratio is often reduced and the
blood flow irregular leading to a heterogeneous drug distribution within the tu-
mour.[77],[78],[74],[79] Areas more than 100 µm distant from blood vessels are therefore
normally not accessible for monoclonal antibodies.[78]
The vascular endothelium is not just a physical barrier around blood vessels:
Functions under physiological and pathological conditions include the active trans-
port of small molecules, regulation of blood pressure and coagulation, adhesion or
transmigration of inflammatory cells and the formation of new blood vessels.[80],[81]
Angiogenesis describes the process of blood vessel sprouting out of pre-existing ves-
sels and is a rare event in an adult, occurring in wound healing, during the menstrual
cycle, and in pathological situations.[82] Examples for angiogenesis under pathologi-
cal conditions are further elucidated in the following.
During solid tumour development, increasing nutrient deprivation and hypoxia ac-
tivate the so-called angiogenic switch, as supply with oxygen and metabolite trans-
port is essential for tumour growth.[83],[84] Physical inhibition of tumour nodule vas-
cularisation in rodents led to a restriction of the tumour diameter to approximately
0.4 mm.[83] Microscopopic tumours with less than 1 mm3 volume are normally avas-
cular and dormant, and are in most cases neither diagnosed nor become harmful
for the host.[85],[86] The point in time of the angiogenic switch depends on the tu-
mour type and its microenvironment, factors like vascular endothelial growth factor
(VEGF) stimulate the sprouting of blood vessels.[84],[87] Tumour vasculature has an
abnormal architecture compared to the normal vasculature. The aberrant vascu-
lar structure is characterised by a hazard and chaotic pattern of interconnections,
vessels are leaky, the endothelial cell monolayer is defective and providing gaps,
pericytes stabilizing the capillary structure are only loosely attached or absent and
the basement membrane is either absent or too thick.[87],[79],[88] Tumour endothelial
cells are irregular in morphology, e.g. exhibiting cytoplasm-filled projections, and
are also distinct at the molecular level as shown by gene expression and proteomic
analyses.[88],[89],[90],[91]
Cell lines are often used to model disease in vitro, but it is well-accepted that
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there is a gap between the model and the in vivo situation.[92] In a comparative
proteomic study using the enriched endothelial fraction of rat lung tissue vs. in
vitro cultured rat lung microvascular endothelial cells, 41% of the in vivo expressed
plasma membrane proteins could not be detected in the in vitro situation.[93]
Besides the prominent example of tumour formation, there are also other patho-
logical situations with angiogenic events.[94] Chronic inflammatory diseases such as
inflammatory bowel or inflammatory liver disease are also reported to promote an-
giogenesis. Inflammatory tissue is often hypoxic, favoring vessel ingrowth and the
high mass of inflammatory cells (e.g. macrophages, lymphocytes, mast cells) further
stimulates angiogenesis.[95],[96],[97] Furthermore, the high blood flow during inflamma-
tion induces shear stress on the endothelium. The increased endothelial surface can
further promote angiogenesis to ensure supply with nutrients and further inflamma-
tory cells.[95],[96] Also rheumatoid arthritis is linked to angiogenesis. The progressive
disease is characterised by hyperplasia of the synovial membrane and the influx of
leukocytes and inflammatory cells.[98] The formation of a pannus, i.e. an abnormal fi-
brovascular tissue layer, is highly dependent on vascularisation.[99],[100] Furthermore,
the pathogenesis of psoriasis is driven by angiogenesis. The skin is massively infil-
trated with immune cells, vessels enlarge, and dermal vascularity increases.[94],[101]
Uncontrolled ocular angiogenesis occurs in retinopathy of prematurity (ROP) in chil-
dren or in proliferative diabetic retinopathy (DR). Fragile blood vessels are formed
leading to leakage of blood (hemorrhage) and fluid accumulation in the ocular cav-
ity. If untreated, consequences include intransparency of the cornea, formation of
macula edema, irreversible damage of the retina and impairment of retinal neurons,
finally resulting in blindness.[102],[103] In cardiovascular medicine, many preclinical
and clinical studies evaluate the potential of angiogenic therapies, e.g. the delivery
of angiogenic growth factors such as VEGF to the ischaemic tissue to stimulate the
growth of novel blood vessels.[94],[104],[105]
As angiogenesis is a characteristic of many pathogenic situations, the identification
of targets on the angiogenic vasculature is of greatest interest for the development
of novel therapies. Monoclonal antibodies targeting vascular biomarkers can on the
one hand interfere with angiogenic processes and disrupt blood flow and supply with
nutrients or oxygen in the diseased tissue mass.[91],[106] On the other hand, an ap-
proach appearing contradictory at first sight was developed. Vascular normalisation,
i.e. recovery of normal blood vessel architecture and function, can be achieved with
certain antiangiogenic agents for example targeting the prolylhydroxylase domain 2
(PHD2) protein. This strategy is used to improve drug delivery to the diseased
tissue mass.[107],[79],[108] Furthermore, the application of antibody conjugates with
diagnostic or therapeutic payloads is possible. Prostate-specific membrane antigen
(PSMA) is a membrane-bound glycoprotein expressed in benign prostate tissue and
with higher abundance rates also in prostate cancer. The antigen is also found at
high levels on tumour neovasculature, not only in prostate cancer, but also in clear
cell renal carcinoma, colonic adenocarcinoma and non-small cell lung carcinoma,
whereas no expression was detectable in normal vasculature.[109] A monoclonar anti-
PSMA antibodiy coupled to Indium 111 has recently been evaluated in a phase-I
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trial for targeted imaging of progressive solid tumours.[110]
The extracellular matrix (ECM) is the non-cellular component of all tissues, pro-
viding not only a physical scaffold, but also an influential microenvironment for
cells. The main components of the extracellular matrix are fibrous proteins (e.g.
fibrillar collagens or fibronectin) as well as proteoglycans. Importantly, the exact
biochemical composition is tissue-specific and highly heterogeneous.[111] Dynamic
remodelling of the extracellular matrix is a regulatory mechanism interfering with
many processes such as cell differentiation and angiogenesis. Remodelling can in-
clude compound degradation, rearrangement or modification e.g. by matrix metallo-
proteinases (MMPs).[112] Anomalies occur in many diseases: Deregulation in cancer
contributes to disease progression, furthermore the extracellular matrix plays a role
as niche for cancer stem cells.[113],[114],[112] Angiogenesis promotes local extracellular
matrix degradation to enable the migration of endothelial cells into the perivascu-
lar space.[87] Gene expression profiling of colorectal tumour-associated endothelium
revealed several deregulated extracellular matrix proteins.[89] In hypertensive heart
disease, cardiac fibrosis occurs due to MMP inhibitor deregulation.[115] Extracellular
matrix changes are also involved in fibrosis development. The excessive accumula-
tion of fibrous connective tissue is observed in many diseases such as chronic ob-
structive pulmonary diseases or hepatic diseases.[116] Also in inflammatory diseases
remodelling occurs. The alternatively spliced EDA domain of fibronectin has been
identified as promising biomarker for tissue remodelling and angiogenesis in inflam-
matory bowel disease. Anti-inflammatory activity of an Interleukin-12-coupled anti-
body against the EDA domain could recently be shown in a colitis mouse model.[14]
The corresponding Interleukin-10 and Interleukin-4 derivatives have also been shown
to reduce arthritic progression, chronic skin inflammation and endometriotic lesion
development.[15],[117],[118]
Finally, to put it all in a nutshell, for the identification of novel, vascular accessible
biomarkers, proteins expressed on the surface of diseased cells, in the surrounding
extracellular matrix or on newly formed blood vessels have to be analysed.
1.2.2. Challenges in Membrane Proteomics
Membranes do not only play a role as physical barrier in cell architecture. Proteins
associated with the lipid bilayers of the plasma membrane or the organelle mem-
branes (e.g. Golgi apparatus, endoplasmic reticulum, mitochondria, nucleus) play
important roles in cellular communication, signal transduction and the transport of
small molecules, metabolites and ions.[119] The membrane proteome is hereby defined
as the “entire complement of membrane proteins present in a cell under a specific
condition and at a specific time”.[119]
Membrane proteins have an amphipathic character, hydrophobic protein regions
hereby interact with the hydrophobic lipid tails. Membrane spanning domains con-
tain sequences of 15-25 hydrophobic amino acids and mainly form transmembrane
α-helices or β-barrel structures.[120] The following classes of membrane proteins can
be distinguished (see Figure 1.2):[120],[121],[122]
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• Type I single-pass transmembrane protein: C-terminus at cytoplasmic side.
• Type II single-pass transmembrane protein: N-terminus at cytoplasmic side.
• Multipass transmembrane protein: typically with 2 to 20 membrane-spanning
domains, prominent example: seven-transmembrane domain (7TM) receptors.
• Peripheral membrane proteins: attached to the membrane surface or to inte-
gral membrane proteins.
• Lipid chain anchored membrane proteins: proteins covalently bound to a lipid
anchor.
• GPI anchored membrane proteins: proteins covalently bound to a glyco-
sylphosphatidylinositol anchor.
C 
C 
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Figure 1.2.: Schematic illustration of different classes of membrane proteins.
Recent estimations report 27% of the human proteome to exhibit α-helical struc-
tural elements, generally most studies map about 30% of the human genome to
membrane proteins.[123],[124],[125] Based on their function, membrane proteins can be
classified into three major groups: Receptors, transporters and enzymes.[123] Mem-
brane proteins account for about 70% of all known drug targets.[119],[126] Due to
their accessibility for drugs and the functional involvement in many signal cascades,
the plasma membrane localised G protein coupled receptors (GPCR or 7TM recep-
tors) are one of the most potent drug target families on the market.[122],[127],[128],[129]
Approximately 25% of all currently known drugs affect GPCRs.[127]
The proteome of a mammalian cell exhibits a high dynamic abundance range of
at least seven orders of magnitude.[41] Typically about 10 000-12 000 genes are ex-
pressed within a cell.[41] The median copy number of a protein per cell is estimated
to about 18 000, the forty most abundant proteins (e.g. Histone proteins, Filamin A,
Pyruvate kinase, Heat shock protein 60) contribute about 25% of the whole protein
mass. The 600 most abundant proteins account for 75% of the total protein mass,
whereas the lower half of the proteome only constitutes to less than 2%.[130] Ri-
bosomal components and the core proteasome subunits as well as many structural
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proteins of the cytoskeleton belong to the most abundant proteins within a cell.[130]
Metabolic enzymes occur across the whole abundance range: Glycolytic enzymes
can account for up to 10% of the protein mass, TCA cycle enzyme expression is
about one order of magnitude below. Components of amino acid metabolism or of
fatty acid synthesis are far lower expressed.[131] In a study performed on HeLa cells,
about 25% of all proteins were found to be integral to membranes, with only a 7.6%
fraction in terms of the total proteome mass.[130] About 10% of the proteins were
annotated to the plasma membrane.[130]
The good accessibility and the wide range of functions make the cell surface
proteins prominent biomarker candidates. The analysis of the mostly low-abundant
plasma membrane proteins is challenging. As indicated above, proteomic approaches
have to deal with the enormous sample complexity and the high dynamic range of
the proteome, leading to an under-representation of the target plasma membrane
proteome fraction in full proteome datasets.[120],[132],[119],[133]
The hydrophobic character of plasma membrane proteins is another challenge in
membrane proteomics: Efficient solubilisation and the prevention of aggregation or
precipitation is crucial for the analysis.[120],[132],[119] Solubilisation approaches include
the application of detergents such as SDS or Triton X-100 to disrupt membrane pro-
tein interactions as well as treatment with organic solvents, e.g. by sonication in 60%
methanol or digest in 90% formic acid.[134],[135],[136],[137] As most detergents negatively
interfere with mass spectrometric analysis by decreasing the chromatographic res-
olution and suppressing ionisation, a detergent removal step has to be included in
every sample preparation strategy.[138],[135] In full proteome samples, solubilisation
agents can be removed by protein precipitation, detergent removal resin columns
or with the filter-aided sample preparation (FASP) protocol using urea to disrupt
detergent micelles.[139] Acid-labile anionic surfactants such as sodium 3-[(2-methyl-
2-undecyl-1,3-dioxolan-4-yl)methoxyl]-1-propanesulfonate commercialised under the
name RapiGest™ (waters) were developed to aid protein solubilisation without in-
terference with the LC/MS analysis. At low pH, the denaturant is cleaved into
non-interfering side-products. The water-immiscible tridecan-2-on can be removed
by a centrifugaton step.[140] Although an improved solubilisation and mass spectro-
metric identification of membrane proteins is reported, the technique might suffer
from co-precipitation of hydrophobic proteins with the hydrophobic surfactant by-
product.[140],[139]
As the hydrophobic transmembrane domains lack polar amino acid side chains
such as arginine and lysine, the digest of those segments with the commonly used
enzymes trypsin or Lys-C does not result in short peptide fragments required for
a proper mass spectrometric analysis.[120],[132],[119] As the methionine content is in-
creased in transmembrane regions, chemical cleavage with cyanogen bromide (cleav-
age C-terminal of methionine) subsequently to tryptic digest was suggested.[141] In a
study on a single transmembrane protein, cyanogen bromide could be shown to dou-
ble the cleavage in transmembrane domains, whereas the cleavage of the hydrophilic
domains was not significantly changed.[142]
Several protocols to analyse membrane proteins are based on different shaving
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methods.[133] Peripheral membrane proteins can be removed from the cell surface by
washing in buffers of high ion strength or of changing pH (also termed carbonate
stripping).[143],[139] To remove plasma membrane proteins anchored by a GPI moiety,
phospholipase D treatment was applied.[144] Proteinase K treatment of cells could be
shown to shave the extracellular hydrophilic protein regions for analysis.[145] Basis
for all those methods is the preservation of the cell membrane integrity during the
procedure.[133]
Density gradient centrifugation has been widely exploited for the step-wise enrich-
ment of different cell organelles and also for the plasma membrane fraction.[120],[146]
Nevertheless, cross-contaminations between different organelle membranes (e.g. plas-
ma membrane, mitochondrial membrane, endoplasmic reticulum membrane) as well
as non-covalent attachment of highly abundant intracellular proteins to membrane
sheets occurs as undesired side-effect.[133] Using an optimized protocol for plasma
membrane protome preparation relying on sequential density-gradient based cen-
trifugations steps, about half of the identified proteome fraction was membrane
annotated, but only about 200 plasma membrane proteins could be identified (20%
fraction).[147]
Further enrichment technologies for the surface proteome fraction will be elu-
cidated in the following chapter, in combination with the biomarker criterion of
vascular accessibility.
1.2.3. Identification of Vascular Accessible Protein Targets
Early vascular accessible, disease-specific biomarkers owe their discovery extensive
immunohistochemical analyses, e.g. with antibodies derived from rodents immunized
with purified endothelial cells from tumours, or sometimes just fortunate coinci-
dences.[148],[149],[150],[151]
Inspired from the phage display technology, in vivo selection of phage libraries
was developed in the late 1990s to select and isolate peptides specifically binding
to vascular targets in the diseased tissue.[152],[153] Peptide phage libraries contain
billions of different bacteriophages displaying a polypeptide sequence on their surface
directly linked to their engineered DNA sequence.[154],[155] The peptide phage libraries
are injected into rodent disease models and, after resection of the tissue of interest,
vascular binders are isolated, amplified and identified or subjected to the next round
of panning.[152],[155] The technique has been applied to identify peptides targeting
both angiogenic and lymphangiogenic vascular changes in tumours.[156],[157],[158] This
cost-intensive technique is not applicable to all organs, as especially the liver captures
too many phages for a specific selection.[152]
In addition to proteomic efforts, vascular biomarkers were also explored in tran-
scriptomic studies. Global transcriptomic studies suffer from the high tissue com-
plexity, therefore the analysis is performed on highly specified parts of the isolated
tissue, for example via comparison of gene expression patterns from normal and
malignant endothelial cells.[89],[159] Nevertheless, the obtained data cannot provide
direct information about localization of the corresponding protein target and its
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vascular accessibility.
The enrichment of vascular accessible proteins, not only on endothelial cells, but
also on the surface of diseased cells or in the perivascular extracellular matrix prior to
mass spectrometric analysis heavily facilitates the identification of novel biomarkers.
First of all, the data provides direct information about vascular accessibility of the
protein target. Furthermore, the enrichment of the surface proteome fraction also
enables a more stable identification and quantification from proteins at the lower
end of the dynamic range of the proteome, especially membrane proteins.[160],[13]
In the following, three experimental approaches for the enrichment of the vascular
accessible proteome fraction prior to mass spectrometric analysis are introduced.
1.2.3.1. Carbohydrate-Based Cell Surface Proteome Enrichment
The glycosylation of cell surface proteins plays a pivotal role in various biological
processes such as cell adhesion and migration or cell communication.[65],[161] As de-
scribed in chapter 1.1.2.6, oligosaccharides are hereby attached to proteins through
N- or O-glycosidic linkages.[65] In a malignant state, altered glycosylation patterns
are found.[65] For example, both in hepatocellular carcinoma and in breast cancer,
an elevated activity level of N-Acetylglucosaminyltransferase V, an enzyme catalyz-
ing the addition of branched N-linked oligosaccharide side chains, is correlated to
increased tumour invasiveness and higher metastasis rates.[162],[163]
One possibility to enrich for glycoproteins is based on the strong, but reversible
interaction between lectin and oligosaccharides.[164] Fractionation of glycopeptides
with different oligosaccharide residues is possible by using a series of different lectins
with various binding specificities (also termed serial lectin affinity chromatography
SLAC).[165],[166] Lectin affinity chromatography was also applied in combination with
isotopic labelling (termed isotope-coded glycosylation-site-specific tagging IGOT).
The enrichment of glycoproteins is hereby followed by peptide-N-glycosidase (PN-
Gase) catalysed 18O-incorporation into N-glycosylation sites.[167] The lectin affinity
chromatography methodology is simple and cost-effective. Drawbacks are the pos-
sible non-specific interactions of non-glycosylated proteins as well as the poor and
often not well-defined selectivity of some lectins.[161]
Besides their affinity to certain molecules, also the chemical reactivity of the
oligosaccharide residues can be exploited for enrichment. Boronic acid derivatives
form covalent bonds with molecules containing cis-diol groups such as mannose,
galactose or glucose.[168] Magnetic beads functionalised with boronic acid can there-
fore be used to enrich both for N- or O-linked glycoproteins.[168],[161] Whereas N-
glycosylation can be easily removed by PNGase F treatment, O-glycosylation of
serine or threonine residues is experimentally more difficult to handle: Thus, a
chemical approach based on beta-elimination followed by Michael addition with
normal or deuterated DTT (BEMAD) enabling the mass spectrometric analysis of
O-linked glycopeptides was developed.[169] Another tagging approach is based on the
enzymatic modification of terminal GlcNAc moieties with a ketone-containing galac-
tose analogue (termed quantitative isotopic and chemoenzymatic tagging (QUIC)).
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Subsequently, the ketone can be used for enrichment by chemical modification with
aminooxybiotin followed by affinity purification.[170]
The cell surface capturing (CSC) technique is based on the oxidation of vici-
nal diol-groups in saccharide residues with periodate. The generated aldehyde
groups can be exploited for site-specific coupling to a solid phase such as a hy-
drazide resin via a hydrazone bond (see Figure 1.3a).[171] Another approach is cou-
pling of the aldehyde group to bifunctional biocytin hydrazide used for subsequent
affinity-based purification.[172] After enzymatic protein digest, non-glycosylated pep-
tide fragments can be removed by washing, whereas glycosylated peptides remain
bound to the resin. Release of N-linked peptides can subsequently be performed with
PNGaseF.[172] As most proteins on the cell surface are glycosylated, the technique
was either applied on proteins derived from crude plasma membrane preparations,
or applied on living cells upon washing under oxidative conditions.[173],[160],[172] The
CSC technique is very specific. In a study on Jurkat cells, 95% of the identified pro-
teins were reported to be cell surface glycoproteins.[172] In a preliminary study, the
technique was also shown to be applicable to whole organs, however requiring the
generation of single cell suspensions prior to labelling.[172] In theory, the technique
should be also suitable for the analysis of endothelial cells isolated from diseased or
healthy tissue environments.[160]
1.2.3.2. Silica Coating Technology
The silica coating technology was originally developed for the isolation of plasma
membrane proteins of intact cells, and was later adapted for in vivo perfusion of
rodents.[174],[175] In brief, cell surfaces or the vasculature surface are coated with
cationic, colloidal silica binding via ionic interactions. Subsequently, the silica beads
are cross-linked with an anionic polymer such as polyacrylic acid, hereby a thin pel-
licle is formed. After cell lysis or tissue homogenisation, the stabilised and density-
increased silica-coated plasma membrane sheets can be purified by density gradient
centrifugation. These sheets also include the attached plasma membrane proteins
(see Figure 1.3b).[174]
The methodology was further refined and applied in many mass spectrometric
biomarker studies.[176],[177] The enrichment of plasma membrane annotated proteins
is reported to be about 50%.[177] For example, the technique was used for in vivo
perfusion of the lung vasculature of rats: Comparison to silica coated, in vitro
cultured rat lung microvascular endothelial cells revealed that 41% of the identified
proteins were exclusively identified in the in vivo setting.[93] Analysis of perfused,
normal rat lungs vs. lungs of rats bearing metastatic breast adenocarcinoma resulted
in the identification of several endothelial biomarkers significantly up-regulated in
the tumour model. In the following, it was shown that targeted therapy against
Annexin A1 could prolong overall rat survival.[90]
Limitations of the technique include intracellular contaminations occurring due
to attachment of positively charged proteins such as histones to the polyanionic
surface after lysis. Furthermore, the degree of the identified intracellular background
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proteome fraction is highly sensitive towards the mechanical shear rate used for tissue
homogenisation: Harsh conditions are not suitable for the technique, therefore the
method is limited to soft tissues.[178]
1.2.3.3. In Vivo and Ex Vivo Biotinylation
Another approach for the labelling of the surface proteome fraction is covalent mod-
ification with membrane impermeable, reactive ester derivatives of Biotin, which
can subsequently be used for affinity-based enrichment of the labelled proteins (see
Figure 1.3c).[160],[13] Efficient biotin labelling of plasma membrane proteins on cells
could be demonstrated by electron microscopy using streptavidin-gold labelling.[179]
The cell surface proteome labelling technique with subsequent mass spectrometric
analysis was applied on various cell types, the identified plasma membrane protein
fractions were hereby reported to be 31-67% in different studies.[180],[126],[181],[182],[183]
Vascular perfusion of rodents with biotinylation reagents enables the in vivo la-
belling of the surface of endothelial cells, cells in close proximity of the blood vessels
and in the perivascular extracellular matrix. In brief, the animals are terminally
perfused with PBS to wash out blood components, followed by perfusion with the
reagent and a quenching solution (see Figure 1.3c).[184],[185] The success of the method
is dependent on the vascularisation of the target tissue to ensure high biotinylation
rates as well as of the efficiency of the biotinylation reagent.[185] The enriched vascu-
lar accessible proteome fractions derived from perfused diseased and healthy mouse
organs can be subjected to comparative mass spectrometric analysis to identify novel
disease-specific biomarkers for antibody-based therapies.[186],[187],[188] The perfusion
technique was also applied ex vivo using surgically resected tumour bearing kidney
or colon: Perfusion with the biotinylation reagent was performed within 2 min after
nephrectomy or ileocolectomy by cannulation of the renal or colic artery.[189],[190] In
both studies, tumour-specific biomarker candidates were found (e.g. Periostin in the
kidney study). These proteins could additionally be shown by immunohistochem-
istry to be strongly over-expressed in the tumour stroma.
The linker between the biotin residue for affinity purification and the reactive
moiety for protein coupling influences the characteristics and the properties of any
biotinylation reagent.[191],[12] In 2010, the novel, peptide-based biotinylation reagent
NHS-β-Ala-(L-Asp)3-biotin was developed, improving the identification of plasma
membrane annotated proteins compared to the commercially available reagent Sulfo-
NHS-LC-biotin.[12] The linker design will be further elucidated later in this thesis.
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Figure 1.3.: Schematic illustration of three technologies for the enrichment of the surface
proteome fraction. (a) Cell surface capturing, (b) Silica coating technology, (c) In vitro
and in vivo biotinylation. See text for further explanations.
1.3. Proteomics and Mass Spectrometry
1.3.1. Mass Spectrometric Approaches
Two basic approaches for mass spectrometric analysis of proteins are known: Top-
down proteomics concentrates on the analysis of intact proteins, whereas the bottom-
up or shotgun approach is focused on the analysis of enzymatic protein digests. The
bottom-up approach is the classical method for large-scale proteomic studies of
complex protein mixtures (see Figure 1.4).[192] Proteins are extracted from their bi-
ological source, subjected to enzymatic digest followed by peptide fractionation and
mass spectrometric analysis.[193] In contrast, top-down approaches provide the ex-
perimental platform for characterisation of post-translational modifications (PTM)
of specific proteins (e.g. complete spatial mapping) or protein isoforms (e.g. alterna-
tive splicing forms). A similar in-depth analysis is restricted in shotgun experiments
due to the high sample complexity limiting sequence coverage and the assignment
of PTMs, the ambiguity of degenerated peptide entries as well as the loss of la-
bile post-translational modifications during sample preparation.[194],[195],[196] Techni-
cal challenges in top-down proteomics are the separation and mass spectrometric
fragmentation of intact proteins during the analysis, the limited sensitivity as well
as the large sample amount needed for analysis.[195],[192] So far, the method works
best when applied to simple protein mixtures.[192] Different attempts to combine
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Figure 1.4.: Schematic illustration of a typical shotgun proteomics workflow.
the large-scale protein identification power of bottom-up approaches with in depth-
characterisation of single proteins via top-down approaches reach from a compromise
of partial digestion with Lys-C into large peptide fragments to combined workflows
integrating data from both analysis methods.[195],[197]
The most important sample preparation step in large-scale biomarker discovery
studies in proteomics is the reduction of sample complexity.[198] Efficient separa-
tion is the prerequisite for sensitive and accurate measurements as well as for the
detection of low-abundant peptides.[192] Gel-based approaches rely on one- or two-
dimensional protein separation via gel electrophoresis and isoelectric focusing fol-
lowed by gel-band excision, spot picking or slicing of whole lanes (pre-fractionation),
and subsequent analysis after in-gel digest.[192],[199] Gel-free approaches are based on
protein and/or peptide separation by liquid chromatography (LC). Reversed-phase
materials (e.g. C18) are commonly applied to separate peptides according to their
hydrophobicity. Ultra-high pressure liquid chromatography systems are capable to
operate with small 1.4-3 µm chromatographic particles reported to provide an im-
proved separation efficiency and chromatographic resolution.[200] Furthermore, mul-
tidimensional methods include orthogonal fractionation principles such as strong
cation exchange or affinity-based separation.[192]
Previous enrichment of the target proteome fraction of interest further reduces
sample complexity and enables stable identification and quantification, even of low-
abundant proteins. Approaches for the enrichment of the vascular accessible surface
proteome fraction have already been illustrated in the previous chapter.
Post-translational modifications (PTM) regulate protein structure and function
and therefore influence most cellular processes.[201] Several hundreds of different
PTMs are known. Phosphorylation, acetylation, methylation, N- and O-linked gly-
cosylation and ubiquitylation are amongst the most abundant.[202],[203] As PTM
deregulation is associated with disease, the global characterisation of PTMs is of
greatest interest in proteomics. Hereby, specific enrichment techniques have to
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be applied.[202] The enrichment of glycoproteins was already elucidated in chap-
ter 1.2.3.1. Phosphorylation is crucial as key regulator of many signalling cascades
and most commonly occurs at serine residues, but also at threonine or tyrosine side
chains.[204] The use of phosphatase inhibitors is essential during sample prepara-
tion to protect the labile modification. Phosphoproteome enrichment is crucial for
analysis to compensate for the low stoichiometry of phosphorylated peptides. En-
richment technologies are either based on electrostatic interactions of the negatively
charged phosphate group with Fe3+ (immobilized metal ion affinity chromatography
IMAC) or TiO2 or on direct or indirect chemical coupling to a solid support by
β-elimination of the phosphate group.[202],[204] Other methodologies for PTM enrich-
ment are antibody-based, e.g. the detection of ubiquitylated side chains by antibody
recognition of the Lys-ϵ-Gly-Gly motif generated by tryptic digest at former ubiq-
uitylation sites.[205]
1.3.2. Ion Sources, Mass Analyzers and Protein Identification
In general, a mass spectrometer consists of three parts: the ion source, the mass
analyser and the detector to amplify signals and register arriving ions.[206] Various
analysis strategies and instrumental configurations have been developed and are
further elucidated in the following.
To introduce the analyte into the system, it is essential to ionize the molecules
and to transfer them into the gas phase. For polar organic macromolecules such
as peptides or proteins two ionisation methods, both established in the 1980s, are
prevailing: electrospray ionization (ESI) and matrix-assisted laser desorption/ioniza-
tion (MALDI).[207],[208],[209] The development of both soft ionisation methods was
crucial for the analysis of biomolecules and was awarded with the Nobel Prize in
chemistry in 2002 (John Bennett Fenn, Koichi Tanaka).
ESI is directly compatible with chromatographic separation. Continuous sample
separation can be performed using an online system, as the ions are created out of
the liquid phase.[198] The analyte solution is guided through a capillary nozzle whose
tip is set under high voltage. Electrostatic Coulomb attraction pulls the ions towards
the counter electrode. Hereby, the analyte is dispersed into an aerosol of analyte-
solvent droplets.[210] The solvent in the droplets evaporates, leading to a decrease
in droplet size and increase in field density. Surface tension and Coulomb repulsion
of like charges are the driving forces for the following declustering process. As soon
as the Rayleigh instability limit is reached, Coulomb fission occurs and smaller and
more stable droplets are created.[210] The ion evaporation model and the charge
residue model have been hypothesized to further describe the processes.[210] Ions
generated by ESI are often multiply charged due to charge redistribution within the
droplets formed.[210]
The use of MALDI uncouples the chromatographic separation from the analy-
sis, which also enables uncoupling of MS1 and MS/MS analysis as well as reanal-
ysis of the sample.[198] The analyte is mixed with a matrix excess and manually
or robotically co-crystallized as spots on a MALDI target plate. Different matrices
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are available for various application: α-Cyano-4-hydroxycinnamic acid (CHCA) and
2,5-dihydroxybenzoic acid (DHB) are commonly used for peptide analysis, Sinapinic
acid for protein measurements.[211] The organic matrix system is able to absorb en-
ergy from intense laser pulses at a defined wavelength, energetic relaxation within the
crystal lattice leads to explosive desorption of matrix molecules together with the an-
alyte molecules.[212] Proton transfer from the photo-excitated matrix molecules to the
analyte ([X+nH]n+) is hypothesized as ionisation mechanism, hereby mostly singly
charged molecules are formed.[212] The ionisation technique currently gains attention
by the development of imaging mass spectrometry, enabling the spatial analysis of
many molecules on clinical tissue sections coated with MALDI matrix.[213],[214]
The first type of mass analysers were magnetic or electric sector field instruments.
The trajectories of the ions within the system are determined by their mass-to-charge
ratio (m/z). Differences in the deflection within the magnetic or electric field are
detected.[215] Time-of-flight (TOF) analyzers accelerate the ions in an electric field,
followed by a field-free drift tube under high vacuum. According to the kinetic
energy and their specific m/z ratio, the ions are separated by different flight ve-
locities.[206],[199] The introduction of an reflector as an ion mirror not only doubles
the flight path, but also corrects for slight differences in the kinetic energy (fo-
cusing).[206] An integrated collision cell in TOF/TOF instruments enables peptide
fragmentation by collision-induced dissociation (CID).[206] Quadrupole analysers are
based on the stabilisation or destabilisation of the path of an ion of a specific m/z
in a time-varying electric field between the four rods. In typical triple quadrupole
instruments, a precursor ion scan is performed (MS1), then, guided by the detected
MS1 signal intensity, Q1 submits a selected m/z to Q2, acting as a collision cell and
inducing fragmentation, followed by fragment ion scan (MS/MS) in Q3 (see Fig-
ure 1.5). Mass accuracy and resolution of triple quadrupole instruments are lower
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Figure 1.5.: Schematic illustration of a mass spectrometric shotgun analysis on a triple
quadrupole instrument.
than for the TOF instruments, whereas the dynamic range and the detection limit
are increased.[216] Ion trap analysers are based on the trapping of ions followed by se-
quential ejection and scan of ions of a specific m/z. Linear ion traps are constructed
as quadrupole, whereas non-linear ion traps consist of two hyperbolic electrodes with
a ring electrode in between.[206],[199] Whereas the sensitivity is high, resolving power
and accuracy are limited.[199],[216] Fourier transform ion cyclotron resonance analy-
sers (FTICR) and Orbitrap mass analysers are based on a fast Fourier transform. In
Orbitrap analysers ions oscillate in circuits around a spindle-shaped electrode. The
time-domain signal is mathematically transformed to a frequency-domain signal,
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which is directly linked to the m/z ratio.[217],[218] Fourier transform based analysers
provide high mass resolution and accuracy.[216],[218] Hybrid instruments are developed
to integrate various performance characteristics in one mass spectrometer.[215]
As already illustrated in Figure 1.5, mass spectrometric protein identification
in shotgun experiments is based on a survey precursor scan (MS1), followed by
intensity-based selection of 1-50 precursors, that are fragmented and analysed (frag-
ment ion scan, MS/MS).[219],[220] The data gained from each MS/MS spectrum can
be directly linked to a corresponding precursor peptide m/z.[221] The most com-
mon way for peptide fragmentation is collision-induced dissociation (CID). Back-
bone fragmentation hereby occurs upon collision with inert gas molecules such as
N2, typical fragment spectra of tryptically digested and CID fragmented peptides
are dominated by the y- and b-ion series (see Figure 1.6).[222] Other fragmentation
techniques are electron capture dissociation (ECD) or electron transfer dissociation
(ETD), which are based on the direct (ECD) or indirect (ETD) transfer of an elec-
tron to the peptide ion. The instability of the formed radical subsequently leads to
backbone fragmentation, preferentially leading to c- and z-ions (see Figure 1.6).[222]
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Figure 1.6.: Nomenclature of peptide fragment ions.
MS/MS spectra are subsequently searched against a database using the in silico
digested protein sequences to identify peptides and the corresponding proteins.[219]
Today, there are many search engines and algorithms known to handle uninterpreted
MS/MS data.[221] Search parameters, including a sequence database, the digestion
enzyme used, introduced modifications (e.g. alkylation of cysteine residues) as well
as the mass tolerance (depending on the instrument type used) are variable and de-
pending on the experiment performed.[221],[219] Various scoring algorithms are known
to score peptide matches, e.g. based on probability such as in Mascot.[221] Besides,
a false discovery rate (FDR) is calculated to validate the search results. A com-
mon way is a repeated search against a decoy database with reversed or shuffled
sequences. The number of matches against the decoy database is an estimate of the
percentage of false positive hits out of the search against the target database.[221]
The identified peptide sequences are finally assigned to the corresponding proteins.
The challenge of handling degenerated peptide entries and proteotypicity is further
elucidated later in this thesis.
46
1.3.3. Quantification
Quantitative proteomics is usually dealing with the ratio-based quantification of
protein up- or down-regulation between different samples (relative quantification).
In contrast, absolute quantification presents exact amounts of the protein present,
nevertheless the quantification is relative to an internal standard such as the corre-
sponding peptides synthesized with a heavy label.[223] The targeted SRM approach
for the quantification of several protein candidates in one run is presented in chap-
ter 1.4.1. The quantification of large-scale shotgun proteomics data, either label-
based or label-free, is subject of this chapter.
1.3.3.1. Label-Based Quantification
Three basic approaches have been used to integrate labels into peptides and proteins
for quantification: Metabolic, enzymatic and chemical labelling. A variety of tech-
niques differing in the point in time of label introduction and the method used for
quantification have been developed. In the following, some of the most frequently
used techniques and reagents are presented.
Stable isotope labelling with amino acids in cell culture (SILAC) is based on
metabolic labelling of cultured cells with isotopic heavy or light versions of amino
acid. For combination with standard tryptic or Lys-C digestion, typically 13C615N2-
lysine and 13C615N4-arginine are used for heavy labelling, generating a mass differ-
ence of 8.0142 Da and 10.0083 Da, respectively.[224] Light and heavy labelled protein
extracts are mixed in a ratio of 1:1, digested and analysed. Relative quantification
is based on the ratio of the corresponding peak intensities of the light and heavy
form in MS1.[224] To enable relative comparison of tissues samples, the super-SILAC
strategy was developed: Several cell lines representing the corresponding tissue type
are grown in heavy medium and combined to a heavy super-SILAC mix, which
is subsequently used for relative quantification against the light proteins derived
from tissues samples.[224] Furthermore, the SILAC method was also applied in vivo.
Metabolic labelling of C. elegans or D. melanogaster could be achieved by feeding
15N-labelled E. coli or yeast.[225] Moreover, SILAC mice could be obtained with a
13C6-lysine containing diet. Incorporation of the heavy label is approximately 85%
within 8-10 weeks, the F2 generation is reported to be fully labelled.[226]
Proteolytic 18O labelling is an enzymatic method to introduce a heavy isotopic
modification. The labelling hereby occurs via enzymatic digest in heavy water
(H218O), leading to the incorporation of 18O into the peptides’ carboxyl terminus.[227]
Light and heavy samples are combined after the enzymatic digestion. Peptides are
distinguished by a 2-4 Da mass shift, depending on the introduction of one or two
18O atoms.[227] Main disadvantage of the method is the possible trypsin-mediated
back-exchange of 18O to 16O occurring in the aqueous solvents used. Furthermore,
mass differences of less than 4 Da complicate accurate quantification.[223]
Chemical labelling for quantification is either performed by modification with
isotope-coded tags or with isobaric tags. The isotope coded affinity tag (ICAT)
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approach was one of the first labelling methods introduced for quantification.[228] The
reagents contain a thiol specific functionality targeting protein cysteine residues, a
biotin residue to purify the labelled peptides after tryptic digest and a light or heavy
(8x deuterated) linker, to evaluate the ratios of the corresponding peak intensities
of the light and heavy samples in MS1.[228] The reduction of sample complexity by
enrichment of the relatively rare cysteine containing peptides is at the same time the
weakness of the method, as the quantification is based on a low number of peptides
per protein.[223] Many variants of the heavy isoptope tags have been developed. For
example, the isotope coded protein label (ICPL) reagents specifically modify free
amino groups with a heavy or light nicotinyl-N-hydroxysuccinimide derivative.[229]
The phosphoprotein isotope-coded affinity tag (PhIAT) approach specifically targets
O-phosphorylation sites with a heavy or light labelled affinity tag.[230]
The isobaric tag for relative and absolute quantification (iTRAQ) approach is
based on the modification of free amino groups (lysine side chains or peptide N-
termini) of digested peptides. The reagents are composed of a reporter group differ-
entially labelled with 15N and/or 13C (with the 4-plex reagents 114-117 Da) and a
balancer group (with the 4-plex reagents 191-188 Da), assembled to identical reagent
masses. The labelled peptides are therefore indistinguishable in the MS1 spectra.
Upon MS/MS fragmentation, the reporter group is cleaved and peptide abundance
differences can be quantified based on the reporter group signal intensity.[231] So far,
4- and 8-plex for multiplexing four or eight samples within one measurement are
known.[231],[232] Variants of isobaric tags are the 6-plex tandem mass tag (TMT) re-
agents, also targeting free amino groups, and the cleavable isobaric labelled affinity
tag (CILAT), allowing for 12-plex measurements, which is the maximum known so
far.[223],[233],[234]
The main advantages of chemical labelling is that the compared samples are pro-
cessed and measured in one run, which minimizes variability. Besides the high
reagent costs, limitations of labelling technologies are the variable labelling effi-
ciency and the additional sample preparation steps necessary for introduction of the
label resulting in decreased reproducibility.[234] Furthermore, sample complexity is
increased by multiplexing approaches and the detectable dynamic range can be as
low as three orders of magnitude.[223],[234] Moreover, the number of comparisons is
limited by the multiplexing capacity of the applied reagent tag.[234]
1.3.3.2. Label-Free Quantification
Label-free quantification is purely based on data analysis. Theoretically unlimited
sample numbers can be processed in individual measurements without any additional
labelling steps.[234] The increased sensibility of label-free methods for handling errors
or technical performance differences emphasizes the need for stringent control of data
quality as well as for data normalisation.[234],[223]
The simplest estimation of protein abundance can be calculated by the expo-
nentially modified protein abundance index (emPAI). The protein abundance index
PAI is defined as the ratio of the number of observed peptides divided by the num-
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ber of calculated observable peptides by in silico digest under a given mass range
detectable by the mass spectrometric method used.[235] The emPAI value is calcu-
lated as 10PAI-1 and was shown to correlate with the protein amount within a sample
(r = 0.89).[236] The absolute protein content in mol% can be estimated as percentage
of the emPAI value of a specific protein divided by the sum of all emPAI values.[236]
Label-free quantification approaches are dominated by two different principles:
Quantification is either based on the area under the curve (AUC) derived from the
precursor ion spectra (MS1, signal intensity based) or on spectral counting, based
on the assumption that more abundant peptides will generate more MS/MS spectra
(see Figure 1.7).[234],[237]
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Figure 1.7.: Schematic illustration of the two main principles of label-free quantification.
Quantification based on the area under the curve (a) or on spectral counting (b).
Spectral counting assumes that high-abundant peptides are present in more chro-
matographic fractions and are more often selected for MS/MS analysis, therefore
more spectra are produced.[237] The method has undergone several modifications to
include normalisation factors and to improve accuracy. Usage of the normalised spec-
tral abundance factor (NSAF) corrects each spectral count for the protein length,
as larger proteins produce more peptides and therefore a higher number of spectra
than smaller ones. The value is subsequently normalised against the sum of all spec-
tral count per protein length ratios from all proteins within the experiment.[238] The
APEX (absolute protein expression) approach adds a correction factor to spectral
counting, which is based on peptide detection probabilities derived from a machine
learning classification algorithm that takes into account different peptide charac-
teristics such as mass, sequence, length and hydrophobicity.[239] Main disadvantage
of spectral counting is the limited dynamic range of only two orders of magnitude.
Saturation of the detector occurs for higher abundant peptides and signal suppres-
sion for lower abundant ones, hindering a linear correlation.[223] Spectral counting is
barely used combined with MALDI as ionisation method. A high number of MS/MS
spectra has to be recorded to obtain a stable quantification, whereas a specific pep-
tide is found only in a few spots and maximally recorded once per spot on a MALDI
target plate.[234]
Ion intensity based quantification relies on MS1 data. Extracted ion chromato-
grams (XIC) are generated by grouping together mass spectrometric signals derived
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from the same peptide, followed by integration over the chromatographic scale.[240]
Linear correlation of the area under the curve (AUC) to the protein concentration
could be shown in a range of 10 fmol-100 pmol (R2 = 0.991).[241] The prerequisites
of a successful signal intensity based quantification are reproducible LC/MS runs to
enable correct feature alignment across the different samples using chromatographic
retention time and m/z ratio. Slight and unavoidable run-to-run variability empha-
sizes the need for data normalisation.[242] In general, data processing is performed
in the following steps: (i) After smoothening of the raw spectra and baseline sub-
traction, the peptide peaks are detected. (ii) Data from detected isotopic patterns
are merged in a deconvolution step. (iii) Chromatographic retention time is aligned
and the peak intensity is normalised. (iv) Detected peaks deriving from the same
peptide (elution and measurement in several fractions) are summed to so-called
features based on retention time and m/z. For ratio-based quantification across
different samples, corresponding features are matched, also based on retention time
and m/z.[242],[234] The identification information derived from the MS/MS spectra
is assigned to the quantification information during the workflow. Most pipelines
are summarization-based, i.e. the intensities of peptides derived from one protein
are finally summed for analysis.[234],[243] Recently, a peptide-based linear regression
model was proposed correcting for peptide characteristics (e.g. varying signal inten-
sity derived from different ionisation efficiency) and the different number of identified
peptides per protein.[243]
1.3.4. Data-Independent Acquisition
The shotgun proteomic discovery workflow presented in the previous sections repre-
sent the so-called data-dependent acquisition (DDA) method. Thereby, the survey
or precursor ion scan (MS1) is the basis for intensity-based selection of precur-
sor ions subsequently submitted to MS/MS analysis (see Figure 1.5). In a typical
mass spectrometric measurement 1-50 precursor ions are selected for fragmentation
and sequential analysis. Precursor and the corresponding fragment ions can hereby
be clearly assigned.[220] Efficient complexity reduction is of greatest importance to
enable the measurement of low-abundant peptides exhibiting a decreased signal in-
tensity.[220] Disadvantages of DDA include the potential under-sampling, especially
of low-abundant peptides, the limited reproducibility of the measurements as well
as analytical problems arising from co-fragmentations of peptides.[244] Targeted pro-
teomic approaches such as SRM (see chapter 1.4.1 and Figure 1.9) investigate spe-
cific fragment ions from defined target peptides and provide a highly reproducible
quantification, but are restricted to less than 100 proteins per run.[220]
The idea behind the data-independent acquisition (DIA) mode is the unbiased
fragmentation of all precursors followed by acquisition of all product ion spectra.
Thereby, a high number of analytes can be detected under high sequence coverage,
accuracy and reproducibility.[220] Recent developments in mass spectrometry created
diverse approaches based on the DIA principle.
Classical sequential window acquisition of all theoretical mass spectra (SWATH)
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analysis is based on cycling through 32 sequential precursor mass windows of 25 Da
width, followed by fragmentation of all precursors within the predefined m/z and
within the specific retention time range under acquisition of all product ions (see
Figure 1.8).[220] As the spectra are multiplexed and fragment ions cannot be clearly
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Figure 1.8.: Schematic illustration of a mass spectrometric SWATH analysis on a Triple
TOF instrument.
assigned to a precursor, a simple database search is not compatible with this type
of data. Powerful bioinformatic tools assign the DIA data to spectral reference
maps (assay libraries) containing peptide coordinates such as precursor and frag-
ment m/z, normalized precursor retention times and relative intensities of fragment
ion signals.[245] The reference libraries are generated from data acquired in shotgun
proteomics experiments (DDA analysis) and by sequencing of libraries of synthetic
peptides.[220]
Multiplexed MS/MS (MSX)-DIA uses five randomly selected 4 Da windows dis-
tributed over the whole mass range per scan (in total 20 Da window). Maximal
10% of 4 Da windows are reported to contain more than one peptide.[244] Thereby,
the precursor sensitivity is increased, as the whole mass range is exploited and the
simultaneous isolation of peptides and modified forms of those peptides (e.g oxidized
methionine) generating overlapping fragment spectra is prevented.[246] Furthermore,
SWATH acquisition variants with variable cycle times or variable window widths
to adapt to the present peptide density is reported.[247] An optimized DIA method
tested on a yeast digest was able to provide almost 4000 protein identifications in
a one hour run with good reproducibility (83% overlap between five replicate sam-
ples).[248]
The MSE approach exploits rapid switches in the collision cell between low and
high collision energies. First, at the low energy state, the precursor spectrum is
obtained. Subsequently, the high energy state favours fragmentation. MS/MS spec-
tra are recorded, hereby the collision energy is ramped.[244] The high-definition MSE
(HDMSE) technology includes travelling wave-based ion mobility separation (IMS)
as additional separation dimension to expand the system’s peak capacity.[249] During
the high-energy scan, a fixed collision energy is set to each IMS cycle. With HDMSE,
approximately 50% more proteins could be detected in comparison to the MSE ap-
proach.[249] In early IMC cycles with low collision energy, peptides with high m/z
remain intact, whereas they are efficiently fragmented in late IMS cycles using high
collision energy, while low m/z are over-fragmented. To optimize the measurement
efficiency by increasing the scan time spent within favourable collision energy win-
dows, ultra-definition MSE (UDMSE) was suggested. The technique further exploits
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the linear correlation between m/z and the collision energy as well as the correlation
of ion mobility with the m/z ratio. The collision energy is ramped within a spe-
cific range during each IMS cycle, late IMS cycles are hereby assigned to a range of
higher collision energies.[249] UDMSE led to an additional increase of protein iden-
tification rates, i.e. approximately 50% more proteins were identified compared to
HDMSE.[249]
The idea behind data-independent acquisition is to miss less information in a mass
spectrometric run compared to DDA or SRM approaches. A future concept is to
perform high-throughput experiments of clinical samples and to store their complete
proteomic profiles. The profiles can be re-analysed at any point in time to answer
new clinical questions or to validate novel biomarker candidates.[220] Future develop-
ments not only include technical developments, but also the establishment of better
associated bioinformatic tools for data analysis and reference libraries.[220] Further-
more, instrumental improvements in scan speed and high resolution will significantly
improve and facilitate both data-independent and data-dependent analysis.
1.4. Biomarker Validation and Targeted Therapies
High-throughput proteomics experiments generate a large number of highly regu-
lated protein hits, yet, only very few biomarker candidates are still successful in the
post-discovery phase and are finally investigated in clinical studies.[129]
First key point is the study design itself.[9] The access to clinical material is often
limited and the analysis time consumptive, therefore often limited sample numbers
are analysed. Results obtained from small sample cohorts might be over-interpreted.
Detailed information about the representative cohort are essential for further classifi-
cation e.g. by the stage of disease, treatment obtained and histopathological charac-
teristics (subtypes). Case and control specimens have to be matched based on several
characteristic such as age and sex to obtain a valuable comparison. Standard pro-
cedures in sample collection, storage and handling minimize artificially introduced
variability. Technical limitations such as slight variability in sample preparation
as well as reproducibility of the measurements emphasize the need for technical
replicates to enable statistical assessment.[9],[250]
Secondly, validation of the biomarker is crucial to evaluate its performance (e.g.
sensitivity and specificity characteristics) in a larger sample cohort and to identify
the technical assay conditions yielding in highly reproducible and precise measure-
ments.[251],[250] Several validation techniques typically used for protein biomarkers
are further elucidated in chapter 1.4.1.
Thirdly, to exploit a biomarker for targeted therapy, binding antibodies have to
been developed (e.g. by phage display), which is time and cost intensive and requires
excessive follow-up validation experiments.[252] The in vivo situation mostly assessed
by use of animal models provides information about accessibility of the target as
well as biodistribution and associated side-effects. Furthermore, blood clearance
characteristics of the drug as well as toxicological safety have to be determined.[252]
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1.4.1. Validation of Protein Biomarkers
In contrast to the discovery experiments, typical validation experiments are based on
a decreased analyte number (biomarker candidate panel), whereas sample numbers
are increased.[253] Traditionally, antibody-based methods such as ELISA on body flu-
ids or protein extracts and immunohistochemical stainings of tissue specimens are
exploited.[220]. Increased sample throughput is enabled by screening multiple tissue
sections on tissue microarrays.[46] A high quality antibody is capable to provide high
sensitivity and selectivity characteristics. Nevertheless, antibody-based methods
have many limitations. Cross-reactivity often limits selectivity and/or specificity
of an antibody, depending on the antibody’s affinity and the concentration of the
cross reacting substance within the sample[45] Multiplexing is difficult and limited
due to cross-reactions between the different antibodies applied. Furthermore, tissue
fixation and preservation affects the staining procedure. Optimization of the sam-
ple preparation and evaluation of different antibodies is crucial, but time and cost
intensive.[220] Though, for many novel candidate proteins, good quality antibodies
are not available so far.[220],[253]
Mass spectrometric selected reaction monitoring (SRM) based quantification pro-
vides high reproducibility, accuracy and sensitivity , a dynamic rage of up to five
orders of magnitude and multiplexing capability.[220],[253],[250],[254] Up to 100 proteins
can be targeted in one run.[220] The SRM analysis is usually performed on a triple
quadrupole instrument with Q1 as precursor mass filter and Q3 as fragment ion mass
filter (see Figure 1.9). The precursor ion of a predefined target peptide is selected,
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Figure 1.9.: Schematic illustration of a mass spectrometric SRM analysis on a triple
quadrupole instrument.
fragmented in Q2 and a predefined fragment ion type, the so-called transition, is
guided to the detector. The SRM signal acquired is derived from monitoring the
transition over a predefined retention time window.[220] The prerequisite of a SRM
analysis is the selection of proteotypic peptides unambiguously identifying the target
proteins within the sample. Secondly, the targeted fragment ions (transitions) are
selected during optimisation experiments, mainly based on their signal intensity.[223]
Synthetic heavy labelled peptides spiked into the sample provide information about
mass spectrometric performance differences and enable quantification via the ra-
tio of the peak area or height of the light sample peak and the heavy standard
peaks.[223] Ion suppression effects are negligible for the quantification, as a similar
behaviour of sample and standard peak can be expected.[223] Still, the analysis of
low-abundant peptides might be hindered by high-abundant peptides in complex
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samples. Furthermore, the injectable amount is limited due to technical restrictions
of the LC/MS system.[223]
Combinations of antibody-based enrichment methods with mass spectrometric
quantification are reported, to enrich for the target proteins prior to analysis en-
abling a more stable quantification.[223] In the SISCAPA method, specific anti-target
peptide antibodies are immobilised on a solid support, which is subsequently packed
into an affinity column. The eluted fractions are guided via a reversed-phase col-
umn to SRM analysis.[255] The SRM analysis of plasma proteins, spanning a dynamic
range of more than ten orders of magnitude, could be heavily improved by SISCAPA.
About 120-fold enrichment could be achieved for over 200 target components.[255]
Successful enrichment also yielded in an improved limit of detection (LOD). The
LOD for SRM analysis of unfractionated plasma samples is about 1 µg/mL. SIS-
CAPA improved the LOD to the low ng/mL range.[250]
1.4.2. Ligands for Vascular Targeting Applications
In contrast to conventional therapeutics, targeted drugs preferentially localise at the
site of disease, preventing side-effects in healthy tissue and increasing the dose fi-
nally reaching the diseased tissue.[252] Besides monoclonal antibodies, also other high
affinity binders are known, which are able to target vascular accessible biomarkers.[91]
For some targets, the isolation of short peptide ligands is possible.[91] The syn-
thesis and selection of peptide binders are enabled by the phage display technique
using peptide libraries presented on the bacteriophages’ surface or by SPOT syn-
thesis allowing the generation of a large peptide pool in a heavily parallelised ap-
proach.[256],[257] Dissociation constants for small peptide binders are usually in the
micromolar range, but can be improved by peptide multimerization to reach the
nanomolar range.[91],[258],[259]
Aptamers typically exhibit dissociation constants in the micromolar to subnano-
molar range.[91] Target-binding nucleotide sequences can be selected in vitro out of a
random pool of single and double stranded DNA sequences in cycles of selection and
amplification.[260],[261] Single-stranded DNA aptamers are able to create a larger vari-
ability of three-dimensional shapes and exhibit increased affinity and specificity.[260]
The in vivo stability can be improved by creating biostable compounds, e.g. so-called
RNA-Spiegelmers by exchanging the D-ribose backbone with its nuclease-stable L-
form.[262] Furthermore, bioorthogonal conjugation of drug molecules to aptamers for
targeted drug delivery has been performed.[263] In comparison to antibodies, the main
disadvantage of both aptamers and small peptide ligands is the increased clearance
rate due to the small molecule size.[263]
Isolation of high-affinity small organic molecules for vascular targeting provides
many advantages. The production is relatively simple, chemical modifications can
easily be introduced, small molecules are not immunogenic, oral administration and
a good distribution within tissues is achievable due to the small molecular weight.[91]
Several methods to provide small molecule libraries are known. Libraries of synthetic
organic molecules used for screening are often created by modular variation of side
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groups of compounds inspired by naturally occurring small molecules.[264] Combina-
torial chemistry is based on the assembly of several building blocks to many diverse
molecules using a defined number of functional groups. Dynamic combinatorial
chemistry hereby exploits reversible reactions, enabling compound rearrangement
during the selection process on the target molecule.[265] Encoded self-assembling
chemical libraries are based on libraries of small organic molecule compounds that
are coupled to defined oligonucleotide sequences used for decoding after target bind-
ing.[266] Dissociation constants can extend to the nanomolar range, but the isolation
of high-affinity binders is still challenging.[91] Multivalent binding hereby helps to
compensate for lower affinity.[267] So far, several small organic ligands for tumour tar-
geting have been discovered, e.g. a folate derivative targeting the highly up-regulated
folate receptor in ovarian cancer, which is currently investigated in a phase II study
using a 99mTc-coupled derivative for imaging purposes.[267],[268] Also coupling to cy-
totoxic payloads can be easily realised with small organic molecule.[267]
For efficient targeting, dissociation constants of at least 10 nM are reported.[267]
High affinity antibodies can reach dissociation constants down to the picomolar
range.[91] Different antibody formats are known, reaching from full immunoglobu-
lins and bispecific antibodies to single chain fragments and diabodies.[91],[73],[269] The
antibody format heavily influences tissue penetration and pharmacokinetic proper-
ties. Biological half-life is increased if the antibody mass is above the renal clear-
ance threshold of 70 kDa. Molecular size, shape, charge and affinity influence the
tissue penetration capability. An 80% fraction of monoclonal antibodies (about
150 kDa) is reported to not leave the blood and reach the diseased tissue.[73] Tradi-
tionally, monoclonal antibodies are prepared by the hybridoma technology via the
fusion of myeloma cells to spleen cells of an immunised donor.[270] Newer technolo-
gies for synthesis and selection of high affinity antibodies or antibody fragments
include phage display or ribosome display as well as colony filter screen.[271],[272],[273]
Monoclonal antibody based therapeutics can affect diseased cells in various ways
such as receptor blockade interfering with signalling pathways or checkpoints, in-
hibition of angiogenesis or via co-activation of immune effector cells.[274] Further-
more, antibodies can be coupled to a payload for diagnostic or therapeutic purposes.
Possible payloads can hereby be radionuclides, cytotoxic agents, immunocytokines
and nanocarriers.[275],[276],[277],[267],[278] The success of antibody-drug conjugates is not
only influenced by the antibody properties, but also by the kinetics of drug release
and the diffusion characteristics of the payload within the diseased tissue.[267] Site-
specific attachment of the payload to the protein antibody can be performed via
bioorthogonal coupling methods. Cleavable linkers can efficiently release the pay-
load at the targeted site.[267] Hereby, diverse strategies such as acide-labile hydrazone
linkers, disulfide linkers sensitive to a reductive environment or enzymatically cleav-
able peptide-based linkers can be applied.[279] Currently, several clinical studies are
performed on non-internalizing antibody-drug conjugates delivering their payload
to the extracellular space, for example armed antibodies targeting alternative splice
variants of the EDA domain of fibronectin.[267],[15]
The development of novel targeted therapies is first of all dependent on the identi-
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fication of vascular accessible biomarkers. The use of state-of-the-art analytical tech-
nologies, the accessibility of a broad range of clinical specimens and an elaborated
biomarker discovery and validation pipeline might be the key factors for successful
discovery experiments. Equally important is the ligand development phase, which
does both involve production of a binder and extensive validation and assessment
of its affinity, pharmacokinetic and toxicological characteristics.
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2. Aim of the Thesis
The development of novel targeted therapies is based on the identification of vascu-
lar accessible, disease-specific biomarkers. The molecules of interest can be targeted
with monoclonal antibodies, antibody fragments or antibody-drug conjugates and
are located on the surface of diseased cells, on newly formed blood vessels or in the
perivascular extracellular matrix. Proteomic approaches for biomarker identifica-
tion are challenging due to the enormous dynamic range of the proteome over at
least seven orders of magnitude, the low abundance of the highly diverse plasma
membrane proteins, as well as the hydrophobic character of membrane proteins.
Therefore, the targetable surface proteome fraction is often under-represented in
full proteome datasets or cannot be quantified stably. The proteins of interest can
be enriched prior to mass spectrometric analysis by their covalent modification with
a membrane-impermeable ester-derivative of biotin, followed by streptavidin-based
affinity capturing. Biotinylation of potential biomarkers can be conducted in vitro
by labelling of cells, via in vivo perfusion of mice and ex vivo using surgically re-
sected tissue material. The linker between the biotin residue and the reactive group
for protein coupling hereby determines the properties of the biotinylation reagent
and influences selectivity and reactivity.
The work in this thesis focuses on the synthesis and multi-step validation of two
novel, peptide-based and site-specifically activated biotinylation reagents as well
as of two novel heparin-based biotinylation reagents. Furthermore, two alkyne-
tagged reagents for bioorthogonal click-chemistry based enrichment are designed and
preliminarily tested for reactivity. First, the reactivity is examined by coupling to a
single protein in different ratios and analysis with linear MALDI mass spectrometry.
Subsequent validation is performed in vitro on HeLa cells and in vivo via perfusion of
healthy NSG mice. The reactivity as well as the efficacy of biotinylation and the in
vivo biotinylation depth around blood vessels is hereby visualised via confocal laser
scanning microscopy, FACS analysis, ELISA and Western Blot of cell and tissue
samples. Main part of the analysis is the mass spectrometric determination of the
accessible proteome fraction performed in comparison to the commercial reagents
Sulfo-NHS-LC-biotin and NHS-PEG12-biotin as well as PBS- or non-treated cells
or tissue samples as negative controls. Data analysis concentrates on the identified
protein and proteotypic peptide numbers as well as on protein localization, relative
quantification is performed against commercial Sulfo-NHS-LC-biotin using the in-
house developed software MSQBAT. Furthermore, the stability of the quantification
of some medium- and low-abundant cell surface and extracellular matrix proteins is
further assessed by SRM-analysis in comparison to full proteome samples.
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3. Materials and Methods
3.1. Chemical Synthesis
3.1.1. Peptide-Based Biotinylation Reagents
3.1.1.1. Synthesis of Biotin-(L-Asp)3-β-Ala
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Biotin-(L-Asp)3-β-Ala 1 was kindly provided by Dr.Yixin Zhang (BCube, Dresden).
Peptide synthesis was performed by solid-phase synthesis on an Intavis peptide syn-
thesizer using 9-fluorenylmethoxycarbonyl (Fmoc) chemistry based on a β-Ala-Wang
resin (0.55 mmol/g). Activation of Fmoc-Asp-t-butyl-OH was achieved with 0.5 M
HBTU in dimethylformamide (DMF). N-terminal deprotection was performed in
20% piperidine in DMF. Cleavage from the resin and deprotection of aspartic acid
side chains was achieved with a mixture of 92.5% trifluoroacetic acid (TFA), 5%
triisopropylsilane (TIPS) and 2.5% water for 2.5 h at room temperature. After
precipitation in cold anhydrous diethyl ether, the peptide was dried under vacuum,
followed by preparative reversed-phase HPLC (Luna® C18 column, 10 µm particle
size, 30 x 250 mm, Phenomenex) with a 30 min linear water/acetonitrile gradient
(0.1% TFA, 20 mL/min) for purification. For monitoring purposes, wavelengths of
the UV/VIS diode array detector (Varian ProStar 325) were set to a range of 214-
280 nm. Biotin-(L-Asp)3-β-Ala 1 was lyophilized and the purity was verified by an
analytical Waters UPLC/MS system (Acquity BEH C18 column, 1.7 µm particle
size, 2.1 x 50 mm, Waters) with tandem quadrupole (TQ) and tunable UV (TUV)
detector. Two synthesis batches of 25 mg peptide product were used for the exper-
iments presented in this thesis.
Biotin-(L-Asp)3-β-Ala 1 (C25H36N6O13S1): MW 660.65 g/mol.
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3.1.1.2. Synthesis of Biotin-(L-Asp)3-β-Ala-NHS and -sNHS
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Biotin-(L-Asp)3-β-Ala 1 was dissolved in dry dimethyl sulfoxide (DMSO) (over
molecular sieve, Sigma-Aldrich, 41648) to a final concentration of 200 mg/mL
(303 mM). The stock solution was stored under inert gas at -20◦C for several months.
For carboxylic group activation, 1.3 eq (1.3 µmol, 150 µg) N-hydroxysuccinimide
(NHS) (200 mM in dry DMSO, ProteoChem, c1101) or 1.3 eq N-hydroxysulfosuccin-
imide (sNHS) (1.3 µmol, 282 µg) (200 mM in dry DMSO, ProteoChem, c1102)
were added to 1 eq (1 µmol, 660 µg) Biotin-(L-Asp)3-β-Ala 1. In the following,
the reaction mixture was either added to 1.1 eq (1.1 µmol, 211 µg) 1-ethyl-3-(3-di-
methylaminopropyl)carbodiimide hydrochloride (EDC-HCl) (200 mM in dry DMSO,
ProteoChem, c1100) for reaction in solution or to an excess of 3-10 eq N,N’-dicyclo-
hexylcarbodiimide (DCC) resin (1.6 mmol/g, 150-300 µm, Agilent Technologies,
PL3417-1689). To achieve effective swelling of the hydrophobic beads, the reaction
solution was 2.5-fold diluted with chloroform (Roth, 7331). The reaction was carried
out for 2.5 h at room temperature. To separate the reaction product from the DCC
resin, the beads were pelletized at 1000×g for 30 s. After separating the beads from
the supernatant, beads were washed twice by 5 min incubation with 10 µL DMSO;
washes were combined with the supernatant from the reaction. The reaction prod-
ucts Biotin-(L-Asp)3-β-Ala-NHS 2 or Biotin-(L-Asp)3-β-Ala-sNHS 3 could be used
for labelling of proteins without further purification. The NHS-activation of Biotin-
(L-Asp)3-β-Ala 1 was performed directly before use. To assess the storability of
the reagent, the reaction mixture was stored for up to one week at -20◦C after the
incubation period of 2.5 h at room temperature. Aliquots of 1 µmol biotinylation re-
agent have been prepared for differential biotinylation of BSA or HeLa cells to assess
the reactivity (see chapters 3.2, 3.3.2). In the following, the activated biotinylation
reagents are named NHS-β-Ala-(L-Asp)3-biotin 2 and Sulfo-NHS-β-Ala-(L-Asp)3-
biotin 3 according to literature.[12]
NHS-β-Ala-(L-Asp)3-biotin 2 (C29H39N7O15S1): MW 757.73 g/mol.
Sulfo-NHS-β-Ala-(L-Asp)3-biotin 3 (C29H38N7NaO18S2): MW 859.76 g/mol.
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3.1.1.3. Synthesis of Biotin-(L-Asp)3-Cys-CONH2
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Biotin-(L-Asp)3-Cys-CONH2 4 was kindly provided by Dr.Yixin Zhang (BCube,
Dresden). Peptide synthesis was performed by solid-phase synthesis on an In-
tavis peptide synthesizer using Fmoc chemistry based on a TentaGel S Ram resin
(0.23 mmol/g). C-terminal activation of amino acid compounds was achieved with
0.5 M HBTU in DMF. N-terminal deprotection was performed in 20% piperidine
in DMF. Cleavage from the resin and deprotection of aspartic acid side chains was
achieved with a mixture of 90% TFA, 5% TIPS, 2.5% water and 2.5% dithiothreitol
(DTT) for 2.5 h at room temperature. After precipitation in cold anhydrous diethyl
ether, the peptide was dried under vacuum, followed by preparative reversed-phase
HPLC (Luna® C18 column, 10 µm particle size, 30 x 250 mm, Phenomenex) with a
30 min linear water/acetonitrile gradient (0.1% TFA, 20 mL/min) for purification.
For monitoring purposes, wavelengths of the UV/VIS diode array detector (Varian
ProStar 325) were set to a range of 214-280 nm. Biotin-(L-Asp)3-Cys-CONH2 4
was lyophilized and the purity was confirmed by an analytical Waters UPLC/MS
system (Acquity BEH C18 column, 1.7 µm particle size, 2.1 x 50 mm, Waters) with
TQ and TUV detector. Four synthesis batches of 25-270 mg peptide product were
used for the experiments presented in this thesis.
Biotin-(L-Asp)3-Cys-CONH2 4 (C25H37N7O12S2): MW 691.73 g/mol.
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3.1.1.4. Coupling of Biotin-(L-Asp)3-Cys-CONH2 to SMCC-Crosslinker or
SM(PEG)6-Crosslinker
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Biotin-(L-Asp)3-Cys-CONH2 4 was dissolved in dry DMSO (over molecular sieve,
Sigma-Aldrich, 41648) to a final concentration of 300 mg/mL (434 mM). The stock
solution could be stored under inert gas at -20◦C for several months. Before cou-
pling to the crosslinker, 0.5 eq (0.5 µmol, 143 µg) tris(2-carboxyethyl)phosphine
(TCEP) (200 mM in dry DMSO, BioVision, 1202) were incubated with 1 eq (1 µmol,
692 µg) peptide educt 4 for 10 min at room temperature. 1.3 eq (1.3 µmol, 435 µg)
succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) (300 mM
in dry DMSO, ProteoChem, c1108) or 1.3 eq (1.3 µmol, 782 µg) succinimidyl-
([N-maleimidopropionamido]hexaethyleneglycol)ester (SM(PEG)6) (300 mM in dry
DMSO, Thermo Scientific, 22105) were added and the crosslinking reaction was car-
ried out for 2.5 h at room temperature. The NHS-activation of Biotin-(L-Asp)3-Cys-
CONH2 4 via the SMCC- or SM(PEG)6-crosslinker was always performed directly
before use. The reaction products 5,6 could be used for labelling of proteins without
further purification. 1 µmol (1.03 mg/1.29 mg) reagent was prepared for differential
biotinylation of BSA for reactivity assessment (see chapter 3.2). For mass spectro-
metric validation experiments, 5 µmol (5.13 mg/6.47 mg) biotinylation reagent per
cell culture flask were used for in vitro biotinylation of HeLa cells (see chapter 3.3.2)
and 25 µmol (25.65 mg/32.33 mg) biotinylation reagent were prepared per mouse
for in vivo perfusion (see chapter 3.4.2). In the following, the activated reagents are
referred to as SMCC-Cys-(L-Asp)3-biotin and SM(PEG)6-Cys-(L-Asp)3-biotin.
SMCC-Cys-(L-Asp)3-biotin 5 (C41H55N9O18S2): MW 1026.06 g/mol.
SM(PEG)6-Cys-(L-Asp)3-biotin 6 (C51H76N10O25S2): MW 1293.33 g/mol.
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3.1.2. Heparin-Based Biotinylation Reagents
3.1.2.1. Synthesis of Biotin-Heparin and Biotin-Enoxaparin
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R1 = Heparin 7 or Enoxaparin 8 chain
7,8
Heparin sodium salt from porcine intestinal mucosa (Calbiochem, 375095) is a highly
sulfated polysaccharide with a mass range of 13 000-17 000 g/mol (average mass
15 000 g/mol). The most common disaccharide unit is composed of 2-O-sulfated
iduronic acid and 6-O- and N-sulfated glucosamine (IdoA(2S)-GlcNS(6S)). Enoxa-
parin sodium (Dongying Tiandong Biochemical Industry Co., Dongying, China) is
a low-molecular weight heparin with an average mass of 4421 g/mol (70% 2000-
8000 g/mol, 20% <2000 g/mol) obtained by alkaline depolymerization of the benzyl
ester derivative of heparin from porcine intestinal mucosa. The non-reducing end
of the enoxaparin chain consists of a 4-enopyranose urinate structure, the degree of
sulphatation is about 2 per disaccharide unit.
For biotinylation of the reducing end of the heparin chains, heparin sodium or
enoxaparin sodium salt were dissolved in 0.1 M sodium acetate buffer, pH 5.0
(Sigma-Aldrich, S8750) to a final concentration of 25 mM or 50 mM, respectively.
10 eq (10 µmol, 2.58 mg) biotin hydrazide (75 mM in dry DMSO, ProteoChem,
b2106) were added to 1 eq (1 µmol, 15 mg) heparin or 1 eq (1 µmol, 4.4 mg) enoxa-
parin. The reaction solution was incubated with 100 eq (100 µmol, 9.3 mg) aniline
(Sigma-Aldrich, 242284) for 5 days at 70◦C. The protocol was scaled to 5 µmol or
25 µmol Biotin-Heparin 7 or Biotin-Enoxaparin 8 if the reagents were used after
consecutive activation for in vitro biotinylation of HeLa cells (see chapter 3.3.2)
or in vivo perfusion per mouse (see chapter 3.4.2). The reaction products were
purified by gel filtration. Biotin-Heparin 7 was purified using PD MiniTrap G-25
(GE Healthcare, 28-9180-07) or PD-10 desalting columns (GE Healthcare, 17-0851-
01); Biotin-Enoxaparin 8 using PD MiniTrap G-10 (GE Healthcare, 28-9180-10) or
PD MidiTrap G-10 (GE Healthcare, 28-9180-11) columns. For optimal recovery,
the gravity protocols were used according to the manufacturer’s instructions. For
equilibration and elution, a five-fold dilution of PBS in water was used. Purified
reaction products were dried in a vacuum concentrator (RVC 2-25 CDplus, Christ)
and stored at -20◦C.
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3.1.2.2. NHS- or sNHS-Activation of Biotin-Heparin and Biotin-Enoxaparin
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The heparin chain with an average mass of 15 000 g/mol (4421 g/mol for enoxa-
parin) consists on average of 25 (8 for enoxaparin) disaccharide units with one
free carboxylic group each. For carboxylic group activation, Biotin-Heparin 7 or
Biotin-Enoxaparin 8 were dissolved in PBS to a final concentration of 50 mM. 25 eq
(25 µmol, 2.9 mg) NHS (500 mM in water, ProteoChem c1101) or 25 eq (25 µmol,
5.4 mg) sNHS (500 mM in water, ProteoChem c1102) and 25 eq (25 µmol, 4.8 mg)
EDC-HCl (500 mM in water, ProteoChem c1100) were incubated with 1 eq (1 µmol,
15.2 mg) Biotin-Heparin 7 for 2.5 h at room temperature. 1 eq (1 µmol, 4.7 mg)
Biotin-Enoxaparin 8 was incubated with 10 eq (10 µmol, 1.2 mg) NHS (500 mM
in water, ProteoChem c1101) or 10 eq (10 µmol, 2.2 mg) sNHS (500 mM in wa-
ter, ProteoChem c1102) and 10 eq (10 µmol, 1.9 mg) EDC-HCl (500 mM in water,
ProteoChem c1100) for 2.5 h at room temperature. The reaction products 9,10
could be used for labelling of proteins without further purification. For mass spec-
trometric validation experiments, 5 µmol biotinylation reagent per cell culture flask
were synthesized for the in vitro biotinylation of HeLa cells (see chapter 3.3.2) and
25 µmol biotinylation reagent were prepared per mouse for in vivo perfusion (see
chapter 3.4.2). For in vitro and in vivo experiments, the activation was always
performed with sNHS. In the following, those activated reagents are referred to as
Biotin-Heparin-sNHS 9 and Biotin-Enoxaparin-sNHS 10.
Activity tests with NHS- or sNHS-activated heparin compounds were performed
using Biotin-Heparin 7 (Biotin-Enoxaparin 8) or unbiotinylated heparin salt (enoxa-
parin salt) as educt. Differential ratios of NHS- or sNHS excess were tested using
the activation protocol described above.
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3.1.3. Click Chemistry-Based Reagents
3.1.3.1. Synthesis of Alkyne-(L-Asp)3-Cys-CONH2
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Alkyne-(L-Asp)3-Cys-CONH2 11 and 12 were kindly provided by Dr.Yixin Zhang
(BCube, Dresden). Peptide synthesis was performed by solid-phase synthesis on an
Intavis peptide synthesizer using Fmoc chemistry based on a TentaGel S Ram resin
(0.23 mmol/g). C-terminal activation of amino acid compounds was achieved with
0.5 M HBTU in DMF. N-terminal deprotection was performed in 20% piperidine
in DMF. Alkyne compounds used were 4-pentynoic acid (PA) and dibenzylcyclo-
octyne (DBCO) acid. Cleavage from the resin and deprotection of aspartic acid side
chains was achieved with a mixture of 90% TFA, 5% TIPS, 2.5% water and 2.5%
DTT for 2.5 h at room temperature. After precipitation in cold anhydrous diethyl
ether, the peptide was dried under vacuum, followed by preparative reversed-phase
HPLC (Luna® C18 column, 10 µm particle size, 30 x 250 mm, Phenomenex) with
a 30 min linear water/acetonitrile gradient (0.1% TFA, 20 mL/min) for purifica-
tion. For monitoring purposes, wavelengths of the UV/VIS diode array detector
(Varian ProStar 325) were set to a range of 214-280 nm. PA-Alkyne-(L-Asp)3-
Cys-CONH2 11 (DBCO-Alkyne-(L-Asp)3-Cys-CONH2 12) were lyophilized and the
purity was confirmed by an analytical Waters UPLC/MS system (Acquity BEH C18
column, 1.7 µm particle size, 2.1 x 50 mm, Waters) with TQ and TUV detector.
One synthesis batch of 18 mg (11 mg) peptide product was used for the experiments
presented in this thesis.
PA-Alkyne-(L-Asp)3-Cys-CONH2 11 (C20H27N5O11S): MW 545.52 g/mol.
DBCO-Alkyne-(L-Asp)3-Cys-CONH2 12 (C38H43N7O13S): MW 837.86 g/mol.
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3.1.3.2. Coupling of Alkyne-(L-Asp)3-Cys-CONH2 to SMCC-Crosslinker
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PA-Alkyne-(L-Asp)3-Cys-CONH2 11 or DBCO-Alkyne-(L-Asp)3-Cys-CONH2 12
was dissolved in dry DMSO (over molecular sieve, Sigma-Aldrich, 41648) to a fi-
nal concentration of 300 mM. Before coupling to the crosslinker, 0.5 eq (0.5 µmol,
143 µg) TCEP (50 mM in dry DMSO, BioVision, 1202) were incubated with 1 eq
(1 µmol, 545 µg or 838 µg) peptide educt 11 or 12 for 10 min at room temperature.
1.3 eq (1.3 µmol, 435 µg) SMCC (300 mM in dry DMSO, ProteoChem, c1108) were
added and the crosslinking reaction was carried out for 2.5 h at room temperature.
The activation via the SMCC-crosslinker was always performed directly before use.
The reaction products 13,14 could be used for labelling of proteins without fur-
ther purification. 0.5 µmol (440 µg/586 µg) reagent was prepared for differential
biotinylation of BSA for reactivity assessment (see chapter 3.2). In the following,
the activated reagents are referred to as SMCC-Cys-(L-Asp)3-DBCO-alkyne and
SMCC-Cys-(L-Asp)3-PA-alkyne.
SMCC-Cys-(L-Asp)3-PA-alkyne 13 (C36H45N7O17S): MW 879.85 g/mol.
SMCC-Cys-(L-Asp)3-DBCO-alkyne 14 (C54H61N9O19S): MW 1172.19 g/mol.
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3.1.4. Commercial Biotinylation Reagents
All validation experiments have been performed in comparison to the commercial re-
agents Sulfo-NHS-LC-biotin (ProteoChem, b2103) and NHS-PEG12-biotin (Thermo
Scientific, 21313). Sulfo-NHS-LC-biotin was stored in solid form at +4◦C, NHS-
PEG12-biotin stock solution was prepared as 250 mM stock in dry DMSO (over
molecular sieve, Sigma-Aldrich, 41648) and stored at -20◦C for several months. Di-
lutions in PBS or water were made directly before use, concentrations were adapted
to those of the synthesized reagents. For mass spectrometric validation experi-
ments, 5 µmol (2.78 mg/4.71 mg) biotinylation reagent Sulfo-NHS-LC-biotin or
NHS-PEG12-biotin per cell culture flask were used for in vitro biotinylation of HeLa
cells (see chapter 3.3.2) and 25 µmol (13.91 mg/23.53 mg) for in vivo perfusion per
mouse (see chapter 3.4.2).
Sulfo-NHS-LC-biotin (C20H29N4NaO9S2): MW 556.58 g/mol.
NHS-PEG12-biotin (C41H72N4O18S): MW 941.10 g/mol.
3.2. Reactivity Assessment
3.2.1. Reaction with BSA as Model Protein
1 mg/ml bovine serum albumin (BSA) stock (Sigma, A2153) was prepared in phos-
phate buffered saline (PBS) (Gibco, 18912-014). Synthesized or commercial bi-
otinylation or click chemistry based reagents (see chapter 3.1) were dissolved or
diluted in water directly before use to a final concentration of 10 mM. The reagents
were added to 100 µg BSA aliquots (1.505 nmol, 1 eq) in different ratios (1 eq -
100 eq). The reaction was quenched after 15 min incubation at room temperature
using ten-fold excess (10 eq - 1000 eq) of 2-amino-2-hydroxymethyl-propane-1,3-diol
(Tris) solution (100 mM, in water, Sigma-Aldrich, T1503). 10% TFA (in water, Pro-
teoChem, LC6203) was added to a final concentration of 0.1% TFA. Biotinylated
BSA samples were desalted using 100 µL OMIX C4 pipette tips (Agilent Technolo-
gies, A57009100). The desalting tips were wetted twice with 100 µL 50% UPLC/MS
grade acetonitrile (Biosolve, 012041) in UPLC/MS grade water (Biosolve, 232141),
followed by equilibration with two times 100 µL 0.1% TFA in UPLC/MS grade wa-
ter. Proteins were bound to the resin by aspirating the sample solution twenty times
into the tip. The desalting tips were washed three times with 100 µL 0.1% TFA in
water. Elution was performed by aspirating ten times 100 µL 75% acetonitrile, 0.1%
TFA in water. Samples were dried in a vacuum concentrator (RVC 2-25 CDplus,
Christ), redissolved by 5 min sonication in 10 µL 5% acetonitrile, 0.1% TFA in water
and co-crystallized with a two- to four-fold excess of sinapinic acid (10 mg/mL, in
50% acetonitrile, 0.1% TFA in water, ProteoChem, p9102) onto an Opti-TOF™ 384
matrix-assisted laser desorption/ionization (MALDI) target plate (AB SCIEX). At
least 8 spots per sample were prepared.
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In addition to the testing of different reagents in various ratios, other parameters
of the biotinylation reaction have been examined using the protocol described. To
assess the storability of the reagents, the reaction mixture in dry DMSO was stored
for up to one week at -20◦C before coupling to the model protein BSA. Moreover,
different incubation times before quenching (30 s - 1 h) as well as different reaction
buffers (PBS buffer, pH 7.45 (Gibco, 18912-014) / MES buffer, pH 6.0 (100 mM,
Sigma-Aldrich, M8250) / Sodium carbonate buffer, pH 9.2 (100 mM, Sigma-Aldrich,
S7795)) were examined.
3.2.2. MALDI MS Linear High Mass Positive Mode
Mass spectrometric analysis of BSA samples was performed on a MALDI TOF/
TOF™ 5800 system (AB SCIEX) using the TOF/TOF™ Series Explorer™ Software
(AB SCIEX, version V4.1.0) with oracle database schema version 4.0.0, data version
4.0.5. Measurements were performed in linear mode with MS acquisition method
Linear High Mass Positive. Operating mode was set to MS Linear High Mass
Positive, the mass range to 10 000-140 000 Da (focus mass 66 000 Da). 250 shots per
sub-spectrum were acquired, 4 subspectra were accumulated (total: 1000 shots per
spectrum). During acquisition, the sample plate was moved with continuous stage
motion with a stage velocity of 600 µm/s. The digitizer used 20 ns bin size with
a vertical scale of 0.05 (V full scale), a vertical offset of -2.5 (% full scale) and an
input bandwidth of 20 MHz. Laser pulse rate was set to 400 Hz. Detector voltage
multiplier was always adjusted following general maintenance of the instrument.
The Y2 and X2 deflector voltages and the laser intensity were manually adjusted
before sample measurement using the MS processing method Linear High Mass
Internal with the m/z of BSA (66 431.000) as reference mass. 100 m/z were taken
as mass tolerance, maximal outlier error was 5 m/z. For sample measurements,
the MS processing method Linear High Mass Default defined the following peak
detection characteristics: Minimal signal-to-noise ratio (S/N) was set to 10, the
local noise window width to 250 m/z and the minimal peak width at the FWHM to
2.9 bins. The default settings were used for calibration with BSA as reference mass
on calibration spots.
3.2.3. Analysis of MALDI MS Linear Mode Data
MS spectra (.t2d files) were analysed using the Data Explorer® Software (Applied
Biosystems/MDS Analytical Technologies, Version 4.10 build 124). The Noise Fil-
ter/Smooth function was used for Gaussian peak smoothing. m/z at the peak max-
imum of the singly charged peak was extracted, average and the standard deviation
was calculated over the spectra acquired from the same sample. The difference to
the m/z of the unmodified BSA and the mass of the added reagent tag were used
to calculate the number of reagent tags added to one BSA molecule.
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3.3. In Vitro Validation
3.3.1. Cell Culture
HeLa cell line (luc+/GFP+) was obtained from Dr.Thomas Höfner (HI-STEM
gGmbH, Heidelberg, Germany). Cell line authenticity was confirmed by Multiplex-
ion GmbH (Heidelberg, Germany) via SNP-profiling of extracted DNA (DNeasy
Blood & Tissue Kit, Qiagen, 69504). The adherent cells were cultured in T75
yellow cap flasks (TPP, 90076) at 37◦C and 5% CO2 (Heracell™ 240i CO2 incuba-
tor, Thermo Scientific) in Iscove’s Modified Dulbecco’s Medium (IMDM) medium
(Gibco, 21980-032) supplemented with 10% fetal calf serum (FCS) (PAN Biotech,
3302-P273105). After reaching 70-80% confluence, cells were washed with 10 mL
PBS (Sigma, D8537) and detached with 5 mL 0.05% Trypsin/EDTA (Gibco, 25300-
054) for 5 min at 37◦C. The detaching solution was diluted with 5 mL of the cell
culture medium, the cell suspension was transferred to a 15 mL Falcon tube (TPP,
91015) and cells were pelletized at 300×g for 5 min. Cells were resuspended in 10 mL
cell culture medium and seeded in fresh cell culture flasks with 9 mL pre-warmed
cell culture medium in a ratio of 1 to 10.
For cryopreservation, HeLa cells were washed and detached as described previ-
ously. Pelletized cells were resuspended in cell culture medium supplemented with
5% DMSO (Sigma-Aldrich, 276855) and aliquoted in Cryo vials (Thermo Scientific,
375353). Cells suspensions were cooled to -80◦C within one day in a Mr. Frosty™
Freezing Container (Thermo Scientific, 5100) and long-term stored in liquid nitro-
gen. For thawing and cell recovery, cells were pre-warmed to 37◦C and immediately
transfered to 10 mL cell culture medium. Cells were pelletized at 300×g for 5 min,
resuspended in 10 mL cell culture medium and seeded in a cell culture flask.
3.3.2. In Vitro Biotinylation
24 h prior to in vitro biotinylation on the cell culture flask for subsequent pro-
teomic analysis, HeLa cells were washed, detached and pelletized as described in
chapter 3.3.1. Cells were resuspended in cell culture medium and counted with a
Neubauer chamber (Brand) using a two-fold dilution with 0.4% Trypan Blue Solu-
tion (Gibco, 15250). About 2.5×106 viable cells were seeded per cell culture flask.
For cell counting and the preparation of a negative control, four cell culture
flasks were washed twice with 10 mL PBS. Cells were detached with 10 mL 10 mM
ethylenediaminetetraacetic acid (EDTA) (Sigma, 03609) in PBS (Gibco, 18912014)
within 10 min at 37◦C. After pelletizing at 300×g for 5 min, HeLa cells were re-
suspended in PBS. The cell number was determined with a Neubauer chamber to
about 5×106 viable cells per cell culture flask.
For in vitro biotinylation on the cell culture flask, HeLa cells were washed twice
with PBS (Sigma, D8537) and overlayed with 4 mL PBS. Biotinylation reagents were
dissolved or diluted with 1 mL PBS directly before use and applied to the adherent
HeLa cells in a final concentration of 5 µmol per cell culture flask. Cells were
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incubated with the reagents for 5 min at 37◦C before quenching the reaction with
a ten-fold excess of a 0.1 M Tris solution (Sigma, T1503) in water. Subsequently,
the adherent cells were washed twice with 10 mL PBS followed by detachment with
10 mL 10 mM EDTA (Sigma, 03609) in PBS (Gibco, 18912014) within 20 min at
37◦C. After pelletizing at 300×g for 5 min, HeLa cells were resuspended in PBS.
During optimization of the biotinylation procedure with Biotin-Heparin-sNHS 9,
5 min pre-incubation of HeLa cells with 2 mg salmon sperm DNA (invitrogen, 15632-
011) in PBS before biotinylation was tested.
For assessment of the influence of the biotinylation procedure on the cell viability,
living and dead cells were counted in PBS after the detachment with a Vi-cell™ XR
(Beckmann Coulter) based on the Trypan Blue method. The biotinylation of ad-
herent cells on cell culture flask was performed with two commercial reagents Sulfo-
NHS-LC-biotin (ProteoChem, b2103) and NHS-PEG12-biotin (Thermo Scientific,
21313), two peptide-based reagents SMCC-Cys-(L-Asp)3-biotin 5 and SM(PEG)6-
Cys-(L-Asp)3-biotin 6 and two heparin-based reagents Biotin-Heparin-sNHS 9 and
Biotin-Enoxaparin-sNHS 10. Negative control cells were only treated with pure
PBS.
Whereas the biotinylation of cells for proteomic analysis was performed on adher-
ent cells as described previously, cells for subsequent FACS analysis for reactivity
assessment by labelling with different amounts of biotinylation reagent were biotiny-
lated in suspension to ensure exact and equal cell count per experiment. After wash-
ing twice with PBS on the cell culture flask, HeLa cells were detached with 10 mL
10 mM EDTA (Sigma, 03609) in PBS (Gibco, 18912014) within 10 min at 37◦C.
After pelletizing at 300×g for 5 min, cells were resuspended in PBS, counted with
a Neubauer chamber and equally aliquoted. Biotinylation reagents were dissolved
or diluted with PBS to a final concentration of 10 mM. 1×106 cells in 100 µL PBS
were incubated with different amounts (ratios) of biotinylation reagents: 0.06 nmol
(1 to 0.01), 0.6 nmol (1 to 0.1), 6 nmol (1 to 1), 60 nmol (1 to 10)). Ratios refer to
a median protein amount of 300 µg (6 nmol) protein content per 1×106 cells with
a median protein weight of 50 kDa.[130] The reaction was quenched with a ten-fold
excess of a 0.1 M Tris solution in water. Cells were pelletized, washed twice with
PBS and resuspended in FACS buffer (2% FCS (PAN Biotech, 3302-P273105) in
PBS).
3.3.3. Visualisation of Biotinylation
3.3.3.1. FACS Analysis
As a control of the biotinylation of adherent HeLa cells, fluorescence-activated cell
sorting (FACS) analysis was performed after biotinylation, detachment and cell
counting in PBS (see chapter 3.3.2). 500 000 cells were pelletized at 300×g for
5 min at 4◦C, resuspended in 500 µL FACS buffer (2% FCS in PBS) and kept on ice.
Staining solution was prepared under light protection as fifty-fold dilution of Strep-
tavidin Pacific Blue™ conjugate (Invitrogen, S-11222) in FACS buffer. For staining,
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cells were pelletized and incubated with 10 µL staining solution per 500 000 cells for
30 min on ice in the dark. After washing with 1 mL FACS buffer, cells were resus-
pended in 250 µL FACS buffer and filtered into FACS tubes (BD Falcon, 352053)
for analysis.
Differential FACS analysis of different amounts of biotinylation reagents on HeLa
cells (see chapter 3.3.2) was also performed by staining the biotinylated cells with
Streptavidin Pacific Blue conjugate according to the protocol described.
Cells were analysed at a medium flow rate with a CyAn™ ADP flow cytometer
(Beckmann Coulter) equipped with 488 nm, 405 nm and 635 nm lasers. At least
10 000 events were recorded using a forward scatter threshold of 0.1%. For Pacific
Blue, data were collected with the 405 nm laser 450/50 bandpass filter. PMT voltage
of the fluorescent channel was adapted with unstained cells to set negative events to
the first decade (log-scale). Flow cytometry data were recorded in peak, area and
log parameters with the CyAn™ ADP Software Summit 4.3 and exported in .fcs
format. Further analysis was performed with FlowJo (version 9.8.5). Viable cells
and singlet cells were gated based on forward scatter (FSC) and side scatter (SSC)
before histogram analysis of Pacific Blue staining.
3.3.3.2. Confocal Laser Scanning Microscopy
For visualization of plasma membrane protein biotinylation, 1×106 HeLa cells in
cell culture medium were seeded in a cell culture insert (1.0 µm, Falcon, 353102)
within a Multiwell™ 6-well plate (Falcon, 353502) and grown at 37◦C and 5% CO2
as described in chapter 3.3.1. After 24 h, cell culture medium was removed and
cells were washed twice with PBS. 3 µmol biotinylation reagent (Sulfo-NHS-LC-
biotin, NHS-PEG12-biotin, SMCC-Cys-(L-Asp)3-biotin, SM(PEG)6-Cys-(L-Asp)3-
biotin) were diluted in 1.5 mL PBS directly before use, pure PBS served as negative
control. Cell inserts were placed on 100 µL of the biotinylation solution on a clean
surface, cells were covered with the rest of the solution and incubated for 5 min
at room temperature. Cells and cell culture inserts were washed three times with
2 mL PBS, followed by 10 min fixation with 1 mL ice-cold methanol (Sigma-Aldrich,
34860) at -20◦C. After washing the cells and the cell insert with PBS, the cell insert
membrane was cut into four parts and stored overnight in 0.1 M glycine solution
(Sigma, G8898) in PBS in a 24-well cell culture plate (Greiner Bio-One, 662160) at
4◦C.
To perform staining for confocal laser scanning microscopy, membrane pieces were
washed for 15 min at room temperature in 0.2% Triton™ X-100 (Sigma-Aldrich,
X100) followed by 5 min in PBS. After transfer to parafilm in a moist chamber,
blocking was performed with 100 µL 10% goat serum (Sigma, G6767) in PBS for
30 min at room temperature. Staining solution was prepared as 200-fold dilution of
4’,6-diamidino-2-phenylindole (DAPI) (5 mg/ml in water, Sigma, D9542) and 200-
fold dilution of Streptavidin Alexa Fluor 488 conjugate (life technologies, S32354)
in 3% BSA in PBS. Membranes were washed with PBS and incubated with staining
solution in a moist chamber for 1 h at room temperature. Subsequent to three
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washing steps in 2 mL PBS, membrane pieces were transferred to a glass slide
(SuperFrost® Plus, Thermo, J1800AMNZ), mounted with Fluorescent Mounting
Medium (Dako, S3023), covered with a glass lid and stored under light protection
at 4◦C.
Slides were analysed with a LSM 700 Confocal Laser Scanning Microscope (Zeiss)
operated with ZEN 2012 software (black edition, Zeiss, version 8.0.5.273) using the
405 nm and 488 nm laser diodes and the EC-Plan-Neofluar 40x/1.3 oil DIC objective
(Zeiss, 420462-9900). Pictures were exported in .lsm format, scale bars were intro-
duced using the ZEN lite 2011 software (blue edition, Zeiss, version 6.1.7601). The
pictures presented in this thesis for direct comparison were taken using the same
laser characteristics and the same optimized contrast properties in the individual
channels for all samples within the analysis.
3.3.4. Cell Lysis
After biotinylation, washing and detachment (see chapter 3.3.2), biotinylated HeLa
cells were pelletized at 300×g for 5 min and resuspended in radioimmunoprecipita-
tion assay (RIPA) buffer (see Table 3.1) containing cOmplete EDTA-free protease
inhibitor cocktail (Roche, 04693132001) to a final concentration of 1×106 cells per
500 µL. The suspension was incubated on ice for 2 h and slightly vortexed from
time to time. Samples were stored at -20◦C overnight. Lysates were thawed and
homogenized on ice 3 times 30 s with a T 10 basic ULTRA-TURRAX® homoge-
nizer (IKA) at 20 000 rpm. Afterwards, samples were sonicated for 2 min with 1 s
pulses at 30% amplitude with the Sonifier® W-250D (Branson). Cell lysates were
centrifuged for 20 min at 20 000×g and 4◦C, supernatants were kept at -20◦C for
downstream analysis (see chapter 3.6.1).
Concentration Reagent Company Ordering No.
50 mM Tris Sigma-Aldrich T1503
150 mM NaCl Sigma-Aldrich 31434
1% NP-40 Sigma-Aldrich 74385
0.5% Sodium deoxycholate Sigma-Aldrich 30970
0.1% SDS Sigma-Aldrich L6026
water (deionized)
1 tablet/50 ml Protease inhibitor cocktail Roche 04693132001
Table 3.1.: RIPA buffer for cell lysis.
72
3.4. In Vivo Validation
3.4.1. Mouse Strain
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice from The Jackson Laboratory (Bar
Harbor, USA) were bred in the German Cancer Research Center (DKFZ) animal
facility. Mice were kept under specific pathogen-free conditions in individually venti-
lated cages. Experiments have been performed with untreated female mice at 18-26
weeks of age. All animal handling and procedures followed german legal regula-
tions and were previously approved by the national authorities (Regierungspräsid-
ium Karlsruhe, TVA number G134/12).
3.4.2. In Vivo Perfusion of Mice
The in vivo perfusion of the vascular system was performed according to the proto-
col of Rösli et al.[185] Perfusion solutions were kept at 40◦C, biotinylation reagents
were dissolved directly before use. Mice were anaesthetized with a mixture of 200 µg
Ketamin (Ketavet, Parke-Davis), 20 µg Xylazin (Rompun, Bayer) and 3 µg Acepro-
mazin (Vetranquil, Ceva) per g of body weight. After complete loss of toe pinch
reflexes, the animal was fixed with tape on a pre-warmed surgery table (Hugo Sachs
Elektronik) with the head on the lower side. Abdominal cavity was opened by dis-
secting the skin and the peritoneum. A median sternotomy was performed followed
by the insertion of a butterfly needle with a small barb into the left ventricle. The
needle was connected to a syringe pump (LA-30, Landgraf Laborsysteme) via Hei-
delberger extensions (B.Braun, 4097300) and a three way valve (Discofix®, B. Braun,
4098102). A small cut was made in the right atrium to allow blood and perfusion
solutions to flow out. The pump was set to a constant flow rate of 1.1 mL/min.
Tubing was pre-filled with 2.5 mL filtered and pre-warmed perfusion solution (10%
Dextran-40 000MW (US Biological, D6030) in PBS). Perfusion was performed using
25 µmol biotinylation reagent in 11 mL pre-warmed perfusion solution, followed by
perfusion with 11 mL of quenching solution (50 mM Tris (Sigma, T1503) in 10%
Dextran in PBS). To inactivate non reacted biotinylation reagent after the whole
body perfusion, the thoracic and abdominal cavity were continuously washed with
sprinkling solution (50 mM Tris in PBS) during the perfusion with biotinylation
reagent and during the first 5 min of the perfusion with the quenching reagent.
Mice were divided into eight perfusion groups: Perfusions were performed with two
commercial reagents Sulfo-NHS-LC-biotin (ProteoChem, b2103) and NHS-PEG12-
biotin (Thermo Scientific, 21313), two peptide-based reagents SMCC-Cys-(L-Asp)3-
biotin 5 and SM(PEG)6-Cys-(L-Asp)3-biotin 6 as well as two heparin-based reagents
Biotin-Heparin-sNHS 9 and Biotin-Enoxaparin-sNHS 10. Negative control mice
were either perfused with pure perfusion solution or stayed unperfused.
After perfusion, liver, kidneys, spleen, tongue and brain were excised, separated
from connective tissue or fat and the renal capsule was removed. Small parts of
the organs were embedded in Tissue-Tek® O.C.T.™ medium (Sakura, 4583) and
73
stored in embedding molds (Polysciences, 18986) at -80◦C for subsequent immuno-
histochemical analysis (see chapter 3.4.3.1). The main part of liver and kidney tissue
was snap-frozen in liquid nitrogen and stored at -80◦C for protein extraction and
proteomic analysis (see chapters 3.4.4, 3.6.2).
3.4.3. Visualization of Biotinylation
3.4.3.1. Confocal Laser Scanning Microscopy
Small parts from kidney, liver, spleen, tongue and brain tissue of perfused mice (see
chapter 3.4.2) embedded in Tissue-Tek® O.C.T.™ medium (Sakura, 4583) were
cut into 8 µm sections using a Microm™ HM 525 cryotome (Thermo Scientific).
Two sections per object were mounted on a glass slide (SuperFrost® Plus, Thermo,
J1800AMNZ). Slide were stored at -80◦C until staining.
Before staining, sections were fixed in acetone (Sigma-Aldrich, 32201) at -20◦C for
8 min. After drying at room temperature, Daco silico pen (Dako, S2002) was applied
around the individual sections. Samples were transferred to a moist chamber and
blocked with 20% goat serum (Sigma, G6767) in PBS for one hour at room temper-
ature. Slides were washed for 5 min with PBS and incubated at room temperature
with a 200-fold dilution of primary antibody (Rat anti-mouse CD31 antibody, BD
Biosciences, 550274) in 12% BSA (Sigma-Aldrich, A2153) in PBS in a moist cham-
ber for 2 h. Control stains were treated on the same slide with 12% BSA in PBS
without the primary antibody. The slides were rinsed three times with PBS before
incubation with a 250-fold dilution of secondary antibody (Alexa Fluor 594 Goat
Anti-Rat IgG, life techologies, A11007), 200-fold dilution of DAPI (5 mg/ml in wa-
ter, Sigma, D9542) and 250-fold dilution of Streptavidin Alexa Fluor 488 conjugate
(life technologies, S32354) in 12% BSA in PBS in a moist chamber for 1 h. The con-
trol stains were performed without Streptavidin Alexa Fluor 488 conjugate. After
washing the slides three times with PBS, sections were mounted with Fluorescent
Mounting Medium (Dako, S3023) and stored at 4◦C under light protection.
Slides were analysed with a LSM 700 Confocal Laser Scanning Microscope (Zeiss)
operated with ZEN 2012 software (black edition, Zeiss, version 8.0.5.273) using
405 nm, 488 nm and 555 nm laser diodes and the Plan-Apochromat 20x/0.8 objec-
tive (Zeiss, 420650-9901). Pictures were exported in .lsm format, scale bars were
introduced using the ZEN lite 2011 software (blue edition, Zeiss, version 6.1.7601).
The pictures presented in this thesis for direct comparison were taken using the
same laser characteristics and the same optimized contrast properties in the indi-
vidual channels for all samples within the analysis.
3.4.4. Protein Extraction of Kidney and Liver Tissue
Snap-frozen kidney and liver of perfused mice (see chapter 3.4.2) were weighed and
hackled tissue was transferred into 15 ml Falcon tubes (TPP, 91015). Protein ex-
traction buffer (see Table 3.2) was added to a final concentration of 25 µL per mg
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kidney tissue and 20 µL per mg liver tissue. Samples were homogenized for 10 min
with a T 10 standard ULTRA-TURRAX® homogenizer (IKA) at 26 000 rpm fol-
lowed by 2 min sonication with 1 s pulse time and 35% intensity using Sonifier®
W-250D (Branson). Tissue homogenates were transferred to 2 ml tubes (eppendorf,
0030120094) and heated to 95◦C for 20 min in a thermomixer (eppendorf). Remain-
ing tissue debris was pelletized at 20 000×g for 20 min at room temperature. The
supernatant was aliquoted and stored at -20◦C for a maximum period of one year
for proteomic analysis (see chapter 3.6.2).
Concentration Reagent Company Ordering No.
2% SDS Sigma-Aldrich L6026
50 mM Tris Sigma-Aldrich T1503
10 mM EDTA Sigma-Aldrich 03609
water (deionized)
50 mM HCl (ad pH 7.0) Sigma-Aldrich 30721
1 tablet/50 ml Protease inhibitor cocktail Roche 04693132001
Table 3.2.: Protein extraction buffer for tissue samples.
3.5. Protein Concentration Determination of Lysates
and Assessment of Biotinylation
3.5.1. Protein Concentration Determination
Protein concentrations of cell lysates and tissue homogenates were determined using
the Pierce™ BCA Protein Assay Kit (Thermo Scientific, 23225). A BSA standard
curve (Thermo Scientific, 23209) was prepared in water in a concentration range
from 1-2000 µg/mL. Microplate procedure with 20 µL sample in duplicate measure-
ments was applied, working reagent was prepared as fifty-fold dilution of reagent B
in reagent A according to the manufacturer’s protocol. The microplate was incu-
bated at room temperature for 30 min before measuring 562 nm absorbance with
a plate reader (SpectraMax® M5, Molecular Devices) operated with SoftMax® Pro
software (version 5.4). Cell lysates were measured undiluted, tissue homogenates in
a five-fold dilution in water. Averaged sample values out of duplicate or triplicate
measurements were corrected by sample buffer absorbance in the dilution used for
the corresponding samples.
3.5.2. ELISA
The ELISA was performed on 96-well MaxiSorp Nunc-Immuno Polystyrene Plates
(Thermo Scientific, 442404) or 96-well Half Area High Bind Polystyrene Plates
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(Corning, 3690). 0.1 nmol protein in 100 µL water were applied per well, i.e. 7.1 µg
kidney or liver protein according to an average protein mass of 71 000 Da.[280]
The ELISA standard curve used for relative quantification of the biotin content
among the samples was generated by combination of different ratios of biotinylated
and unbiotinylated BSA (in water, 1 mg/mL stock each) to a total concentration of
0.1 nmol in 100 µL (6.65 µg in 100 µL). For preparation of the ELISA standard, bi-
otinylation of BSA in PBS (Sigma, A2153) was performed with Sulfo-NHS-LC-biotin
in a 1 to 10 ratio as described in chapter 3.2.1. Biotinylated BSA was purified using
Vivaspin 15R columns (Sartorius, VS15RH01) with three washing steps (15 mL wa-
ter, 15 min, 3000×g) and three elution/rinsing steps using 5 ml water each. Protein
concentration of the purified product was determined as described in chapter 3.5.1
and adapted with water to a final concentration of 1 mg/mL. Standard curve was
prepared in a concentration range of 0-0.5 µg biotinylated BSA with six narrow
intervals from 0-0.1 µg.
ELISA plates were coated with 0.1 nmol protein (ELISA standard curve or sam-
ple) in 100 µL water per well and incubated overnight at 4◦C. Wells were washed
three times with PBS and free binding sites were blocked with 2% BSA in PBS
(1 h, room temperature). After washing with PBS, 100 µL Streptavidin-horseradish
peroxidase (HRP) solution (1:1000 in 2% BSA in PBS, GE Healthcare, RPN 1231)
was incubated on the wells for 1 h at room temperature. Wells were washed three
times with 0.1% Tween® 20 (Sigma-Aldrich, P1379) in PBS and three times with
PBS. For detection, 100 µL (50 µL on half area plates) BM Blue POD Substrate so-
lution (Roche, 11484281001) were applied. The colour reaction was quenched after
5-20 min with 70 µL (35 µL on half area plates) 1 M sulfuric acid (Sigma-Aldrich,
258105). Absorbance at 450 nm subtracted by absorbance at 690 nm was measured
with a plate reader (SpectraMax® M5, Molecular Devices) operated with SoftMax®
Pro software (version 5.4). For analysis, averaged sample values out of duplicate or
triplicate measurements were corrected by sample buffer absorbance.
3.5.3. SDS-PAGE and Western Blot
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was con-
ducted using the XCell SureLock™ Mini-Cell Electrophoresis System (Invitrogen)
with NuPAGE® Novex® 4-12% Bis-Tris, 1.5 mm, 10- or 15-well gels (Life Technolo-
gies) and 1x NuPAGE® MOPS SDS Running Buffer (Life Technologies, NP0001).
5x Loading Buffer (see Table 3.3) and, if performed under reducing conditions, 10x
DTT (500 mM in water, Sigma-Aldrich, D9779) was added to the samples to a
final 1x concentration and heated to 95◦C for 10 min before loading on the gel.
PageRuler™ Plus Prestained Protein Ladder (Life Technologies, 26619) or Spec-
tra™ Multicolor Broad Range Protein Ladder (Life Technologies, 26634) were used
as markers. Gels were run for 1 h at 180 V and stained with the one-step Coomassie
based InstantBlue™ gel stain (Expedeon, ISB1L) for 1 h at room temperature.
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Concentration Reagent Company Ordering No.
208 mM Tris-HCl (pH 6.8) Sigma-Aldrich T1503, 30721
33% Glycerine Sigma-Aldrich G6279
5% SDS Sigma-Aldrich L6026
0.06% Bromophenol Blue Sigma-Aldrich B8026
water (deionized)
Table 3.3.: 5x Gel loading buffer.
Western Blots were performed as semi-wet transfer using the XCell II™ Blot Mod-
ule (Invitrogen) with Immobilon-P PVDF transfer membranes (Millipore, IPVH-
00010). Biotinylated protein samples as well as Biotin-Heparin-sNHS 9 were run in
NuPAGE® Novex® 4-12% Bis-Tris, 1.5 mm, 10- or 15-well gels (Life Technologies)
and blotted during 90 min at 30 V using 1x Transfer Buffer (see Table 3.4) containing
10%Methanol (Sigma-Aldrich, 34860). Free binding sites on the transfer membranes
were blocked in 4% milk powder (Sigma-Aldrich, 70166) in PBS overnight at 4◦C,
followed by incubation with Streptavidin-HRP solution (1:1000 in 2% Milk Powder
in PBS, GE Healthcare, RPN 1231) for 30 min at room temperature. Transfer mem-
branes were washed twice with 0.1% Tween® 20 (Sigma-Aldrich, P1379) in PBS and
twice with PBS. For detection, Amersham® ECL® Prime Western Blotting Detec-
tion Reagents A and B (GE Healthcare, RPN2232) were used in five-fold dilution in
water. Western Blot CL-XPosure™ films (Thermo, 34090) were incubated on the
transfer membrane in a film cassette (Hypercassette™, GE Healthcare, RPN12642)
and developed in a Classic EOS film developing machine (AGFA).
Concentration Reagent Company Ordering No.
0.5 M Bicine Sigma-Aldrich B3876
0.5 M Bis-Tris Sigma-Aldrich B9754
20 mM EDTA Sigma-Aldrich 03609
1 mM Chlorobutanol hemihydrat Sigma-Aldrich 112054
water (deionized)
Table 3.4.: 20x Western blot transfer buffer.
3.6. Sample Preparation for Mass Spectrometric
Analysis
3.6.1. Capturing of Surface Proteins out of Cell Lysates
Cell lysates of biotinylated HeLa cells were prepared and protein concentration was
determined as described in chapters 3.3.4 and 3.5.1. Samples were processed by
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capturing of biotinylated proteins out of 500 µg total protein amount on streptavidin-
sepharose resin under reductive conditions, followed by alkylation, tryptic digest and
desalting for proteomic analysis.
100 µL Streptavidin-sepharose slurry (GE Healthcare, 17-5113-01) per tube were
prepared by washing three times with 500 µL 1% 4-nonylphenyl-polyethylene glycol
(NP-40) (Sigma, 74385), 0.1% sodium dodecyl sulfate (SDS) (Sigma, L6026) in PBS
(termed Wash Buffer in the following). Cell lysate with a total protein content of
500 µg was added to the washed streptavidin-sepharose. 2 mM TCEP (BioVision,
1202) in 20% SDS in PBS were added to a final concentration of 2% SDS, followed
by 2 h tumbling (tube rotator, Cole-Parmer) at room temperature. After the incu-
bation period, the streptavidin-sepharose with the captured proteins was separated
from the supernatant by centrifugation at 300×g for 30 s at room temperature.
After resuspending the streptavidin-sepharose in 500 µL Wash Buffer, the slurry
was transferred to a centrifugal filter tube (Ultrafree®-MC SV Centrifugal Filters,
Merck Millipore, UFC30SV00) for washing. The filter device was centrifuged at
300×g for 30 s, flow-through was discarded. The streptavidin-sepharose was washed
twice with 150 µL 50 mM iodoacetamide (IAA) (Sigma-Aldrich, I1149) in PBS be-
fore resuspending in 150 µL of the IAA solution and transferring to a new tube.
The filter tube was rinsed twice with another 150 µL of the IAA solution, yielding
a total volume of about 500 µL streptavidin-sepharose in IAA solution. Samples
were incubated for 30 min in the dark before quenching the alkylation reaction with
300 µL 100 mM L-cysteine (Sigma-Aldrich, 30089) in water. After 15 min of incuba-
tion, streptavidin-sepharose was separated from the supernatant by centrifugation at
300×g for 30 s, resuspended in 500 µL Wash Buffer and transferred to a centrifugal
filter device. The streptavidin-sepharose was washed ten times with 500 µL 50 mM
Tris-HCl (Sigma-Aldrich, T1503, 30721), 1 mM CaCl2 (Sigma-Aldrich, C4901) in
water, pH 8 (termed Tryptic Digestion Buffer in the following), before transferring
it in two steps in a total of 1 ml Tryptic Digestion Buffer to a new tube. After
centrifugation at 300×g for 30 s, supernatant was discarded and 200 µL Tryptic
Digestion Buffer were added. The tryptic digest was carried out using 1.6 µg Se-
quencing Grade Modified Trypsin (20 µg vial in 250 µL Tryptic Digestion Buffer,
Promega, V511A) for 10 h at 37◦C at 1000 rpm. The modified enzyme provides
resistance to autolytic digestion as well as high tryptic specificity as a consequence
of tosylphenylalanylchloromethylketone (TPCK) treatment.
Following tryptic digest, the streptavidin-sepharose slurry was transferred to a
centrifugal filter device and the digest was separated from the beads by centrifu-
gation at 300×g for 1 min, the flow-through was kept. For desalting, 2.2 µL 10%
TFA (ProteoChem, LC6203) were added to a final concentration of 0.1% TFA. De-
salting was carried out using OMIX C18 pipette tips (100 µL, Agilent Technologies,
A57003100). The desalting tips were wetted twice with 50% UPLC/MS grade ace-
tonitrile (Biosolve, 012041) in UPLC/MS grade water (Biosolve, 232141), followed
by two times equilibration with 0.1% TFA in UPLC/MS grade water. Proteins were
bound to the resin by aspirating the sample solution twenty times into the tip. The
desalting tips were washed three times with 0.1% TFA in water. Elution was per-
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formed by aspirating ten times 75% acetonitrile, 0.1% TFA in water. Samples were
dried in a vacuum concentrator (RVC 2-25 CDplus, Christ) and stored at -20◦C for
subsequent LC/MS analysis.
During optimization of the heparin sample capturing procedure, the following
steps were included after alkylation of the captured proteins on the streptavidin-
sepharose beads: (i) Washing with high-salt buffer: five washing steps with 0.1%
SDS, 2 M NaCl (Sigma-Aldrich, 31434) in PBS; (ii) Washing with pH shift: 3× three
washing steps, 10 mM phosphate buffer (Sigma-Aldrich, 71500, 30412, 222003), 0.1%
SDS (pH 5, pH 8, pH 12); (iii) Carbonate extraction: tumbling for 1 h at 4◦C in
1 mL 100 mM sodium carbonate (Sigma-Aldrich, S7795), pH 11; (iv) Delipida-
tion: tumbling for 30 min at room temperature in 400 µL Wash Buffer, 800 µL
1-butanol/diisopropylether solution (40:60, Chemsolute, 2513, AppliChem, A4322).
3.6.2. Capturing of Vascular Accessible Proteins out of Kidney
and Liver Tissue Homogenates
Homogenates of perfused mouse kidney and liver tissue were prepared and protein
concentration was determined as described in chapters 3.4.4 and 3.5.1. Samples were
processed by capturing of biotinylated proteins out of 1.25 mg total protein amount
of kidney homogenate or 2.55 mg of liver homogenate on 100 µL streptavidin-
sepharose resin under reductive conditions, followed by alkylation, delipidation,
tryptic digest and desalting for proteomic analysis.
The procedure follows the protocol described in chapter 3.6.1, but includes a
delipidation step: After alkylation and quenching with L-cysteine, 400 µL Wash
Buffer and 800 µL 1-butanol/diisopropylether solution (40:60, Chemsolute, 2513,
AppliChem, A4322) were added to the streptavidin-sepharose and tumbled for
30 min at room temperature. After centrifugation at 300×g for 30 s, the solvent
phase and the water phase were discarded and the streptavidin-sepharose was washed
once with 500 µL Wash Buffer. Following resuspension in 500 µL Wash Buffer,
the streptavidin-sepharose slurry was transferred to a centrifugal filter device and
washed with Tryptic Digestion Buffer as already described.
Desalting of kidney samples was carried out using OMIX C18 pipette tips (100 µL,
Agilent Technologies, A57003100), whereas the liver samples were desalted in par-
allel using a 96-well, C18 Lab-in-a-plate Flow-Thru Plate (Glygen, FNSC18) with
3 min, 200×g centrifugation steps: Wells were wetted with 200 µL 50% UPLC/MS
grade acetonitrile (Biosolve, 012041) in UPLC/MS grade water (Biosolve, 232141),
followed by equilibration with 200 µL 0.1% TFA in UPLC/MS grade water. Samples
were applied on the wells in three steps. The plate was washed three times with
0.1% TFA in water. Elution was performed with 100 µL 75% acetonitrile, 0.1%
TFA in water in three steps. Samples were dried in a vacuum concentrator (RVC
2-25 CDplus, Christ) and stored in Protein LoBind tubes (Eppendorf, 022431081)
at -20◦C for subsequent LC/MS analysis.
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During optimization of the procedure, the following steps were tested on kidney
samples (capturing of biotinylated proteins out of 2.00 mg total protein): (i) Washing
after alkylation with high-salt buffer: three steps, 1% NP-40 (Sigma, 74385), 0.1%
SDS (Sigma, L6026), 2 M NaCl (Sigma-Aldrich, 31434) in PBS; (ii) Pre-blocking
the streptavidin-sepharose before capturing: washing streptavidin-sepharose as de-
scribed, 2 h tumbling at room temperature with 750 µL 10 mg/mL BSA solution
before capturing sample homogenate; (iii) Ultracentrifugation of samples before tak-
ing the supernatant for capturing: 1 h, 100 000×g (Sorvall Discovery M120SE,
Thermo Scientific); (iv) Benzonase treatment of samples before capturing: chlo-
roform/methanol precipitation (see chapter 3.6.3), resolubilisation in 4 M urea
(Sigma-Aldrich, 33247), 0.1% Triton™ X-100 (Sigma-Aldrich, X100), 100 mM Tris
(Sigma-Aldrich, T1503), 1 mM magnesium chloride (Sigma-Aldrich, M8266), incu-
bation with 250 U benzonase nuclease (Novagen) per mL lysate for 30 min at room
temperature.
3.6.3. Preparation of Full Proteome Samples from Kidney and
Liver Tissue Homogenates
Protein concentration of kidney and liver homogenates of PBS-perfused or unper-
fused mice was determined as described in chapter 3.5.1. 200 µg protein samples
were processed by reduction, alkylation and precipitation, followed by tryptic digest
and desalting for proteomic analysis.
Tissue homogenate with 200 µg protein content was incubated in a 5 mM TCEP
solution (50 mM in water, BioVision, 1202) for 30 min at 60◦C. Alkylation was
performed by incubation in 15 mM IAA solution (100 mM in water, Sigma-Aldrich,
I1149) for 30 min at 37◦C in the dark. 100 µg protein aliquots per sample were pre-
cipitated with chloroform/methanol as described previously.[281] Briefly, the protein
solution was diluted with 4 volumes of methanol (Sigma-Aldrich, 34860), 1 volume
chloroform (Roth, 7331.2), 3 volumes of water and centrifuged for 2 min at 15 000×g.
The upper organic phase was discarded, 4 volumes of methanol were added and the
proteins were pelletized for 2 min at 15 000×g. The protein pellets were resolubi-
lized in 0.1% RapiGest™ SF Surfactant (Waters, 186001861) in Tryptic Digestion
Buffer (50 mM Tris-HCl, 1 mM CaCl2 in water, pH 8) by sonication (Ultrasonic
Cleaner, VWR) for 20 min and digested with trypsin (1:50, w/w, Promega, V511A)
for 16 h at 37◦C and 1200 rpm. Samples were acidified to 0.5% TFA (10% TFA
in water, ProteoChem, LC6203) and incubated for 30 min at 37◦C at 1200 rpm.
Acidified protein solutions were separated from insoluble detergent by-products by
10 min centrifugation at 20 000×g. Samples were desalted using a 96-well, C18 Lab-
in-a-plate Flow-Thru Plate (Glygen, FNSC18) as described in chapter 3.6.2, dried
in a vacuum concentrator (RVC 2-25 CDplus, Christ) and stored in Protein LoBind
tubes (Eppendorf, 022431081) at -20◦C for subsequent LC/MS analysis.
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3.7. Mass Spectrometric Analysis
3.7.1. Discovery Experiment
3.7.1.1. UPLC-Based Separation
Prior to MALDI-MS analysis, samples were separated by a nanoACQUITY UPLC
system (Waters) equipped with a nanocapillary, reversed-phase Peptide BEH C18
nanoACQUITY Column, 130 Å pore size, 1.7 µm particle size, 75 µm x 250 mm
(Waters, 186003545) or a M-Class Peptide BEH C18 Column, 130 Å pore size,
1.7 µm particle size, 75 µm x 250 mm (Waters, 186007484, used for liver samples, see
chapter 3.6.2). Column temperature was set to 45◦C. Separation was achieved with
a 110 min gradient (see Table 3.5) of solvent A (UPLC/MS grade water, Biosolve,
232141, with 0.1% TFA, ProteoChem, LC6203) and solvent B (UPLC/MS grade
acetonitrile, Biosolve, 012041, with 0.1% TFA, ProteoChem, LC6203) at a flow rate
of 350 nL/min. 7.9 µL (in vitro validation) or 7.3 µL (in vivo validation) of each
Time (min) % A % B
0 95 5
0.33 89 11
1 89 11
3.66 86 14
67.66 70 30
81 60 40
90 15 85
95 15 85
97 95 5
110 95 5
Table 3.5.: UPLC gradient used for discovery experiment. A step-wise increased, linear
gradient of solvent B (acetonitrile, 0.1% TFA) in solvent A (water, 0.1% TFA) was applied
for peptide elution.
sample were injected by partial loop injection and loaded on the column within
40 min (5% solvent B). Samples were separated into 1200 fractions by spotting on
a Opti-TOF™ LC/MALDI target plate (AB SCIEX, 1018497) using a SunCollect
MALDI Spotter (SunChrom) with 10 min delay time, 4 s per spot and 2 µL/min
matrix flow rate. Eluted fractions were thereby robotically mixed with α-cyano-4-
hydroxycinnamic acid (CHCA) matrix (3 mg/mL, in 80% acetonitrile, 0.1% TFA
in water, ProteoChem, p9100) combined with four internal standard peptides (see
Table 3.6). Standard peptide mixture was prepared out of 0.333 nmol/µL stock
solutions of the single peptides in 50% acetonitrile, 0.1% TFA in water, aliquoted
and dried in a vacuum concentrator to be mixed with 2 mL CHCA matrix directly
before use. MALDI target plates were stored dry at -20◦C for subsequent MALDI-
MS analysis.
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Peptide Sequence [M+H]+ c (fmol/µL) fmol/spot
EEQPSTPAPKVEQQEEILC 2155.0231 300 40
CLEHMYHDLGLVRDF 1846.8732 150 20
TGVFDEAIRTVGF 1411.7221 75 10
TVFDEAIR 951.0688 37.5 5
Table 3.6.: Internal standard peptides. Standard peptides were spiked into CHCA sample
matrix in the given concentration. Per spot, 133 nL were mixed with eluted peptide
fractions (23 nL) before being deposited on a MALDI target plate.
For in vitro validation, peptides derived from a total protein amount of 500 µg
were subjected per LC/MS run. Kidney samples were derived from 750 µg, liver
samples from 1.25 mg total protein amount per LC/MS run.
3.7.1.2. MS Acquisition (MALDI-TOF System)
Mass spectrometric analysis was performed on a MALDI TOF/TOF™ 5800 system
(AB SCIEX) using the TOF/TOF™ Series Explorer™ Software (AB SCIEX, version
V4.1.0) with oracle database schema version 4.0.0, data version 4.0.5.
MS1 spectra acquisition was performed with MS Reflector Positive as operating
mode within the MS acquisition methodMS_reflector (orMS_reflector_1000Shots).
Mass range was set to 750-4000 Da (focus mass 2000 Da). 250 shots per sub-
spectrum were acquired, 8 (4) subspectra were accumulated (total: 2000 (1000)
shots per spectrum). During acquisition, the sample plate was moved with contin-
uous stage motion with a stage velocity of 1000 µm/s. The digitizer used 0.5 ns
bin size with a vertical scale of 0.5 (V full scale), a vertical offset of -0.5 (% full
scale) and an input bandwidth of 1000 MHz. Laser pulse rate was set to 400 Hz.
Detector voltage multiplier was always adjusted following general maintenance of
the instrument. The Y2 and X2 deflector voltages were manually adjusted before
sample measurement using the MS processing method MS_Reflector_Internal_new
and five internal standard peptides as reference masses, that were deposited manu-
ally on calibration spots (see Table 3.7). The reference peptides were prepared by
mixing one Peptide Calibration Standard Set vial (ProteoChem, s6104) with one
ACTH 18-39 vial in UPLC-grade water to a stock solution with a final concentra-
tion 200 µg/mL per peptide. The stock solution was stored and twenty-fold diluted
with CHCA matrix solution before use. For calibration, 0.5 m/z were taken as mass
tolerance, maximal outlier error was 10 ppm. The laser intensity was adjusted on
a sample spot using the MS processing method MS_Reflector_3IntPeptides and
the internal standard peptides as reference masses (see Table 3.6). For sample
measurements, the MS processing method MS_Reflector_3IntPeptides defined the
following peak detection characteristics: Minimal S/N was set to 5, the local noise
window width to 250 m/z and the minimal peak width at the FWHM to 1 bin.
Raw spectrum filtering contained peak smoothing with FFT and Poisson Denoise.
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Protein name Peptide Sequence [M+H]+ c (pmol/µL)
Leu-Enkephalin YGGFL 556.277 18
Gonadoliberin pEHWSYGLRPG 1182.581 8.4
Angiotensin I DRVYIHPFHL 1296.685 7.7
Neurotensin pELYENKPRRPYIL 1690.928 5.9
ACTH 18-39 RPVKVYPNGAEDESAEAFPLEF 2465.199 4.0
Table 3.7.: Standard peptides for calibration. Standard peptides were spiked into the
CHCA matrix in the given concentration. 0.8 µL per spot were manually deposited on
the eight calibration spots on the MALDI target plate.
Monoisotopic peaks were flagged using H adduct and the generic formula C6H5NO.
Cluster area S/N optimization was performed with a S/N threshold of 20. For inter-
nal calibration, the four internal peptides spiked into the sample matrix were used
as reference masses (see Table 3.6). Only monoisotopic peaks were used, 0.3 m/z
were taken as mass tolerance, maximal outlier error was 10 ppm. After sample plate
alignment, MS analysis was submitted as batch acquisition with plate model and
default calibration.
MS/MS spectra acquisition was performed with MS-MS 1KV Positive as oper-
ating mode within the MS/MS acquisition method MSMS_DynamicExit. Collision
induced dissociation and automatic acquisition control were activated. Metastable
suppressor was selected, 250 shots per sub-spectrum were acquired and a maximum
of 12 subspectra were accumulated (total: 3000 shots per spectrum) or stopped
when the final spectrum reached the desired quality (high). During acquisition,
the sample plate was moved with continuous stage motion with a stage velocity of
1200 µm/s. The digitizer used 1.0 ns bin size with a vertical scale of 0.5 (V full
scale), a vertical offset of 0.1 (% full scale) and an input bandwidth of 200 MHz.
Laser pulse rate was set to 1000 Hz. Detector voltage multiplier was always adjusted
following general maintenance of the instrument. Y2 and X2 deflector voltages, TIS
offset and the laser intensity were manually adjusted before sample measurement us-
ing the MS/MS acquisition method MSMS_Tune (total: 2000 shots per spectrum)
and the MS/MS processing method MSMS_Positive_Internal_Cal_2465 using the
1326.6800 m/z fragment of the ACTH peptide as reference mass, that was deposited
manually on calibration spots (see Table 3.7). 0.4 m/z were taken as mass toler-
ance, maximal outlier error was 0.05 m/z. For sample measurements, the processing
method MSMS_Default defined the following peak detection characteristics: Mini-
mal S/N was set to 15, the local noise window width to 250 m/z and the minimal
peak width at the FWHM to 1.5 bins. Raw spectrum filtering contained Savitsky-
Golay smoothing of peaks with 5 points across the peak and polynomial order 4.
Monoisotopic peaks were flagged using H adduct and the generic formula C6H5NO.
Cluster area S/N optimization was performed with a S/N threshold of 15. The inter-
pretation method for sample runs triggering the acquisition and processing method
was LC_Precursor_Selection_Dynamic_Exit (or LC_Precursor_Selection_Dyna-
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mic_Exit_StrongestFirst, used for tissue samples) with a mass range of 750-4000 Da
and a minimum S/N filter of 50. A maximum of 35 precursors per fraction was se-
lected (maximum of 40 000 per LC run) and, based on MS1 intensity, weakest (or
strongest) precursor was acquired first. After sample plate alignment, MS/MS anal-
ysis was submitted as batch acquisition.
3.7.2. SRM Analysis
3.7.2.1. Peptide Selection
Based on the SRM Atlas data (www.srmatlas.org, March 2015) for human and
mouse, up to five proteotypic peptides per target protein were selected for selected
reaction monitoring (SRM). Mouse-specificity and proteotypicity of the selected can-
didate peptides as well as the existance of a tryptic cleavage site before the target
sequence was tested using PepSir (see chapter 3.8.3) and the NCBI Protein Blast®
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) with peptide sequence information from
UniProt database (www.uniprot.org, March 2015). Peptides were restricted to a
mass range of 600-2000 Da, methionine and cysteine containing peptides were ex-
cluded if possible. To determine the levels of the endogenous target peptides in
kidney and liver mouse samples, heavy peptide standards corresponding to their
natural counterparts (light) were synthesized with heavy isotopic lysine (13C615N2)
or arginine (13C615N4) at the C-terminus (Intavis, Heidelberg, Germany), pooled and
spiked into the digested and desalted samples to a final concentration of 0.5 pmol/µL.
3.7.2.2. UPLC-Based Separation
Samples subjected to SRM analysis were separated by a nanoACQUITY UPLC
system (Waters) equipped with a nanocapillary, reversed-phase M-Class Peptide
CSH C18 Column, 130 Å pore size, 1.7 µm particle size, 300 µm x 150 mm (Wa-
ters, 186007563). Column temperature was set to 55◦C. Separation was achieved
with a 120 min gradient (see Table 3.8) of solvent A (UPLC/MS grade water, Bio-
solve, 232141, with 0.1% FA, 0.01% TFA, ProteoChem, LC6202) and solvent B
(UPLC/MS grade acetonitrile, Biosolve, 012041, with 0.1% FA, 0.01% TFA, Pro-
teoChem, LC6202) at a flow rate of 6 µL/min. 10 µL of each sample were injected
by full-loop injection (overfill factor 1.3, kidney samples or 1.1, liver samples) and
loaded on the column within 4 min (3% solvent B).
For in vivo kidney validation, peptides derived from 1.5 mg total protein amount
were subjected per SRM experiment and peptides from 1.4 mg total protein amount
for the liver samples. For the full proteome kidney and liver samples, peptides
derived from 40 µg precipitate were analysed per run.
3.7.2.3. SRM Acquisition
SRM analysis was performed on a QTRAP® 6500 system (AB SCIEX) operated
with Analyst® software (version 1.6.2 build 8489). For peptide identity confirma-
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Time (min) % A % B
0 97 3
1 96 4
110 70 30
111 15 85
114 15 85
115 97 3
119 97 3
Table 3.8.: UPLC gradient used for SRM experiment. A step-wise increased, linear gradi-
ent of solvent B (acetonitrile, 0.1% FA, 0.01% TFA) in solvent A(water, 0.1% FA, 0.01%
TFA) was applied for peptide elution.
tion and SRM method optimization/validation, IDA runs were performed on the
heavy peptide pool. Using the positive mode, Enhanced MS spectra were acquired
with a scan speed of 10 000 Da/s in a mass range of 400-2000 Da, followed by En-
hanced Resolution MS spectra acquisition of the three most intense peaks in the
individual spectra with a scan speed of 50 Da/s. Selection criteria included only
ions in a mass range of 450-2000 Da with charge state +2 or +3. Former target
ions were excluded for 1 min after 15 occurrences. Rolling collision energy was used,
mass tolerance was set to 250 mDa, isotopes within a 4 Da window were excluded.
Enhanced resolution scans were used to confirm charge states by the isotope pat-
tern. MS/MS spectra were acquired in the trap mode (Enhanced Product Ion) with
dynamic fill time, a mass range of 100-2000 Da and a scan speed of 10 000 Da/s. To
confirm peptide identity, .wiff files were searched in the ProteinPilot™ software (see
chapter 3.8.2) against a database containing the .fasta file information for the target
proteins spiked into an E.coli background (4303 entries, downloaded 2013/08/01 +
39 entries, downloaded 2015/04/02). The best three transitions for each peptide
were selected using the Skyline software (version 2.6.0.6851) based on maximum
signal intensities. Final transition lists were created by selecting two peptides per
protein based on signal intensities, peptide length, cysteine content and retention
time. Retention times were adapted by a scheduled SRM measurement of the heavy
peptides in a real sample background.
For the final SRM quantification experiment, two reproducibly detectable peptides
per protein with at least 2 charges were targeted with three SRM transition signals
per heavy or light peptide (see Suppl. Tables B.1, B.2). This resulted in a total
of 384 (252) transitions for 64 (42) peptides deriving from 32 (21) proteins for the
kidney (liver) dataset acquired. Scheduled SRM analyses were performed with Q1
operated in unit resolution, Q3 in low resolution, a target scan time of 2 s, a median
(minimal) dwell time of 106 ms (34 ms) and retention time windows of ±2 min
around the specific elution time within the kidney dataset and a median (minimal)
dwell time of 162 ms (43 ms) and retention time windows of ±2.25 min around the
specific elution time within the liver dataset.
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3.8. Analysis of Mass Spectrometric Data
3.8.1. Data Extraction and Generation of 2D Peptide Maps
1200 MS spectra (.t2d files) per sample run were extracted using a macro running
in the Data Explorer® Software (Applied Biosystems/MDS Analytical Technologies,
Version 4.10 build 124), resulting in the creation of a Peak and a Spectra folder. For
visualisation of the UPLC based separation and the MS measurements, 2D-Peptide
maps were generated from the spectra files using 2D Peptide Map (version 0.1.5.0)
created by Dr.Tim Fugmann in Microsoft Visual Basics. Settings used included
1411 m/z as internal standard peptide peak (see Table 3.6), normalization to a
standard peak height of 1000 or 500 and peak height capping at 100, 500 or 1000,
depending on spectral intensity.
3.8.2. Peptide and Protein Identification
Spectra from MS/MS analysis were processed with the ProteinPilot™ Software (AB
SCIEX, version 4.5, revision 1656). Searches for peptide and protein identification
were performed using the Paragon™ algorithm (AB SCIEX, version 4.5.0.0, 1654).
The MALDI TOF/TOF™ 5800 system was selected as instrument, iodoacetamide as
cysteine modification and trypsin as digestion enzyme. ID focus included biological
modifications and amino acid substitutions. Search effort was set to Thorough ID,
a protein confidence score of 1.3 (95%) was used as threshold and a false discovery
rate (FDR) was calculated for every search. Depending on sample type, spectra
were searched against a human (70101 entries, downloaded 2012/07/30) or mouse
database (51514 entries, downloaded 2012/08/08) downloaded as .fasta files from
www.uniprot.org. Exported peptide summaries were used for further analysis.
3.8.3. Determination of Peptide Proteotypicity
Peptide Summaries from the ProteinPilot™ search were dragged and dropped into
PepSir (version 1.6.1), a software tool for identification of proteotypic peptides
with respect to a given database, created by Dr.Alexander Kerner.[282] Depend-
ing on sample type, files were searched against a human (68485 entries, downloaded
2015/05/11) or mouse database (44628 entries, downloaded 2015/01/26) without
isoforms downloaded as .fasta files from www.uniprot.org. Protein/Gene Name was
used as identifier of proteotypicity if a peptide sequence was found more than once.
Filtering was set to Filter by Confidence and ignore below 95%. Peptides classi-
fied as not proteotypic (degenerated) or not found were automatically removed from
the resulting peptide summary. The summaries of proteotypic peptides were either
analysed with respect to the number of identified proteotypic peptides/proteins in
different samples or used as part of the input file to MSQBAT for propagation of
annotations (see chapter 3.8.5) or relative quantification (see chapter 3.8.4).
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3.8.4. Relative Quantification Using MSQBAT
The peptide summary of proteotypic peptides (see chapter 3.8.3) was included in
the corresponding peak file folder of the extracted MS1 data (see chapter 3.8.1)
and dragged and dropped into MSQBAT software (version 2.2.1) for MS1 based,
label-free quantification created by Dr.Alexander Kerner.[282] To compensate for
run-to-run variability between different samples, a fraction-wise intensity normal-
ization against the four internal standard peptide peaks (see Table 3.6) identified
with a tolerance range of ±0.5 Da was performed as a first step. Secondly, the
normalized MS1 peaks were annotated based on m/z and retention time using the
information from the peptide summaries of proteotypic peptides (MS/MS data).
Hereby, a fraction delta of ±1 and a m/z delta of 50 ppm was used; fraction length
was set to 4 s, column identifiers for m/z, sequence and protein ID were given in ac-
cordance to the peptide summary headers. Next, individual features were extracted.
Feature identification was based on (i) m/z tightening with a mass shift of 50 ppm
threshold, (ii) fraction tightening with a gap size of maximal 5 fractions (6 for in
vivo validation of liver samples) and (iii) annotation tightening to ensure that there
is only one peptide identification per feature. To obtain a more stable quantification
by reduction of noise, the total feature number per sample was drastically reduced
with a complexity reduction step: Applied S/N filter as well as feature length fil-
ter were automatically optimized in a range of 0-400 in intervals of 10 and 0-4 in
intervals of 1, respectively, so that at least 99.5% of the identifications were kept.
To map features between different sample runs, feature alignments of pairs of
two samples (cross-alignments) were performed with a maximal fraction delta of
±20 and a maximal mass delta of ±10 ppm during mapping. Alignments with a
difference of more than ±4 to the alignment path, that maps the retention times
from sample A to retention times from sample B, were orphanized. In the next step,
the alignments of feature pairs were used to propagate the annotation information
between two samples, if a feature was not annotated in one sample, but in the other.
Hereby, annotations were only propagated between pairs of samples treated with the
same biotinylation reagent.
An alignment by a genetic algorithm (GEAL alignment) was used to find the best
parameters for the alignment of single samples or super-samples (GEAL alignment
of several samples combined in one file) against each other, which is the basis for
relative quantification. 200 iterations were performed per GEAL alignment with the
values given for the cross-alignment as starting values. Alignment settings included
a fraction range of 10-200 (interval 10), a m/z range of 10-200 ppm (interval 10) and
an alignment path range of 2-60 (interval 2). If the annotation information of two
aligned features did not match, the alignment was not considered for quantification.
Annotations only present in one sample were automatically transferred to the other
sample as described in the annotation propagation step. In presence vs. absence
situations, MSQBAT replaced the non-existing value with an introduced background
intensity value to enable relative quantification. If more than two samples were
aligned to each other, MSQBAT automatically calculated a sample similarity score
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before starting the GEAL alignment with the samples of highest similarity.
GEAL alignments were used to quantify proteins between pairs of technical or
biological replicates as well as between pairs of super-samples biotinylated with dif-
ferent reagents. Protein quantification was based on the ratio between the summed
peptide intensity values belonging to this protein. P-values for the single proteins
were calculated with an unpaired t-test based on peptide intensity values. Quan-
tification tables containing information about protein ID and intensity values per
sample, intensity ratio, p-values and the number of peptides used for the quantifi-
cation were exported using the raw intensity values.
For quantification against another sample type (biotinylated with a different re-
agent), technical or biological replicates were combined to super-samples by GEAL
alignment. If technical and biological replicates were present within the same
dataset, the alignment was performed in a two-step procedure: Super-samples of
technical replicates were aligned to a combined super-sample of all biological repli-
cates. For the in vitro validation experiment (see chapter 3.6.1), technical triplicates
per biotinylation reagent were combined to super-samples. For in vivo validation
(see chapter 3.6.2), two technical and four biological replicates per biotinylation re-
agent were combined to super-samples in the kidney dataset; and three biological
replicates were combined in the liver dataset. All samples were quantified against the
super-sample from biotinylation with the commercial reagent Sulfo-NHS-LC-biotin.
3.8.5. Propagation of Annotations Using MSQBAT
To account for mass spectrometric performance differences during optimization of
the sample preparation procedure, annotations were transferred between comparable
samples biotinylated with the same reagent. The peptide summary of proteotypic
peptides (see chapter 3.8.3) was included in the corresponding peak file folder of
the extracted MS1 data (see chapter 3.8.1) and dragged and dropped into MSQBAT
software (version 2.2.1). The following steps have been performed as described in
chapter 3.8.4: annotation, feature extraction, cross-alignment of all possible sample
pairs and propagation of annotations. The resulting MSQBAT files were saved and
analysed with respect to the number of identified proteotypic peptides/proteins in
different samples.
3.8.6. Analysis of Protein Localization
For analysis of protein localization, subcellular localization information was ex-
tracted from www.uniprot.org using the NextDataTool (versions 2.1.3, 2015/02/25
and 2.1.4, 2015/05/20) created by Dr.Alexander Kerner. Localization information
was manually curated using the following categories: plasma membrane (pm), extra-
cellular and secreted (ex), intermembrane or cytoplasmic side of plasma membrane
(ipm), membrane associated (mem), intracellular (int), no localization information
found (no).
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3.8.7. Analysis of SRM Data
SRM data was processed using the Skyline software (MacCoss Laboratory, version
2.6.0.6851). For correct peak detection, the default peak boundary assignment based
on Savitzky-Golay smoothing was manually reassigned if required. Peptides with
unfavorable elution profile or interfering peaks in the light transitions were excluded
from further data analysis. To exclude peptides exhibiting only background noise in
the light transitions leading to instable background quantification, the peak areas of
the three measured transitions per peptide were normalized to the summed peak area
(100%) within the Skyline software. Only peptides exhibiting a stable distribution
of the transition ratios in the light transitions among all samples but the negative
controls were included in further data analysis.
Information including background-reduced peak area of heavy and light peptides
were exported for further analysis. For each peptide, peak areas of corresponding
transitions were summed. The ratio between the background reduced peak area of
the light transition and the background reduced peak area of the heavy transition
was calculated to correct for ionization or spray differences between runs.
To evaluate, if the signals of the light transitions are within the background and
therefore not suitable for a proper quantification, the average background-reduced
peak area across all biotinylated surface enriched samples or across all full proteome
samples was compared to the background-reduced peak area of the light peak back-
ground signal of heavy peptide pool in solvent. To obtain a reliable quantification,
peptides with an average peak area less than four-fold up-regulated compared to the
background signal were excluded from analysis. In the following, peak areas were
normalised to the maximal peak area achieved among the enriched surface samples
for this specific peptide. Mean and standard deviation of four (kidney dataset) or
three (liver dataset) biological replicates were calculated per reagent group or full
proteome sample.
3.8.8. Further Data Analysis Tools
Raw data of the mass spectrometric datasets were analysed with Microsoft Excel
2007. Statistical analyses and data visualisation was performed with GraphPad
Prism (version 6.05).
Enrichment analysis of cellular component and molecular function was performed
by gene ontology (GO) analysis using the WEB-based GEne SeT AnaLysis Toolkit
(Webgestalt).[283],[284] Homo sapiens or mus musculus was selected as organism, data
were loaded with uniprot_swissprot_accession selected as ID type. GO analysis was
performed with the organism’s genome sets as reference for the enrichment analysis.
Data were visualized as directed acyclic graph.
Cluster analysis was performed using the data visualisation platform GENE-E.[285]
City-block distance was used as distance metric, average linkage as linkage method.
Color settings were customized using a global color scheme with 4-fold up-regulation
depicted in red and 4-fold down-regulation in blue.
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Protein abundance information was extracted from PaxDB, an absolute protein
abundance database containing protein abundance data across various organisms
and tissues.[286],[287] The abundance information is based on the integration of several
publicly available experimental datasets via a spectral counting pipeline.
The ProtParam tool was used to compute protein parameters such as protein or
peptide mass and the amino acid composition.[288]
Chemical structures were visualized with ChemBioDraw Ultra (version 14.0.0.117).
3D models were generated in Chem3D Pro (version 14.0.0.117).
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4. Results
4.1. Biotinylation Reagents: Chemical Entities
4.1.1. Rationales and General Design of Biotinylation Reagents
The identification of vascular accessible, disease-specific biomarkers is a prerequisite
for the development of novel diagnostics or targeted therapies with fewer effects in
healthy tissues. Hereby, the molecules of interest, targetable with specific mono-
clonal antibodies or antibody-drug conjugates, are proteins expressed on the cell
surface of diseased cells, on endothelial cells of newly formed blood vessels in the
diseased tissue or in the perivascular extracellular matrix.[160],[289] Global proteomic
approaches for the identification of novel biomarkers have to deal with low expression
levels of the highly heterogeneous surface proteome fraction compared to the intra-
cellular fraction as well as with their hydrophobic character.[146],[120] The nature of
a membrane protein is determined by hydrophobic membrane interacting domains
on the one hand and by hydrophilic protein regions as well as polar posttransla-
tional modifications like glycosylation on the cell surface on the other hand.[146],[161]
Peripheral membrane proteins can be associated with the cell membrane by interac-
tion with integral proteins or the lipid bilayer itself via hydrophobic regions, whereas
integral membrane proteins contain 1-20 transmembrane domains consisting of 15-
25 hydrophobic amino acids each.[133],[120] Therefore, besides the low abundance,
the main challenges in membrane proteomics are the prevention of protein aggre-
gation and efficient solubilisation with detergents compatible with LC/MS analysis,
as well as the lack of polar arginine or lysine residues for tryptic cleavage within
former membrane-spanning domains complicating the generation of short peptide
fragments for proper mass spectrometric analysis.[290],[119]
Enrichment of the proteome fraction of interest prior to analysis reduces sam-
ple complexity and enables a stable identification and quantification of potential
biomarkers. One avenue towards the enrichment of vascular accessible, surface
biomarkers is their modification with membrane-impermeable biotin derivatives fol-
lowed by protein extraction and streptavidin-based enrichment on a solid support
before proteomic analysis. A biotinylation reagent for enrichment of vascular acces-
sible proteins consists of three building blocks:
(i) A biotin moiety used for streptavidin-based enrichment.
(ii) A linker determining the properties of the biotinylation reagent.
(iii) A reactive moiety for covalent labelling of target proteins.
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The complex formed by streptavidin homotetramers and biotin exhibits a very
strong interaction (Kd ~ 10-15 M)[291] and has therefore been widely exploited for
affinity-based detection or capturing of biotinylated target molecules.[292] Whereas
the tetrahydroimidizalone ring is of greatest importance for the binding to the avidin
site, the terminal carboxylic group at the valeric acid side chain can be used for
coupling of the biotin residue to another molecule.[291],[191]
Proteins are composed of a variety of functional groups exploitable for chemical
derivatization: Carboxylic groups react with amide-bond forming reagents upon ac-
tivation, primary amino groups can be derivatized with activated ester compounds,
secondary amino groups with tetra- or pentafluorophenyl ester derivatives. Thiol
groups can be addressed with maleimido, haloacetyl or thiol groups to form thioether
or disulfide bonds. Aldehyde groups generated by periodate oxidation of N-terminal
serine or attached carbohydrate residues can be targeted with hydrazide compounds.
Phenolic side chains of tyrosine residues can be alkylated, acylated or can undergo
electrophilic addition.[191],[293] For successful labelling of the whole cell surface pro-
teome fraction, the targeted functional group has to be expressed in high frequency
and in an accessible form on the cell surface. Thiol groups in cysteine residues are
rare and often occurring in oxidized form as disulfide bonds stabilizing the protein’s
tertiary structure.[293],[294] Activation of the carboxylic acid side chains of glutamic
or aspartic acid or the protein C-terminus would lead to a certain degree of protein
polymerization on the cell surface as both carboxylic and amino groups are present.
Therefore, the highly abundant, primary amino groups occurring as ϵ-amines in
lysine side chains or as α-amine at the protein N-terminus are the coupling sites of
choice for stable labelling with biotin ester derivatives in a one-step reaction (see
Scheme 4.1), although some lysine residues are lost as tryptic cleavage sites within
the protein.
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Scheme 4.1.: Modification of protein amino groups (ϵ-amines in lysine side chains or N-
termini) with NHS-ester derivatives.
As outlined above, the linker between the biotin moiety for affinity purification
and the reactive group for protein labelling determines the properties of any biotiny-
lation reagent. First of all, the linker serves as a spacer to avoid steric hindrance
during labelling of the bulky protein with reagent molecules as well as during the
capturing process on the streptavidin resin. In order to allow for the biotinylation of
proteins on living cells, the reagent has to be soluble in aqueous buffers at reasonable
concentrations. Furthermore, the reagent must not cross biological membranes due
to the localization of potential vascular accessible biomarkers on the surface of cells.
To maintain plasma membrane integrity, the cell viability should not be affected
during the biotinylation procedure.
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4.1.2. Commercial Biotinylation Reagents and Advancements
Sulfo-NHS-LC-biotin (see Figure 4.1a) is one of the most popular biotinylation re-
agents available on the market. Sulphation of the ester group supports the water
solubility of the molecule, but the 8.7 Å LC (long chain) linker between the biotin
moiety and the activated carboxylic group still determines the clear hydrophobic
character of the spacer arm. In other commercial compounds the aliphatic chain
is substituted with a more hydrophilic polyethylene glycol (PEG) linker available
in different spacer lengths up to 45.9 Å (see Figure 4.1b). Within this thesis, all
validation experiments of the novel biotinylation reagents are performed against the
commercial reagents Sulfo-NHS-LC-biotin and NHS-PEG12-biotin.
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Figure 4.1.: Commercial biotinylation reagents used for various validation experiments.
(a) Sulfo-NHS-LC-biotin, MW 556.58 g/mol; (b) NHS-PEG12-biotin, MW 941.10 g/mol.
The analysis of whole cell lysate samples without prior enrichment yields ap-
proximately 10% of all identified proteins to be annotated to the plasma mem-
brane.[130],[180] By biotinylation reagent based enrichment, both the total number of
identified surface proteins as well as the surface proteome fraction are increased to
about 30%.[180] The analysis of datasets from in vivo biomarker discovery studies
performed with the commercial Sulfo-NHS-LC-biotin also confirms the identifica-
tion of a considerable proportion of proteins not annotated to the cell surface or
the extracellular matrix.[186],[295],[296] Explanations for this phenomenon include (i)
plasma membrane crossing of the reagents via diffusion or biotin transporters, (ii)
co-purification of intracellular proteins attached to the biotinylated membrane pro-
teins, (iii) wrong or incomplete GO annotation of the protein localization within the
database as well as (iv) the presence of a fraction of apoptotic cells with increased
membrane permeability.[12]
In 2010, the novel biotinylation reagent NHS-β-Ala-(L-Asp)3-biotin was published
(see Figure 4.2).[12] Compared to commercial Sulfo-NHS-LC-biotin, the reagent is
highly water soluble due to three negatively charged aspartic acid side chains and
exhibits a 36% increase in molecular weight. A comparative proteomic analysis of
the top 50 regulated proteins of NHS-β-Ala-(L-Asp)3-biotin or Sulfo-NHS-LC-biotin
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perfused mouse kidney and liver tissue revealed a clear up-regulation of surface or
extracellular matrix annotated proteins with the novel reagent.[12] Nevertheless, only
364 proteins (kidney) and 392 proteins (liver) with a surface proteome fraction of
60% and 42%, respectively, were identified. The poor reactivity of the NHS-β-Ala-
(L-Asp)3-biotin is further elucidated in chapter 4.1.4.
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Figure 4.2.: NHS-β-Ala-(L-Asp)3-biotin, MW 757.73 g/mol published by Strassberger et
al. in 2010 with optimal NHS-activation.[12] See Figure 4.5 for 3D model.
4.1.3. Analysis of the Biotinylation Procedure
The reactivity of different biotinylation reagents as well as particular labelling con-
ditions were assessed with BSA as model protein. BSA contains 60 primary amino
groups (59 lysine side chains and the N-terminus). Biotinylation reagents were dis-
solved or diluted in aqueous buffer directly before use and were incubated with 1 eq
BSA in different ratios (1 eq - 100 eq) for 15 min at room temperature in PBS
buffer (if not indicated differently). Mass spectrometric analysis of the desalted
BSA samples was performed on a MALDI TOF/TOF™ 5800 system (AB SCIEX).
The difference between the m/z at the peak maximum of the singly charged peak to
the m/z of unmodified BSA was used to calculate the number of reagent tags added
to one BSA molecule.
The labelling reaction occurs very fast: A prolongation of the biotinylation re-
agent’s incubation time with the target protein from 30 s to 1 h did not change the
degree of modification (see Figure 4.3a). Hydrolysis of the NHS ester always com-
petes with the favored reaction of the primary amino group, because the labelling
reaction has to be performed in aqueous buffer when working in an in vitro or in
vivo system. Therefore, biotinylation reagents have to be stored in dried form or
in a water-free solvent and have to be dissolved or diluted directly before use. De-
creasing the temperature of the biotinylation solution also decreases the hydrolysis
rate (see Figure 4.3b). The coupling reaction is very efficient at physiological to
slightly acidic pH, whereas the hydrolysis rate is heavily increased at basic pH (see
Figure 4.3c). Batch-to-batch variations occur not only with freshly synthesized, but
also with commercial reagents (see Figure 4.3d), most likely due to slightly different
storage conditions leading to varying water content. Due to the fast reaction with
primary amino groups, a non-reacted reagent excess can be efficiently quenched with
an amine containing solution, such as Tris buffer.
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Figure 4.3.: Biotinylation of model protein BSA with Sulfo-NHS-LC-biotin under different
conditions, analysis with linear MALDI-MS (mean and standard deviation, six to eight
data points per condition). (a) Variation of incubation time with BSA, biotinylation
ratio 1:64; (b) storage in PBS at 0◦C or 20◦C before incubation with BSA, biotinylation
ratio 1:64; (c) storage in PBS (pH 7.45), MES (pH 6.0) or carbonate buffer (pH 9.2) at
20◦C before incubation with BSA, biotinylation ratio 1:100; (d) reactivity comparison of
different reagent batches.
4.1.4. Reactivity of NHS- and sNHS-β-Ala-(L-Asp)3-biotin
NHS- and sNHS-β-Ala-(L-Asp)3-biotin (see Figure 4.2) were synthesized to further
assess the poor reactivity during the labelling procedure. Carboxylic group activa-
tion was performed with an excess of 1.3 eq of NHS or with the hydrophilic sNHS
in the presence of carbodiimide according to the authors’ instructions.[12] As the
activated reagent is applied on protein samples without further purification, a large
carbodiimide excess during activation has to be avoided to prevent crosslinking of
the target proteins, a possible side reaction. Therefore, activation was either per-
formed with 1.1 eq 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
(EDC-HCl) or with a 3- to 10-fold excess of N,N’-dicyclohexylcarbodiimide (DCC)
resin, which was subsequently separated from the reaction mixture. Both activation
strategies proved to be comparable as examined in reactivity tests on BSA.
The reactivity assessment of NHS-β-Ala-(L-Asp)3-biotin and Sulfo-NHS-β-Ala-
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(L-Asp)3-biotin on BSA clearly indicates the poor reactivity of the peptide reagent
compared to commercial Sulfo-NHS-LC-biotin (see Figure 4.4). The significantly
decreased biotinylation rate originates from the structural difference of the linkers
between the biotin moiety and the activated carboxylic group: The aspartic acid
side chains in the peptide reagent need more space than the simple aliphatic linker of
Sulfo-NHS-LC-biotin. This is why the reaction with protein amino groups in bulky
protein regions is sterically hindered. Furthermore, the NHS- or sNHS-activation of
the peptide is not possible in a site-specific manner: Biotin-(L-Asp)3-β-Ala not only
contains the C-terminal carboxylic group, but also three aspartic acid side chains.
Activation with the slight excess of 1.3 eq NHS or sNHS leads to an undefined
product mixture with more or less sterically hindered structures around the ester
group, depending on the modified carboxylic group (see Figure 4.5). A decreased
reactivity on target proteins is the consequence.
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Figure 4.4.: Biotinylation of model protein BSA in different ratios with commercial Sulfo-
NHS-LC-biotin and the peptide reagent NHS-β-Ala-(L-Asp)3-biotin (Sulfo-NHS-β-Ala-
(L-Asp)3-biotin) published by Strassberger et al.[12] Analysis with linear MALDI-MS
(mean and standard deviation, seven to eight data points per condition).
4.2. Synthesis of Novel Biotinylation Reagents
4.2.1. Peptide-Based Biotinylation Reagents
4.2.1.1. Design and Synthesis of Peptide-Based Biotinylation Reagents
Two novel biotinylation reagents SMCC-Cys-(L-Asp)3-biotin and SM(PEG)6-Cys-
(L-Asp)3-biotin have been designed to improve the low reactivity of NHS-β-Ala-
(L-Asp)3-biotin, while keeping desired features such as the increase in size and po-
larity to decrease the membrane crossing potential compared to commercial reagents.
A C-terminal thiol residue is introduced to the peptide linker and exploited for site-
specific coupling to a bifunctional N-hydroxysuccinimide/maleimide crosslinker for
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Figure 4.5.: Site-unspecific activation of Biotin-(L-Asp)3-β-Ala. Arrows indicate possible
positions for activation with NHS or sNHS. Activation at position (a) results in the least
sterically hindered reaction product. 3D models of two exemplary product structures
(activation at positions (a), (b)) demonstrate differential steric hindrance of the activated
carboxylic group; atoms depicted in grey (C), white (H), red (O), blue (N), yellow (S).
activation of the reagent (see Scheme 4.2). The maleimide group efficiently un-
dergoes alkylation with the peptide thiol group within 2.5 h at room temperature
yielding a thioether linkage. The reaction efficacy could be improved by pre-treating
the peptide with 0.5 eq TCEP for the reduction of disulfide bonds (to avoid the
formation of peptide dimers and to generate free thiol groups). Subsequently, a
slight excess of 1.3 eq succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxy-
late (SMCC) or succinimidyl-([N-maleimidopropionamido]hexaethyleneglycol)ester
(SM(PEG)6) crosslinker was added to the previously reduced peptide. As the bi-
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DMSO
Scheme 4.2.: Activation of novel peptide-based reagents by a bifunctional N-hydroxy-
succinimide/maleimide cross linker.
functional crosslinkers already contain the activated NHS-ester group for protein
amino group coupling, the reagent synthesis was performed in a water-free solvent
to prevent hydrolysis. The structures of the novel peptide-based biotinylation re-
agents SMCC-Cys-(L-Asp)3-biotin and SM(PEG)6-Cys-(L-Asp)3-biotin are depicted
in Figure 4.6.
97
HN
NH
S
O
H
N
O
N
H
H
N
O
O
O
N
H
OH
O
O
OHOH
O
S
O NH2
N
O
O
O
O N O
O
HN
NH
S
O
H
N
O
N
H
H
N
O
O
O
N
H
OH
O
O
OHOH
O
S
O NH2
N
O
O
O
HN
O
O
O
N
O
O
6
(a)
(b)
Figure 4.6.: Novel peptide based biotinylation reagents. (a) SMCC-Cys-(L-Asp)3-biotin,
MW 1026.06 g/mol; (b) SM(PEG)6-Cys-(L-Asp)3-biotin, MW 1293.33 g/mol.
4.2.1.2. Reactivity of Peptide-Based Biotinylation Reagents
For reactivity assessment on BSA as model protein, SMCC-Cys-(L-Asp)3-biotin and
SM(PEG)6-Cys-(L-Asp)3-biotin were compared with the commercial reagents Sulfo-
NHS-LC-biotin and NHS-PEG12-biotin as well as with the non-specifically activated
reagent NHS-β-Ala-(L-Asp)3-biotin (see Figure 4.7). The C-terminal, site-specific
activation of the novel reagents significantly improves the reactivity compared to
the non-specifically activated NHS-β-Ala-(L-Asp)3-biotin, while the basic structure
of the peptide linker is kept. Steric hindrance is drastically reduced, but cannot
be fully avoided due to the more bulky peptide linker compared to the aliphatic
(Sulfo-NHS-LC-biotin) or pegylated (NHS-PEG12-biotin) linkers of the commercial
reagents. The novel reagents are triply negatively charged at physiological pH and
exhibit an 84-133% increase in size compared to Sulfo-NHS-LC-biotin. Due to the
significant tag size, the resulting peaks in mass spectra of BSA biotinylated in high
ratios are broadened, preventing a proper analysis of ratios above 1:64.
Different peptide synthesis batches have been used for the experiments performed
within this thesis. Batch-to-batch variations (see Figure 4.8a) most likely arise
from varying water content and pH in the lyophilized powder leading to different
hydrolysis rates. The activated reagent undergoes a slight loss of activity upon
storage in dry DMSO under inert gas (see Figure 4.8b) as hydrolysis cannot be fully
prevented. All experiments within this thesis are performed with reagents that were
directly activated before use.
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Figure 4.7.: Biotinylation of model protein BSA in different ratios, analysis with linear
MALDI-MS (mean and standard deviation, five to eight data points per condition). The
commercial reagents Sulfo-NHS-LC-biotin and NHS-PEG12-biotin are depicted in grey,
NHS-β-Ala-(L-Asp)3-biotin published by Strassberger et al.[12] in red, the novel reagents
SMCC-Cys-(L-Asp)3-biotin and SM(PEG)6-Cys-(L-Asp)3-biotin in blue.
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Figure 4.8.: Biotinylation of model protein BSA with SMCC-Cys-(L-Asp)3-biotin, anal-
ysis with linear MALDI-MS (mean and standard deviation, up to eight data points per
condition). (a) Reactivity of different peptide educt batches used for the validation exper-
iments within this thesis; (b) reactivity loss upon storage in dry DMSO under inert gas
at -20◦C for 24 h or 6 days.
4.2.2. Heparin-Based Biotinylation Reagents
4.2.2.1. Design and Synthesis of Heparin-Based Biotinylation Reagents
Heparin is a mixture of linear glycosaminoglycans of different chain lengths com-
posed of variable modified L-iduronic acid and D-glucosamine saccharide subunits
joined through 1→4 glycosidic linkages. The exact composition is depending of the
tissue type used for extraction of the heparin.[297] The heparin sodium salt from
porcine intestinal mucosa used within this thesis mainly consists of disaccharide
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units composed of 2-O-sulfated iduronic acid and 6-O- and N-sulfated glucosamine
(see Figure 4.9) and has a mass range of 13 000-17 000 g/mol with an average mass
of 15 000 g/mol (25 disaccharide units). So-called low molecular weight (LMW) hep-
arin can be obtained via alkaline depolymerization of heparin. The LMW heparin
enoxaparin also used within this thesis originates from heparin of porcine intestinal
mucosa and has an average mass of 4421 g/mol (8 disaccharide units). As a result
of the high sulphation degree and the free carboxylic groups, the polymer is highly
negatively charged in a wide pH range. Heparins are reported to still contain 2-10%
water after extensive drying due to their extreme hydrophilicity and are practically
insoluble in organic solvents.[297]
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Figure 4.9.: Structure of heparin: the most common IdoA(2S)-GlcNS(6S) disaccharide
subunit and the reducing end of the heparin chain. Arrows label the reactive groups used
for synthesis of novel heparin-based biotinylation reagents.
The heparin chain incorporates a variety of functional groups exploitable for chem-
ical derivatization. Every single heparin chain contains an intramolecular hemiacetal
at the reducing end (see Figure 4.9), that is in equilibrium with its open-chain alde-
hyde form. Nucleophilic compounds such as hydrazides can target the anomeric
centre.[298],[299],[300] Moreover, each disaccharide subunit contains a free carboxylic
group, several sulfo and hydroxyl groups, in some disaccharide units also as vicinal
diols, as well as an average of 0.3 unmodified amino groups per heparin chain.[297]
The large size, multiple charges, hydrophilicity and the various functional groups
make the heparin structure to an ideal candidate for the synthesis of novel, membrane-
impermeable biotinylation reagents.
The reducing chain ends were exploited to introduce one biotin residue per heparin
chain. The reaction rate of this process is low, as the equilibrium is in favor of the
ring-closed form.[301] Elevated temperature and an excess of nucleophile are required
to drive the coupling reaction. Moreover, nitrogen nucleophiles more reactive than
simple amines. Hydrazines, hydrazides or hydroxylamines are commonly used for
modification.[293],[302],[303] A pH range of 3.0 - 5.5 of the reaction buffer is reported to
support favorable reaction kinetics.[302],[300],[304] Here, a biotin hydrazide derivative
was chosen for coupling in sodium acetate buffer at pH 5.0 (see Scheme 4.3). The
reaction can be performed under reducing conditions, e.g. with sodium cyanoboro-
hydride, to form of a stable, reduced hydrazone linkage or under non-reducing condi-
tions yielding hydrazone/glycosylhydrazide formation.[298],[299] The latter is reported
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Scheme 4.3.: Biotinylation of heparin at the reducing end.
to be stable against hydrolysis in a range from slightly acidic to basic pH.[305],[306]
The reaction rate can be further increased using aniline as nucleophilic catalyst by
the formation of an aniline Schiff base intermediate.[302],[303],[304]
For coupling to the target proteins’ amino groups, carboxylic group residues at the
Biotin-Heparin or Biotin-Enoxaparin subunits were used upon activation with sNHS
or NHS. As heparin is insoluble in non-aqueous buffers, the reaction was performed in
PBS with the water-soluble 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydro-
chloride (EDC-HCl) (see Scheme 4.4).[307],[308],[309] Each repeating disaccharide unit
contains one free carboxylic group. If not indicated differently, the sNHS or NHS
excess is chosen according to the average number of subunits in the heparin chain
to fully activate the side groups.
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Scheme 4.4.: Carboxylic group activation at heparin side chains.
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4.2.2.2. Reactivity of Heparin-Based Biotinylation Reagents
Mass spectrometric analysis of the heparin modified model protein BSA is in most
cases not possible. Heparin tags are very heavy, leading to extreme peak broadening
and flattening in mass spectra. Furthermore, the reagent mass is distributed over
a wide mass range and modified proteins exhibit different properties during sample
preparation, possibly resulting in losses of the polar molecule during desalting on an
unpolar material. If BSA is modified with higher reagent excesses, the effects are
increased by the addition of multiple tags to a single protein molecule. Activation
of the carboxylic side-groups with high ratios of sNHS can additionally lead to
protein crosslinking and further increase the mass of the resulting complex. Only
the detection of modification with LMW heparins like enoxaparin in a 1:1 ratio to
BSA and low sNHS excess was possible (see Figure 4.10).
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Figure 4.10.: Biotinylation of model protein BSA with Enoxaparin-sNHS in a ratio of 1:1.
Mass spectra of unmodified BSA (red), 3x (light green) and 5x (dark green) activated
Enoxaparin-sNHS are shown.
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4.2.3. Biotin-Free System
4.2.3.1. Click Chemistry-Based Approach
Click chemistry is a general term describing a way to join subunits by a heteroatom
linkage in a modular and stereospecific way, with high atom economy, under simple
reaction conditions, with high yields and with no or inoffensive by-products.[310]
One of the most popular reactions is the Huisgen 1,3-dipolar cycloaddition of azides
and terminal alkynes, that is catalyzed by Cu(I) using either a Cu(I) halide with an
amine base and a stabilizing ligand or a stable Cu(II) salt under reductive conditions
as Cu(I) source.[311],[312],[313] The system is suitable for bioorthogonal reactions, as
azides and alkynes are not present in biomolecules and can therefore be used for
selective modification. As the reaction can proceed under mild conditions and in
aqueous buffers under physiological pH and temperature, the so-called click reaction
has been applied in many biological systems: Functionalisation of proteins, lipids,
nucleic acids and glycans by chemical derivatisation or metabolic labelling and many
applications including detection and imaging, enrichment and dynamic monitoring
are reported.[314],[315],[316],[317],[318],[319],[320]
The labelling of cell surface proteins with alkyne-tagged reagents, followed by click
chemistry mediated capturing on azide-modified beads would provide a bioorthog-
onal enrichment platform (see Scheme 4.5). Avoidance of the biotin system could
prevent the co-purification of intrinsically biotinylated, high-abundant, intracellular
proteins co-enriched on streptavidin-sepharose.
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Scheme 4.5.: Protein modification and click-chemistry-mediated capturing. (a) Modifica-
tion of protein amino groups with NHS-ester derivatives. (b) Bioorthogonal capturing
based on click reaction.
The usage of a Cu(I) source as catalyst is essential for the click reaction success,
but might favor a certain degree of protein precipitation in the desired applica-
tion.[321],[322] Furthermore, the Copper-mediated click protocols using standard Cu(I)
stabilizers such as TBTA in aqueous buffers exhibit slow reaction kinetics.[323],[324]
Moreover, the standard Cu(I) stabilizer TBTA also leads to protein precipitation,
as evaluated in a BSA solution by adding TBTA to a final concentration of 4 mM.
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To overcome the toxicity of copper during applications in living systems, a catalyst-
free variant of the click reaction has been developed.[325] The terminal alkyne is ex-
changed by a cylooctyne: The acetylene bond massively deforms the bond angles
leading to an enormous ring strain that favors the alkyne reaction.[325] The method
has been widely exploited in various applications such as metabolic labelling in cell
systems for imaging purposes, cell surface glycan labelling for the study of internali-
sation kinetics as well as metabolic labelling in mice using azido glycans.[326],[327],[328]
The usage of a cylooctyne such as DBCO instead of a terminal alkyne might
provide an easy way to capture alkyne-labelled proteins without dealing with copper-
related effects on proteins. Still, the Cu-mediated click capturing is worth to be
examined, as the generation of the terminal alkyne compound is cheaper and there
are other Cu(I) stabilizers such as THPTA not causing protein precipitation.[323]
4.2.3.2. Synthesis and Reactivity of Click Chemistry-Based Reagents
Two novel click chemistry-based reagents have been designed and synthesized, either
with an terminal alkyne (SMCC-Cys-(L-Asp)3-PA-alkyne) or a cylooctyne (SMCC-
Cys-(L-Asp)3-DBCO-alkyne) (see Figure 4.11). The linker structure corresponds to
the structure used for the peptide-based biotinylation reagents. Activation of the
reagent has been performed as already described for the peptide-based biotinyla-
tion reagents (see chapter 4.2.1.1): A C-terminal cysteine residue was exploited for
site-specific coupling to a bifunctional N-hydroxysuccinimide/maleimide crosslinker
within 2.5 h at room temperature.
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Figure 4.11.: Novel click-chemistry-based reagents. (a) SMCC-Cys-(L-Asp)3-PA-alkyne,
MW 879.85 g/mol; (b) SMCC-Cys-(L-Asp)3-DBCO-alkyne, MW 1172.19 g/mol.
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The reactivity was assessed with BSA as model protein as described before (see
chapter 4.1.3). As expected from the structural similarity, the reactivity of SMCC-
Cys-(L-Asp)3-PA-alkyne and SMCC-Cys-(L-Asp)3-DBCO-alkyne (see Figure 4.12)
correspond to the reactivity of the peptide-based biotinylation reagents (compare
Figure 4.7). As only minimal peptide amount was synthesized for initial tests, only
a selection of labelling ratios were acquired for the latter reagent. Slight differences
between both click chemistry-based reagents most likely occur due to minimally
varying water content in the dried peptide influencing hydrolysis, an effect similar
to batch-to-batch variability.
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Figure 4.12.: Labelling of model protein BSA in different ratios with SMCC-Cys-(L-Asp)3-
PA-alkyne (grey) and SMCC-Cys-(L-Asp)3-DBCO-alkyne (blue), analysis with linear
MALDI-MS (mean and standard deviation, six to eight data points per condition).
In vitro labelling of cells with the novel click chemistry-based reagents SMCC-
Cys-(L-Asp)3-PA-alkyne and SMCC-Cys-(L-Asp)3-DBCO-alkyne with subsequent
capturing on azide-modified beads is currently set up.
4.3. In Vitro Validation of Novel Biotinylation
Reagents
4.3.1. Workflow In Vitro Validation
A proof-of-principle study of the novel biotinylation reagents was performed in com-
parison to the commercial reagents Sulfo-NHS-LC-biotin and NHS-PEG12-biotin. In
vitro biotinylation was examined with HeLa as model cell line (see Figure 4.13). Bi-
otinylation efficacy on cells was visualised by FACS analysis, confocal laser scanning
microscopy (CLSM) or Western Blot using streptavidin conjugates for detection.
Mass spectrometric analysis of the biotinylated proteome fraction was performed as
comparative analysis of cells biotinylated with Sulfo-NHS-LC-biotin, NHS-PEG12-
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biotin, SMCC-Cys-(L-Asp)3-biotin, SM(PEG)6-Cys-(L-Asp)3-biotin, Biotin-Hepa-
rin-sNHS or Biotin-Enoxaparin-sNHS and PBS-treated cells as negative control.
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Figure 4.13.: Workflow in vitro validation.
4.3.2. Visualisation of Cell Surface Biotinylation
4.3.2.1. Peptide-Based Biotinylation Reagents
The degree of cell surface biotinylation with different amounts of biotinylation re-
agents could be assessed by FACS analysis of counted cell fractions after non-tryptic
detachment with 10 mM EDTA, biotinylation and staining with a streptavidin Pa-
cific Blue conjugate. HeLa cells were incubated with different amounts of biotiny-
lation reagent, covering a range from 1:0.01 to 1:20. The molecular ratios refer to
a median protein amount of 300 µg (6 nmol) protein content per 1×106 cells with
a median protein weight of 50 kDa.[130] The FACS reactivity profile corresponds to
the results obtained by reactivity tests on BSA (see chapter 4.2.1.2): Sulfo-NHS-
LC-biotin is the most reactive biotinylation reagent, reaching signal saturation at
a ratio of 1:5 (30 nmol reagent per 1×106 cells) with three log-shifts difference to
the control. The non-specifically activated NHS-β-Ala-(L-Asp)3-biotin is less reac-
tive compared to the site-specifically activated SMCC-Cys-(L-Asp)3-biotin, proven
by smaller peak shifts at the same ratios as well as a saturation level at two vs.
three log-shifts, i.e. demonstrating the saturation of the cell surface with less and
more spacious reagent tags (see Figure 4.14). The reactivity of both novel peptide-
based reagents SMCC-Cys-(L-Asp)3-biotin and SM(PEG)6-Cys-(L-Asp)3-biotin is
comparable as shown in Figure 4.15.
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Figure 4.14.: FACS analysis of HeLa cells biotinylated with NHS-β-Ala-(L-Asp)3-biotin
(red) published by Strassberger et al.[12] in comparison to Sulfo-NHS-LC-biotin (grey)
and SMCC-Cys-(L-Asp)3-biotin (blue). Biotinylation ratios between 0.01 eq (0.06 nmol)
and 10 eq (60 nmol) reagent per 1×106 cells. Non-biotinylated control depicted in black.
Figure 4.15.: FACS analysis of HeLa cells biotinylated with the novel peptide-based re-
agents SMCC-Cys-(L-Asp)3-biotin (dark blue) and SM(PEG)6-Cys-(L-Asp)3-biotin (light
blue) in comparison to commercial Sulfo-NHS-LC-biotin (grey). Biotinylation ratios be-
tween 0.1 eq (0.6 nmol) and 20 eq (120 nmol) reagent per 1×106 cells. Non-biotinylated
control depicted in black.
Biotinylation of plasma membrane proteins could be shown by CLSM analysis (see
Figure 4.16). Membrane staining with a streptavidin Alexa 488 conjugate could be
observed with all reagents, but the total signal intensity was lower with the peptide-
based reagents compared to the commercial ones. These findings were in line with
the previously examined differences in reactivity. Therefore, laser properties were
optimized for both cases individually.
4.3.2.2. Heparin-Based Biotinylation Reagents
The reactivity of heparin-based reagents on cells could be assessed by FACS analysis
of counted cell fractions after detachment, biotinylation and staining with a strep-
tavidin Pacific Blue conjugate. Heparin-based biotinylation reagents only reach a
maximum of one log-shift for fully biotinylated cell surfaces, directly correspond-
ing to the enormous size of the reagent tags allowing less biotin reagent molecules
per surface area compared to the commercial or peptide-based reagents. Additional
to the incubation with different amounts of the biotinylation reagent, differential
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Figure 4.16.: CLSM of biotinylated HeLa cells. DAPI (blue), biotin staining (green), scale
bars: 10 µm. Commercial reagents (a) and peptide-based reagents (b) were acquired
with different laser intensities to depict membrane biotinylation. Biotinylation with Sulfo-
NHS-LC-biotin A, NHS-PEG12-biotin B, SMCC-Cys-(L-Asp)3-biotin E or SM(PEG)6-
Cys-(L-Asp)3-biotin F, corresponding PBS treated controls (C,G) and staining controls
for Sulfo-NHS-LC-biotin and SMCC-Cys-(L-Asp)3-biotin without biotin staining (D,H).
grades of NHS-activation at the heparin chains were examined (see Figure 4.17).
No unspecific binding of non-activated heparin-based biotinylation reagents to the
cells was observed. Very low NHS-activation degrees led to reagent tags with de-
creased binding potential. Maximum log-shift was examined by full sNHS-activation
of every disaccharide subunit.
(a) (b) (c) (d) 
Figure 4.17.: FACS analysis of HeLa cells biotinylated with the novel heparin-based re-
agents Biotin-Heparin-sNHS and Biotin-Enoxaparin-sNHS. Biotinylation reagent excess
1 eq (green), 10 eq (orange) and 20 eq reagent (red). Biotinylation with 2x (a) and
5x (b) activated Biotin-Enoxaparin-sNHS or with 5x (c) and 25x (d) activated Biotin-
Heparin-sNHS. Non-biotinylated control depicted in black, treatment with non-activated
Biotin-Enoxaparin (a,b) or Biotin-Heparin (c,d) in blue.
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4.3.3. Sample Preparation for Mass Spectrometric Analysis
For subsequent mass spectrometric analysis, HeLa cells were treated with biotiny-
lation reagents while still adherent on the cell culture flask to avoid an increase in
dead and therefore membrane permeable cells by the detachment procedure. 5 µmol
biotinylation reagent per cell culture flask containing about 5×106 cells have been
used. To perform a comparable analysis, the same amount was used for every
reagent. The optimal amount for biotinylation of adherent cells was determined
by FACS analysis. As the reagents on adherent cells in the cell culture flask are
about ten-fold diluted compared to biotinylation of detached cell aliquots as used
in chapter 4.3.2, the total reagent amount had to be increased. Maximal log-shift
was achieved for all reagents using 1 µmol biotinylation reagent per 1×106 adherent
cells (see Figure 4.18).
(a) (b) 
Figure 4.18.: FACS analysis of HeLa cells biotinylated on the cell culture flask. (a) Bi-
otinylation with novel peptide-based reagents SMCC-Cys-(L-Asp)3-biotin (dark blue) and
SM(PEG)6-Cys-(L-Asp)3-biotin (light blue) in comparison to commercial Sulfo-NHS-LC-
biotin (dark grey) and NHS-PEG12-biotin (light grey). (b) Biotinylation with novel
heparin-based reagents Biotin-Heparin-sNHS (dark green) and Biotin-Enoxaparin-sNHS
(light green) in comparison to commercial Sulfo-NHS-LC-biotin (grey). Non-biotinylated
control depicted in black in (a,b).
The cell viability is of greatest importance for a valuable mass spectrometric
dataset of the cell surface proteome. During cell death, the plasma membrane under-
goes substantial changes including increased membrane permeability, which would
lead to labelling of intracellular proteins with the biotinylation reagents.[329],[330],[331]
Viability was assessed under different conditions with the Trypan Blue method.
Non-tryptic detachment with 10 mM EDTA is slow, but necessary to preserve the
surface proteins, however cell viability after subsequent biotinylation with Sulfo-
NHS-LC-biotin is decreased to 71-79%, leading to an extreme contamination with
labelled intracellular proteins. This is why for subsequent mass spectrometric anal-
ysis, cells were pre-washed with PBS and directly incubated with the biotinylation
reagents in PBS while still attached to the cell culture flask. Reaction time was
kept short to minimize negative effects on the cells and a subsequent quenching step
inactivated non-reacted reagent before continuing with the detachment.
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The novel peptide-based reagents were synthesized in dry DMSO to decrease hy-
drolysis rate of the activated carboxylic group to a minimum, and were diluted with
PBS directly before use. DMSO is reported as membrane permeability enhancer
increasing the cellular uptake as well as the solubility of small molecule drugs at
low concentrations of 10-20% DMSO. Furthermore, a concentration dependent in-
crease in cell death is observed, whereby the toxic concentration is cell line depen-
dent.[332],[333],[334] No cytotoxicity of DMSO on HeLa cells could be observed after
5 min incubation in up to 5% DMSO. Synthesis of novel peptide-based reagents was
performed in highly concentrated solutions to ensure a final DMSO concentration
on the cells below 1%.
Biotinylated proteins were captured out of full cell lysates on streptavidin-sepha-
rose, starting with the same amount of total protein per sample for comparative
analysis. Disulfide bonds were reduced and alkylated prior to tryptic digestion of
the captured proteins on the streptavidin beads to enhance the enzymes’s cleavage
efficiency. Capture efficiency could be demonstrated by Western Blot analysis of
HeLa cells biotinylated with commercial Sulfo-NHS-LC-biotin (see Figure 4.19).
Due to decreased reactivity of the peptide- and heparin-based reagents, Western Blot
analysis of the novel reagents is not possible without loading vast protein amounts
severely compromising the quality of the analysis. FACS and CLSM analysis are
the method of choice to reliably evaluate the biotinylation of cells.
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Figure 4.19.: SDS-PAGE and Western Blot analysis of cell lysate from HeLa. Cell surface
protein biotinylation with Sulfo-NHS-LC-biotin (B), PBS treated cell lysate as negative
control (A), supernatant of B after capturing with streptavidin-sepharose (C); 15 µg total
protein loaded per lane.
The captured and digested amount of biotinylated proteins resulting from origi-
nally 500 µg of total protein was analysed per LC/MS run. According to experience
with the LC/MS system and 2D peptide map densities, the biotinylated proteome
fraction is estimated to be 1-2% of the total protein content within the cell lysate.
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4.3.4. In Vitro Validation: Mass Spectrometric Analysis
4.3.4.1. Peptide-Based Biotinylation Reagents
Adherent HeLa cells were biotinylated with equal amounts of 5 µmol biotinylation
reagent (SMCC-Cys-(L-Asp)3-biotin, SM(PEG)6-Cys-(L-Asp)3-biotin, Sulfo-NHS-
LC-biotin or NHS-PEG12-biotin and PBS as negative control) per cell culture flask.
For comparative analysis, capturing of biotinylated proteins was performed with
identical total protein amounts of 500 µg. The analysis of technical triplicates per
reagent was performed on a MALDI TOF/TOF™ 5800 system (AB SCIEX).
MS1 spectra were extracted using the Data Explorer® Software. For visualisa-
tion of successful chromatographic separation and differences in captured protein
amount, 2D peptide maps were generated (see Figure 4.20).
A B 
C D 
E 
Figure 4.20.: 2D peptide maps of in vitro biotinylated samples (exemplary maps). Biotiny-
lation with Sulfo-NHS-LC-biotin (A), NHS-PEG12-biotin (B), SMCC-Cys-(L-Asp)3-biotin
(C), SM(PEG)6-Cys-(L-Asp)3-biotin (D), PBS (negative control) (E). m/z ratio (x-axis),
UPLC fractions (y-axis) and normalized signal intensity as grey scale. Normalization to
internal standard at m/z 1411 with standard peak height set to 1000, peak height capping
at 500.
MS/MS spectra were searched against a human database using the ProteinPilot™
Software with the Paragon™ algorithm.[335] Peptide proteotypicity was determined
against a human database without isoforms with the in-house developed PepSir
software.[282] Degenerated peptide entries as well as peptides not reaching the 95%
confidence limit filter were not included for further analysis.
The summaries of proteotypic peptides were used to analyse the differences in
identified peptides/proteins with the particular biotinylation reagents. The informa-
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tion obtained from triplicate measurements was summed for analysis to compensate
for technical run-to-run differences. In total, 1574 proteins were identified, thereof
1090 proteins with more than one proteotypic peptide in at least one reagent group
(termed without one hit wonders, in brackets) (see Suppl. Table B.3). 1374 (1015)
proteins were identified with commercial Sulfo-NHS-LC-biotin, 983 (830) with NHS-
PEG12-biotin. With the novel peptide-based reagent SMCC-Cys-(L-Asp)3-biotin
1096 (888) proteins were obtained, 517 (488) with SM(PEG)6-Cys-(L-Asp)3-biotin.
Numbers and overlap between samples are shown in Figure 4.21.
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Figure 4.21.: Venn diagram showing numbers of identified proteins (without one hit won-
ders) of in vitro biotinylated samples. Commercial reagents Sulfo-NHS-LC-biotin (dark
grey), NHS-PEG12-biotin (light grey) and peptide-based reagents SMCC-Cys-(L-Asp)3-
biotin (dark blue), SM(PEG)6-Cys-(L-Asp)3-biotin (light blue).
Within the PBS-treated negative control 65 (62) proteins were identified. The
degree of non-specific binding of highly abundant proteins to the streptavidin-
sepharose is low. The top hits identified with high peptide numbers within the
negative control (see Table 4.1) are not binding non-specifically to the streptavidin
resin: Biotin is a covalently bound cofactor for carboxylases, leading to their co-
purification with the biotinylated target proteins.[336],[337]
ID Protein name Gene name PBS LC PEG SMCC SMPEG
Q13085 Acetyl-CoA carboxylase 1 ACACA 99 101 91 98 104
P11498 Pyruvate carboxylase PC 76 57 58 69 64
P05165 Propionyl-CoA carboxylase alpha chain PCCA 29 21 15 29 30
Q96RQ3 Methylcrotonyl-CoA carboxylase subunit alpha MCCC1 21 13 11 26 21
O00763 Acetyl-CoA carboxylase 2 ACACB 8 8 4 6 13
Table 4.1.: Top hits identified in PBS control. Numbers of identified proteotypic peptides
are shown for the negative control (PBS), the commercial reagents Sulfo-NHS-LC-biotin
(LC) and NHS-PEG12-biotin (PEG) as well as for both peptide-based reagents SMCC-
Cys-(L-Asp)3-biotin (SMCC) and SM(PEG)6-Cys-(L-Asp)3-biotin (SMPEG).
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The identification of a high number of proteotypic peptides from low-abundant
plasma membrane proteins is the prerequisite for a stable quantification in biomarker
research. The enrichment of low-abundant plasma membrane proteins and the si-
multaneous decrease in identification of high-abundant intracellular proteins is ex-
emplary demonstrated in the following by comparison to a full proteome dataset
of the HeLa cell line obtained by Nagaraj et al.[130] The summary of all identified
peptides within the literature dataset was filtered for proteotypicity using the in-
house developed PepSir software with the same human database used for the surface
proteome dataset. Nagaraj et al. identified 10255 proteins, thereof 10% annotated
to the plasma membrane. Based on MS1 signal intensities, Nagaraj et al. estimated
cellular abundance (copies per cell) of the identified proteins by intensity based ab-
solute quantification (iBAQ): The sum of all peptide peak intensities divided by the
number of all theoretically observable peptides was translated to an absolute protein
amount based on the total protein amount in the analyzed sample.[130],[42] Hereby,
a median copy number of 18 000 molecules per protein and cell was obtained; the
lower abundant half of the proteome only accounted for 2% of its mass.[130]
The significantly decreased identification of high-abundant intracellular proteins
is demonstrated exemplarily with the 20S core unit of the 26S proteasome (see Ta-
ble 4.2). The ubiquitin-proteasome pathway is a major pathway for protein degrada-
tion within cells.[338] The eukaryotic 26S proteasome consists of a 20S core and two
19S regulatory subunits at the ends.[339] The barrel-shaped 20S core unit is composed
of 28 subunits, namely two copies of seven α- and seven β-type subunits forming
outer and inner rings, the PSMB8 subunit can hereby replace PSMB5.[339],[340] The
ID Protein name Gene name copies full LC PEG SMCC SMPEG PBS
per cell proteome
P25786 Proteasome subunit alpha type-1 PSMA1 1.2×106 9 - - - - -
P25787 Proteasome subunit alpha type-2 PSMA2 2.2×106 13 - - - - -
P25788 Proteasome subunit alpha type-3 PSMA3 1.3×106 16 - - - - -
P25789 Proteasome subunit alpha type-4 PSMA4 1.2×106 15 1 - 1 - -
P28066 Proteasome subunit alpha type-5 PSMA5 3.3×106 21 - - - - -
P60900 Proteasome subunit alpha type-6 PSMA6 1.8×106 21 2 3 1 - -
O14818 Proteasome subunit alpha type-7 PSMA7 2.8×106 14 - - - - -
P20618 Proteasome subunit beta type-1 PSMB1 2.8×106 12 - - - - -
P49721 Proteasome subunit beta type-2 PSMB2 2.7×106 3 1 - 1 - -
P49720 Proteasome subunit beta type-3 PSMB3 1.3×106 4 - - - - -
P28070 Proteasome subunit beta type-4 PSMB4 1.7×106 3 - - - - -
P28074 Proteasome subunit beta type-5 PSMB5 1.0×106 4 1 - 1 - -
P28072 Proteasome subunit beta type-6 PSMB6 1.3×106 7 - - - - -
Q99436 Proteasome subunit beta type-7 PSMB7 4.3×105 6 - - - - -
P28062 Proteasome subunit beta type-8 PSMB8 1.7×105 8 - - - - -
Table 4.2.: Subunits of the 20S core of the 26S proteasome identified in the in vitro dataset.
Copy numbers per cell as well as the full proteome data taken from Nagaraj et al.[130]
Numbers of identified proteotypic peptides are shown for the full proteome dataset, the
commercial reagents Sulfo-NHS-LC-biotin (LC) and NHS-PEG12-biotin (PEG) as well as
for both peptide-based reagents SMCC-Cys-(L-Asp)3-biotin (SMCC) and SM(PEG)6-Cys-
(L-Asp)3-biotin (SMPEG) and the negative control (PBS).
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proteasome subunits are high-abundant within the cell (on average 1.7×106 copy
numbers per subunit and cell). Whereas the identification was stable within the full
proteome dataset of Nagaraj et al., only a few subunits are identified with very low
peptide numbers within the surface proteome dataset in all biotinylation reagents
groups.
On the other hand, low copy number plasma membrane proteins were compared
between the full proteome from Nagaraj et al. and the surface proteome dataset
(see Table 4.3). Low-abundant proteins are under-represented in the full proteome
dataset. Some proteins are not identified at all within the full proteome dataset,
but also for identified, low-abundant proteins, the number of identified, proteotypic
peptides is mostly small, impairing stable quantification of the protein. The numbers
of identified proteotypic peptides is heavily increased across the surface proteome
dataset with all different biotinylation reagents enabling a stable quantification.
ID Protein name Gene name copies full LC PEG SMCC SMPEG PBS
per cell proteome
Q9NPH3 Interleukin-1 receptor accessory protein IL1RAP 200 - 14 13 10 12 -
Q14517 Protocadherin Fat 1 FAT1 260 10 40 35 50 37 -
Q02413 Desmoglein-1 DSG1 730 1 3 - 9 2 -
O14786 Neuropilin-1 NRP1 1300 1 14 13 14 11 -
Q6UVK1 Chondroitin sulfate proteoglycan 4 CSPG4 1500 3 68 70 67 60 -
P02751 Fibronectin FN1 2000 9 10 7 16 18 -
Q6YHK3 CD109 antigen CD109 3500 8 43 38 36 27 -
P23229 Integrin alpha-6 ITGA6 1.1×104 13 21 21 17 14 -
P26006 Integrin alpha-3 ITGA3 3.3×104 14 16 14 8 4 -
P32004 Neural cell adhesion molecule L1 L1CAM 5.4×104 18 49 48 55 48 -
Q14126 Desmoglein-2 DSG2 6.3×104 23 47 45 40 37 -
P13987 CD59 glycoprotein CD59 5.4×105 8 7 6 4 3 -
Q4KMG0 Cell adhesion molecule-related/ CDON - - 2 1 2 2 -
down-regulated by oncogenes
Q8N441 Fibroblast growth factor receptor-like 1 FGFRL1 - - 5 5 3 2 -
Table 4.3.: Plasma membrane proteins (examples) identified in the in vitro dataset. Copy
numbers per cell as well as the full proteome data taken from Nagaraj et al.[130] Num-
bers of identified proteotypic peptides are shown for the full proteome dataset, the com-
mercial reagents Sulfo-NHS-LC-biotin (LC) and NHS-PEG12-biotin (PEG) as well as for
both peptide-based reagents SMCC-Cys-(L-Asp)3-biotin (SMCC) and SM(PEG)6-Cys-
(L-Asp)3-biotin (SMPEG) and the negative control (PBS).
Enrichment for cell surface proteins with all biotinylation reagents could be demon-
strated by gene ontology (GO) analysis using the WEB-based GEne SeT AnaLysis
Toolkit (Webgestalt).[283],[284] Cell surface and cell periphery are the main enriched
branches in the directed acyclic graph. Moreover, cytosolic ribosome is an enriched
category: Within the dataset, ribosomal subunits are identified throughout all bi-
otinylation reagent groups with a median number of three proteotypic peptides per
protein. Ribosomal subunits belong to the highest abundant proteins in the HeLa
cell line as shown by Nagaraj et al.: More than 70% of the identified ribosomal
background proteins belong to the top 150 (< 2%) proteins in terms of abundance
and have a median copy number of 4.9×106 molecules per cell.[130] Reasons for the
identification of intracellular background proteins will be elucidated later.
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Figure 4.22.: Enrichment analysis of the cellular component of the core proteome (419
proteins) identified with all reagents, but not in the negative control. Visualisation as
directed acyclic graph using Webgestalt.[283],[284] Enriched GO categories are depicted in
red, name of the GO category, number of included genes and adjusted p-value are shown.
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To analyse differences in protein localization across the various biotinylation re-
agents, subcellular localization information was extracted from the UniProt website.
The localization information was curated by screening for the categories plasma
membrane, extracellular and secreted, membrane associated, intracellular and no
information available (see Figure 4.23). Membrane associated proteins (depicted
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Figure 4.23.: Protein localization in the in vitro dataset. Percentage and total protein
numbers are depicted. Categories: Plasma membrane, extracellular and secreted (red),
membrane associated (orange), intracellular (grey), no annotation information available
(black). Data (all proteins and without one hit wonders) for the commercial reagents
Sulfo-NHS-LC-biotin (LC) and NHS-PEG12-biotin (PEG) as well as for both peptide-
based reagents SMCC-Cys-(L-Asp)3-biotin (SMCC) and SM(PEG)6-Cys-(L-Asp)3-biotin
(SMPEG) is shown.
in orange) contain hydrophobic transmembrane domains and are often reported to
have receptor or cell adhesion functions. As plasma membrane proteome enrichment
was used, those proteins are most likely also localised in the plasma membrane. The
fraction of plasma membrane, secreted or membrane associated proteins is slightly
increased, when proteins identified with only one proteotypic peptide are excluded
from the analysis (without one hit wonders). The reason therefore is most likely
the less stable identification of intracellular proteins, which is also visible in terms
of numbers of identified proteotypic peptides per protein: Intracellular proteins are
identified with an average number of 4.28 proteotypic peptides, whereas proteins
belonging to the categories plasma membrane, extracellular or membrane associated
are identified with 6.75 proteotypic peptides on average.
Plasma membrane, extracellular and membrane-associated proteins constitute be-
tween 38% (SMCC-Cys-(L-Asp)3-biotin) and 49% (SM(PEG)6-Cys-(L-Asp)3-biotin)
of all identified proteins (without one hit wonders). Both reagents with a pegylated
linker (NHS-PEG12-biotin, SM(PEG)6-Cys-(L-Asp)3-biotin) show a decreased reac-
tivity: Whereas the fraction of surface proteins is increased, the total number of
identified proteins is decreased. Size of the reagents and steric hindrance on the cell
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surface may play a role. Moreover, also the previously determined lower reactivity
of SMCC-Cys-(L-Asp)3-biotin compared to Sulfo-NHS-LC-biotin is visible in terms
of numbers of identified proteins. 38% (48% without one hit wonders) of the surface
proteins are identified with all four biotinylation reagents. 16% (7%) are identi-
fied exclusively with Sulfo-NHS-LC-biotin, 9% (6%) only with SMCC-Cys-(L-Asp)3-
biotin, at which protein binding and transmembrane transporter activity are the main
functional categories. The reactivity differences between the reagents is mirrored in
the dataset in protein numbers, a fact also having an impact on the localization anal-
ysis. It was shown in chapter 4.2.1.2 that SMCC-Cys-(L-Asp)3-biotin exhibits 59%
reactivity (on average) compared to Sulfo-NHS-LC-biotin. In contrast, speaking of
identified protein numbers, the number of identified surface annotated proteins is
72% (79% without one hit wonders) of the Sulfo-NHS-LC-biotin protein numbers.
Both selectivity of the reagent and reactivity play contrary roles. The reactivity
differences will be further examined later in this chapter.
Despite the surface proteome enrichment, a considerable fraction of intracellular
proteins is identified within the dataset. Non-specific attachment of proteins to the
streptavidin resin is negligible, as there are only few proteins identified in the PBS
control. One reason is the sample preparation: The presence of some apoptotic cells
with permeable plasma membranes leads to biotinylation of intracellular proteins.
Especially very high-abundant proteins such as ribosomal subunits (see Figure 4.22)
are therefore stably identified across all different reagents sets but the PBS control.
Furthermore, co-purification of intracellular proteins attached to the labelled plasma
membrane proteins is possible. A certain extent of plasma membrane crossing of
small biotinylation reagents such as Sulfo-NHS-LC-biotin cannot be excluded: Bi-
otin transport across the cell membrane is reported to be carrier-mediated at low
concentrations, but non-saturated at high concentrations suggesting passive diffu-
sion.[341],[342],[343] An additional explanation can be found within the data analysis
strategy: The analysis of subcellular localization relies on database entries of GO
annotation, which might be incomplete or wrong. It is known, that antigens re-
ported as intracellular can be translocated to the plasma membrane under specific
conditions such as in a pre-apoptotic state or on malignant cells and cancer cell
lines.[16],[17],[18],[19]
In the following, similarity of technical replicates and reactivity differences be-
tween the biotinylation reagents is further examined. Relative quantification was
performed using the in-house developed software MSQBAT, a label-free method
based on MS1 signal intensities of proteotypic peptides.[282] The method is further
described in chapter 3.8.4. Briefly, MS1 intensities were normalized against internal
standard peptides, followed by annotation using the peptide summaries of proteo-
typic peptides. Individual features were extracted based on m/z, retention time and
annotation. Data complexity was reduced by applying a S/N and feature length
filter to obtain a more stable quantification. Hereby, 39% of the features could
be dismissed on average, while 99.5% of the identifications were kept. On average,
458 712 peaks per biotinylated sample were extracted to 79 289 features and reduced
to 50 669 features after the complexity reduction step.
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Cross-alignments within technical triplicates were used to propagate annotation
information, decreasing the variability from mass spectrometric performance differ-
ences and creating a more stable dataset (see Figure 4.24).
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Figure 4.24.: Annotation propagation with MSQBAT. Peptide/protein numbers before and
after annotation propagation within technical triplicates (mean and standard deviation).
Samples: Sulfo-NHS-LC-biotin (LC), NHS-PEG12-biotin (PEG), SMCC-Cys-(L-Asp)3-
biotin (SMCC), SM(PEG)6-Cys-(L-Asp)3-biotin (SMPEG), negative control (PBS).
Pairs of technical replicates were compared by feature alignment followed by pro-
tein quantification. The variability between technical replicates is low as shown in
Figure 4.25.
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Figure 4.25.: Quantification of pairs of technical replicates, median with interquartile
range. Blue dotted line (y = 0) indicates no regulation between samples, blue straight
lines (y = ±1) illustrate two-fold up- or down-regulation. Commercial reagents Sulfo-
NHS-LC-biotin (LC) and NHS-PEG12-biotin (PEG), peptide-based reagents SMCC-
Cys-(L-Asp)3-biotin (SMCC) and SM(PEG)6-Cys-(L-Asp)3-biotin (SMPEG) and negative
control (PBS).
Subsequently, technical triplicates were combined to super-samples via align-
ment by a genetic algorithm (GEAL alignment). For relative quantification, each
super-sample was GEAL aligned against the Sulfo-NHS-LC-biotin super-sample (see
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Figure 4.26.: Quantification of all biotinylation reagents (NHS-PEG12-biotin (PEG),
SMCC-Cys-(L-Asp)3-biotin (SMCC), SM(PEG)6-Cys-(L-Asp)3-biotin (SMPEG) and neg-
ative control (PBS)) vs. Sulfo-NHS-LC-biotin, median with interquartile range. Blue dot-
ted line (y = 0) indicates no regulation between samples. All proteins (a) or without one
hit wonders (b).
Suppl. Table B.4 and Figure 4.26). In total, 1526 proteins could be quantified,
thereof 1037 with more than one proteotypic peptide. Compared to the variability
between technical replicates, the protein distribution is widespread, and narrowing a
bit, if proteins quantified with only one proteotypic peptide are excluded from anal-
ysis as outliers are reduced. The variability between the commercial reagents Sulfo-
NHS-LC-biotin and NHS-PEG12-biotin is low. The peptide-based reagents exhibit
a larger difference to commercial Sulfo-NHS-LC-biotin visualized by a widespread
distribution. As already expected in terms of identified protein numbers, the de-
creased reactivity is evident by a shift of the median with a two-fold down-regulation
with SMCC-Cys-(L-Asp)3-biotin, and a five-fold down-regulation with SM(PEG)6-
Cys-(L-Asp)3-biotin. Between the negative control and Sulfo-NHS-LC-biotin, 1274
(962) proteins are quantified, which is a sign for a presence vs. absence situation: To
enable relative quantification, MSQBAT replaces non-existing values with an artifi-
cially introduced background intensity value, resulting in a more than twenty-fold
down-regulation (median).
The in vitro proof-of-principle study could demonstrate that the novel peptide-
based reagents stably identify proteins annotated to the cell surface, whereas the
identification of intracellular proteins is decreased. Previously determined reactivity
differences across the biotinylation reagents were also mirrored in the mass spectro-
metric dataset.
4.3.4.2. Heparin-Based Biotinylation Reagents
Adherent HeLa cells were biotinylated with equal amounts of biotinylation reagent
(Biotin-Heparin-sNHS, Biotin-Enoxaparin-sNHS, Sulfo-NHS-LC-biotin and PBS as
negative control) with at least 1 µmol per 106 cells. For comparative analysis, captur-
ing of biotinylated proteins was performed with identical total protein amounts. The
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analysis of technical duplicates per reagent was performed on a MALDI TOF/TOF™
5800 system (AB SCIEX). Data from consecutive mass spectrometric evaluation of
different sample preparation strategies was acquired as singular measurements. Data
extraction, database searches and extraction of proteotypic peptides were performed
as described in chapter 4.3.4.1. To account for mass spectrometric performance
differences and run-to-run variability, annotations were propagated across samples
biotinylated with the same reagent based on MS1 data using MSQBAT.
693 (598 without one hit wonders) proteins have been identified with Biotin-Eno-
xaparin-sNHS, 756 (619) proteins with Biotin-Heparin-sNHS, 1259 (928) proteins
with Sulfo-NHS-LC-biotin and 37 (35) proteins in the negative control (see Suppl.
Table B.5a). Overlap between technical duplicates was more than 95% in terms of
protein identification. Subcellular localization was analysed using information from
the UniProt website (see Figure 4.27). The surface proteome fraction was signifi-
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Figure 4.27.: Protein localization in the in vitro dataset. Percentage and total protein
numbers are depicted, all proteins without one hit wonders. Categories: Plasma mem-
brane, extracellular and secreted (red), membrane associated (orange), intracellular (grey),
no annotation information available (black). Data for the commercial reagent Sulfo-NHS-
LC-biotin (LC) as well as for both heparin-based reagents Biotin-Heparin-sNHS (Hep)
and Biotin-Enoxaparin-sNHS (Enox) are shown.
cantly reduced with the heparin-based reagents compared to Sulfo-NHS-LC-biotin.
To identify the reason for the reduced identification of the desired protein classes, an
enrichment analysis was performed using Webgestalt based on all proteins identified
with at least two peptides with both heparin-based reagents (see Figure 4.28).[283],[284]
As already shown in chapter 4.3.4.1, some high-abundant background proteins be-
longing to the cytosolic ribosome are enriched. For the heparin-based reagents,
around half of all identified proteins belong to the highly enriched categories nu-
clear part, heterocyclic compound binding/nucleotide binding/RNA binding.
NHS-activation of the carboxylic group was shown to work efficiently and to be
crucial for protein binding: The treatment of adherent cells with non-activated
Biotin-Heparin led to the identification of only 21 (20) proteins, in accordance with
the negative control (see Suppl. Table B.5c). In order to identify reasons for the
co-purification of nuclear proteins mentioned above, different sample preparation
strategies have been tested (see Suppl. Table B.5b). Variation of the number of
charges by activation with nine- (half activated) or twenty-fold (fully activated hep-
arin chains) excess of sNHS did not influence the result.
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Figure 4.28.: Enrichment analysis of cellular component and molecular function of 545
proteins identified within all sample based on Biotin-Heparin-sNHS and Biotin-Enoxapa-
rin-sNHS (without one hit wonders). Visualisation as directed acyclic graph using We-
bgestalt.[283],[284] Enriched GO categories are depicted in red, name of the GO category,
number of included genes and adjusted p-value are shown.
With the twenty-fold activated Biotin-Heparin-sNHS, 649 (558) proteins were
identified with an intracellular fraction of 76.5%, with the nine-fold activated Biotin-
Heparin-sNHS 639 (551) proteins were identified, thereof 76.6% with intracellular an-
notation (see Table 4.4). Moreover, captured protein samples have been subjected to
various washing strategies. Gradients of 0-1 M sodium or potassium chloride, chang-
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ing pH values as well as extraction in alkaline sodium carbonate solution are reported
to disrupt non-covalent protein-protein or heparin-protein interactions.[344],[345],[346]
Therefore, washing with high-salt buffer (2 M NaCl), buffers with changing pH
(pH 5, pH 8, pH 12) and carbonate extraction were examined on samples treated
with Biotin-Heparin-sNHS (see Table 4.4). No significant change of the fraction
of identified intracellular proteins was obtained with any strategy. Furthermore,
the influence of delipidation with organic solvents (1-butanol/diisopropylether) was
evaluated, a technique reported for efficient release and solubilisation of plasma
membrane proteins from the surrounding lipids (see Table 4.4).[347]. Both with Bio-
tin-Heparin-sNHS and the commercial reagent Sulfo-NHS-LC-biotin, the result was
not changed, i.e. delipidation was shown to be unnecessary when working in an
in vitro system. Reduction of disulfide bridges with TCEP and alkylation with
IAA was used for all samples, as it is reported to improve tryptic digest, sequence
coverage and the detection of cysteine-containing peptides in standard proteomic
workflows.[348],[349] Pre-incubation of the adherent cells with an excess of free DNA
to non-covalently bind free nuclear proteins deriving from apoptotic cells did neither
change the number of identified proteins nor the identified surface proteome frac-
tion (437 proteins without one hit wonders, thereof 75.7% intracellular) (see Suppl.
Table B.5c).
Sample Preparation Protein number % intracellular
20x Biotin-Heparin-sNHS reduction/alkylation 558 76.5%
20x Biotin-Heparin-sNHS reduction/alkylation/high-salt 535 77.8%
20x Biotin-Heparin-sNHS reduction/alkylation/pH 413 78.0%
20x Biotin-Heparin-sNHS reduction/alkylation/carbonate 541 76.9%
20x Biotin-Heparin-sNHS reduction/alkylation/delipidation 560 75.9%
9x Biotin-Heparin-sNHS reduction/alkylation 551 76.6%
9x Biotin-Heparin-sNHS reduction/alkylation/high-salt 554 76.5%
9x Biotin-Heparin-sNHS reduction/alkylation/pH 435 77.9%
9x Biotin-Heparin-sNHS reduction/alkylation/carbonate 545 76.1%
Sulfo-NHS-LC-biotin reduction/alkylation 1095 61.5%
Sulfo-NHS-LC-biotin reduction/alkylation/high-salt 1048 60.9%
Sulfo-NHS-LC-biotin reduction/alkylation/pH 956 60.6%
Sulfo-NHS-LC-biotin reduction/alkylation/carbonate 1084 60.9%
Sulfo-NHS-LC-biotin reduction/alkylation/delipidation 1098 61.1%
Table 4.4.: Sample preparation tests on HeLa cells biotinylated with differentially acti-
vated Biotin-Heparin-sNHS or commercial Sulfo-NHS-LC-biotin. Numbers of identified
proteins (without one hit wonders) and percentage of the intracellular fraction are shown.
Sample preparation strategies are further described in the text.
Two hypotheses either based on non-covalent or on covalent binding can help
to explain the co-enrichment of nuclear proteins with the heparin-based reagents.
Reason for the severe enrichment of DNA- or RNA-binding proteins can be found
in the structural similarity of the heparin chain to the DNA backbone. Since a
long time, heparin beads have been widely used in affinity purification of heparin-
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or DNA-binding proteins or other positively charged proteins such as transcrip-
tion factors, nucleotide-binding enzymes, Antithrombin III, lipoprotein lipase or
Interleukin-8.[350],[344],[351],[352],[353],[354] The interaction between DNA and proteins are
mostly based on ionic interactions, van der Waals contacts and H bonds, thereof
about two thirds are reported to be non-specific with the sugar-phosphate back-
bone.[355],[356] Charges of amino acid side chains are hereby distributed topologically
so that the protein behaves like a dipole with the positive charge facing the DNA.[357]
The DNA blocking strategy might not show any significant effect, because the highly
sulfated heparin chains mimic the structure of the negatively charged, ribose-based
backbone of nucleotide chains and are reported to compete with the DNA for protein
binding.[358],[359]
Attachment of nuclear proteins to the heparin chains might not only occur dur-
ing the labelling reaction due to a fraction of membrane permeable apoptic cells,
but also within the cell lysates by non-covalent, polarity-based interactions. Due
to the extremely high number of charged side groups in the heparin chains, the
protein interaction might be too strong for effective elution of all non-covalently
bound proteins when using the applied washing strategies. However, for elution of
DNA-binding proteins from heparin columns, typically 0 M to 1 M, in rare cases
also up to 2 M sodium or potassium chloride gradients are used.[350],[344],[360] There-
fore, the applied washing strategies, e.g. with 2 M sodium chloride, should at least
decrease the fraction of nuclear proteins to support the hypothesis of a non-covalent
interaction.
If covalent attachment is taken as a basis, the labelling reaction must occur on
the adherent cells, before quenching of the reagent. Due to their size, heparin-based
reagents are unlikely to cross the plasma membrane, therefore nuclear proteins must
be derived from membrane-permeable apoptotic cells. The co-enrichment of the
intracellular proteins cannot be dependent on pure protein abundance, as especially
the nuclear fraction is severely enriched. Therefore, the labelling of those proteins
might be mediated by a primary non-covalent interactions immediately becoming
covalent due to the activated carboxylic groups. However, the reaction of activated
carboxylic groups is so fast, that one can doubt the high specificity of the labelling
reaction for a specific class of proteins. Nevertheless, compared to commercial Sulfo-
NHS-LC-biotin, the same amount of heparin-based reagent has far more activated
carboxylic groups (on average 25-fold activation) and therefore more possibilities for
side-reactions.
The unavailability of further Biotin-Heparin unfortunately prevents the elucida-
tion of this phenomenon. If possible, the coupling of non-activated Biotin-Heparin
to streptavidin-sepharose, followed by addition of a whole cell lysate should be ex-
amined to shed some light on the undesired co-enrichment of nuclear proteins.
Importantly, the in vitro study of heparin-based biotinylation reagents has shown
that the surface proteome enrichment is suffering from the ability of the heparin
chains to interact with nucleic acid binding proteins leading to co-enrichment of
nuclear proteins.
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4.4. In Vivo Validation of Novel Biotinylation
Reagents
4.4.1. Workflow In Vivo Validation
In vivo validation of the novel peptide- and heparin-based biotinylation reagents
was performed via perfusion of healthy NSG mice in comparison to the commer-
cial reagents Sulfo-NHS-LC-biotin and NHS-PEG12-biotin (see Figure 4.29). Bi-
otinylation efficacy was visualised by confocal laser scanning microscopy (CLSM)
of tissue sections from kidney, liver, spleen, tongue and brain as well as by ELISA
and Western Blot analysis using streptavidin conjugates for detection. Mass spec-
trometric analysis of the biotinylated proteome fraction was performed with kid-
ney and liver samples from mice perfused with Sulfo-NHS-LC-biotin, NHS-PEG12-
biotin, SMCC-Cys-(L-Asp)3-biotin, SM(PEG)6-Cys-(L-Asp)3-biotin, Biotin-Hepa-
rin-sNHS, Biotin-Enoxaparin-sNHS and PBS or non-perfused tissue as negative
controls. Enrichment levels of selected protein candidates were further assessed
via SRM analysis.
Reduction/Alkylation 
Delipidation 
Perfusion 
Biotinylation  
reagent 
Tissue 
homogenisation Capturing 
Streptavidin 
resin 
CLSM Western Blot 
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Digestion on resin 
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Separation UPLC 
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MS analysis 
MALDI TOF/TOFTM 5800 
(AB SCIEX) 
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Organ excision 
Proteins 
Blood vessel 
SRM analysis 
QTRAP® 6500 (AB SCIEX) 
Figure 4.29.: Workflow in vivo validation.
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4.4.2. Visualization of Biotinylation of Vascular Accessible
Proteins
4.4.2.1. Biotinylation Depth Around Blood Vessels
For the development of novel diagnostics or targeted therapies, biomarkers exclu-
sively expressed on the surface of diseased cells, in the surrounding extracellular
matrix or on newly formed blood vessels have to be identified. Angiogenesis is a
rare event in an healthy adult, occuring during wound healing and under pathologi-
cal conditions.[82] For instance, the formation of new blood vessels in tumour tissue
is needed, as nutrient supply is essential for tumour growth and viability.[361],[84]
Hereby, tumour vessels exhibit an abnormal structure compared to the normal vas-
culature: Vessels are leaky and highly interconnected, endothelial cells have an
aberrant morphology and are also distinct on molecular level.[79],[91],[89],[90] Biodis-
tribution studies proved targeted drugs to be stably enriched in the tumour tissue
for several days.[362],[363],[364] Other pathological situations with angiogenic events
include chronic inflammatory diseases such as inflammatory bowel disease, rheuma-
toid arthritis, atherosclerosis, psoriasis or ocular angiogenesis in blinding eye disease
such as proliferative diabetic retinopathy.[14],[94],[365],[102],[100]
However, not all biomarkers within a diseased tissue are accessible by a specific
monoclonal antibody or an antibody-drug conjugate: The distance around blood
vessels reached by a diagnostic agent or a drug depends on the size and charge of
the molecule (diffusion characteristics) as well as on the affinity to the target struc-
ture and the target concentration within the diseased tissue.[72] Immunofluoresce-
nence studies revealed tumour penetration with various labelled antibodies against
tumour-specific antigens: Clear vascular staining and an antibody-dependent pene-
tration depth around blood vessels of at least three cell layers were detected.[366],[367]
Stable identification and quantification of novel vascular-accessible targets by mass
spectrometric analysis is enabled by vascular perfusion with biotinylation reagents
labelling the surface of endothelial cells, cells in close proximity of the blood vessels
and in the perivascular extracellular matrix.
In vivo perfusion of mice was performed according to the protocol from Rösli
et al. with 25 µmol per biotinylation reagent and mouse.[185] Immunofluorescent
staining against CD31 as endothelial marker, nuclear staining with DAPI and biotin-
staining with a streptavidin derivative was performed to reveal the biotin-labelled
areas in various tissue samples. Successful vascular labelling and a biotinylation
depth of a few cell layers around the blood vessels could be proven (see Figure 4.30)
Kidney tissue exhibited the strongest signal, liver tissue was mainly stained around
vascular structures. Furthermore, it could be shown that biotinylation reagents
are able to enter highly vascularized regions such as the glomeruli in kidney tissue
(see Figure 4.30A) or capillary structures between muscle fibers in the tongue (see
Figure 4.30D).
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Figure 4.30.: Visualisation of biotinylation depth around blood vessels. DAPI (blue), bi-
otin (green), endothelial marker CD31 (red), scale bars: 50 µm. Sections from mouse tissue
perfused with SMCC-Cys-(L-Asp)3-biotin: kidney A, liver B, spleen C and tongue D.
4.4.2.2. Biotinylation With Different Reagents
The successful biotinylation of kidney, liver, spleen, tongue and brain tissue was
examined with commercial, peptide- (see Figure 4.31) and heparin-based reagents
(see Figure 4.32). Vascular biotin labelling as well as the biotinylation depth around
blood vessels are comparable across all reagents. Biotin staining from tissue sections
of mice perfused with Biotin-Heparin-sNHS or Biotin-Enoxaparin-sNHS is weak,
as expected for the enormous size of the reagents allowing less biotin derivatives
per area compared to the commercial or peptide-based reagents. Therefore, laser
properties were optimized for the two subgroups individually. PBS-perfused or non-
perfused mice served as negative controls; corresponding staining controls to all
samples are shown in Suppl. Figure A.1.
CLSM analysis of all samples taken for mass spectrometric validation of the novel
peptide- and heparin-based biotinylation reagents as well as the corresponding stain-
ing controls are shown in Suppl. Figures A.2 and A.3 for kidney tissue and in Suppl.
Figures A.5 and A.6 for liver tissue. Immunofluorescent staining intensity is both
dependent on the biotinylation reagent and on the perfusion efficacy of a particular
mouse. Biotin signal intensity was observed to be stronger for kidney tissue than for
liver samples. Especially the signals for the heparin-based biotinylation reagents are
close to the detection limit in liver tissue; non-specific and non-vascular background
biotin-stain occurs in the corresponding PBS- or non-perfused negative controls.
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Figure 4.31.: CLSM of mouse tissue perfused with commercial and peptide-based reagents.
DAPI (blue), biotin (green), endothelial marker CD31 (red), scale bars: 50 µm. Sections
from mouse tissue perfused with Sulfo-NHS-LC-biotin (a), NHS-PEG12-biotin (b), SMCC-
Cys-(L-Asp)3-biotin (c), SM(PEG)6-Cys-(L-Asp)3-biotin (d), PBS perfused controls (e),
non-perfused controls (f). Corresponding staining controls see Suppl. Figure A.1.
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Figure 4.32.: CLSM of mouse tissue perfused with heparin-based reagents. DAPI (blue),
biotin (green), endothelial marker CD31 (red), scale bars: 50 µm. Sections from mouse
tissue perfused with Biotin-Heparin-sNHS (a), Biotin-Enoxaparin-sNHS (b), PBS per-
fused controls (c), non-perfused controls (d). Corresponding staining controls see Suppl.
Figure A.1.
4.4.3. Sample Preparation for Mass Spectrometric Analysis
Healthy NSG mice were perfused with equal amounts of 25 µmol per biotinylation re-
agent (4 mice per reagent group, perfusion with Sulfo-NHS-LC-biotin, NHS-PEG12-
biotin, SMCC-Cys-(L-Asp)3-biotin, SM(PEG)6-Cys-(L-Asp)3-biotin, Biotin-Hepa-
rin-sNHS, Biotin-Enoxaparin-sNHS, PBS- and non-perfused as negative controls),
followed by perfusion with a Tris containing quenching solution to inactivate non-
reacted reagent. Proteins were extracted from kidney and liver tissue by tissue ho-
mogenisation, sonication and one freeze-thaw cycle in a detergent-containing buffer.
The amount of biotinylated proteins within the tissue homogenates was assessed by
ELISA (see Figure 4.33) and Western Blot (see Figure 4.34).
All ELISA samples were measured against a BSA standard biotinylated with ten-
fold excess of Sulfo-NHS-LC-biotin in a 1 to 10 ratio. Absolute ELISA biotinylation
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Figure 4.33.: ELISA of biotinylated mouse kidney (a,b) and liver (c,d) tissue. Biotinylation
with Sulfo-NHS-LC-biotin (LC), NHS-PEG12-biotin (PEG), SMCC-Cys-(L-Asp)3-biotin
(SMCC), SM(PEG)6-Cys-(L-Asp)3-biotin (SMPEG), Biotin-Heparin-sNHS (Hep), Bio-
tin-Enoxaparin-sNHS (Enox), perfusion with PBS (PBS) or non-perfused (no) tissue as
negative controls. Unpaired t-test with significance levels *** (P≤0.0001), ** (P≤0.01), *
(P≤0.05), ns (P>0.05).
values are therefore artificial and at best a rough estimation, but relative differences
in biotinylation efficacy can be displayed within and across the sample groups. Dif-
ferences in the biotinylation efficacy among biological replicates show the variation
of perfusion efficacy, but also biological variation among non-perfused tissue from
different mice. As already seen by CLSM measurements (see chapter 4.4.2.2), kid-
ney tissue biotinylation is stronger than the biotinylation of liver tissue. Samples
exhibit clear biotinylation within all reagent groups when compared to the PBS-
perfused control. Nevertheless, reactivity differences between commercial, peptide-
and heparin-based reagents are visible: For the highly biotinylated kidney tissue,
commercial and peptide-based reagents cannot be evaluated within the same ex-
periment, in order to ensure a linear correlation within the ELISA standard range.
Heparin-based reagents exhibit low biotinylation levels. Background signal from
PBS- or non-perfused mice is derived from endogenous biotin-containing proteins
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(e.g. carboxylases), or, in the case of non-perfused mice, additionally from endoge-
nous biotin serum-levels of about 4 ng/mL in blood.[368]
Reactivity differences across the different reagents could also be shown by West-
ern Blot analysis of kidney tissue homogenates using Streptavidin-HRP for detec-
tion. To obtain signals for liver tissue or heparin-based reagents, vast total protein
amounts have to be loaded, severely restricting the quality of the Western Blot.
The biotin-detection from perfusion with peptide-based reagents (see Figure 4.34)
is only achievable following loading of triple total protein amount compared to the
commercial reagents and by prolonging the Western Blot film exposure time.
Biotin-dependent carboxylases play pivotal roles in the carbohydrate, fatty acid
and amino acid metabolism.[369] The pyruvate carboxylase (M = 127 kDa) is lo-
calized in the mitochondrial matrix and is essential in kidney and liver tissue as
main gluconeogenic organs.[370] Methylcrotonoyl-CoA carboxylase (M = 75 kDa,
subunit α) and Propionyl-CoA carboxylase (M = 75 kDa, α-chain) are also local-
ized in the mitochondrial matrix and play pivotal roles in fatty acid and amino acid
catabolism.[369] The enzymes are known to be detectable by Western Blot analysis
and are stably identifiable in the PBS- or non-perfused negative controls.[370]
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Figure 4.34.: Western Blots of biotinylated kidney homogenates. Perfusion with Sulfo-
NHS-LC-biotin (LC), NHS-PEG12-biotin (PEG), SMCC-Cys-(L-Asp)3-biotin (SMCC),
SM(PEG)6-Cys-(L-Asp)3-biotin (SMPEG), PBS (PBS) or non-perfused (no) as negative
controls. 20 µg (a) or 60 µg (b) total protein loaded per lane. 5 min (a) or 20 min (b)
exposure time.
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4.4.4. Mass Spectrometric Analysis of Biotinylated Kidney
Tissue
4.4.4.1. Discovery Experiment Kidney
For comparative proteomic analysis, capturing of biotinylated proteins was per-
formed with equal amounts of 1.25 mg total kidney protein on 100 µL streptavidin-
sepharose. Samples were processed by reduction, alkylation, delipidation and tryp-
tic digest. Peptides derived from 750 µg total protein amount were examined
per LC/MS run. Four biological replicates per reagent group (commercial re-
agents: Sulfo-NHS-LC-biotin, NHS-PEG12-biotin, peptide-based reagents: SMCC-
Cys-(L-Asp)3-biotin, SM(PEG)6-Cys-(L-Asp)3-biotin, heparin-based reagents: Bio-
tin-Heparin-sNHS, Biotin-Enoxaparin-sNHS, negative controls: PBS- or non-per-
fused) were analysed in two technical replicates each.
MS1 spectra were extracted using the Data Explorer® Software. Consistent chro-
matographic separation across the samples was visualised by 2D peptide mapping
(see Suppl. Figure A.8). MS/MS spectra were searched against a mouse database
using the ProteinPilot™ Software with the Paragon™ algorithm.[335] Peptide pro-
teotypicity was determined against a mouse database without isoforms using the
in-house developed PepSir software.[282] Degenerated peptide entries as well as pep-
tides not reaching the 95% confidence limit filter were not included for further anal-
ysis. Peptide identification information was summed within one reagent group to
compensate for technical run-to-run differences and to obtain a stable dataset.
In total, 1965 proteins were identified, thereof 1409 proteins with more than one
proteotypic peptide in at least one reagent group (without one hit wonders, in brack-
ets) (see Suppl. Table B.6). 1543 (1252) proteins were identified with commercial
Sulfo-NHS-LC-biotin, 1142 (1026) with NHS-PEG12-biotin. With the novel peptide-
based reagent SMCC-Cys-(L-Asp)3-biotin 1514 (1263) proteins were obtained, 1441
(1239) with SM(PEG)6-Cys-(L-Asp)3-biotin. 1209 (1053) proteins were found with
Biotin-Heparin-sNHS, 1469 (1200) with Biotin-Enoxaparin-sNHS. 44% (58%) of all
identified proteins within the datasets were found with every biotinylation reagent.
Variability between heparin-based and commercial reagents is higher compared to
peptide-based and commercial reagents: 1018 (957) proteins were identified with
all commercial and peptide-based reagents, corresponding to a proportion of 56%
(70%) within the subset, whereas 876 (831) proteins were identified with all commer-
cial and heparin-based reagents, corresponding to a fraction of 48% (60%) within
the subset. The overlap in protein identification between pairwise subsets of both
commercial, peptide-based or heparin-based reagent is large with 72% (81%) for
Sulfo-NHS-LC-biotin and NHS-PEG12-biotin, 77% (85%) for Biotin-Heparin-sNHS
and Biotin-Enoxaparin-sNHS and 77% (88%) for SMCC-Cys-(L-Asp)3-biotin and
SM(PEG)6-Cys-(L-Asp)3-biotin.
Within the PBS- or unperfused negative controls, 1008 (912) and 633 (597) pro-
teins have been identified, respectively. As expected from the in vitro dataset,
carboxylases carrying biotin as cofactor (e.g. Methylcrotonyl-CoA carboxylase, Pro-
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pionyl-CoA carboxylase, Acetyl-CoA carboxylase) are within the top-hits, very sta-
bly identified with proteotypic peptide counts in the two-digit range. The identified
background proteome is further elucidated in chapter 4.4.4.2.
Differences in protein localization across the various biotinylation reagents was
analysed via extraction of subcellular localization information from the UniProt
website. The localization information was curated by screening for the categories
plasma membrane, extracellular and secreted, internal side of the plasma membrane,
membrane associated, intracellular and no information available (see Figure 4.35).
Similar to the in vitro dataset, plasma membrane, extracellular and membrane-
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Figure 4.35.: Protein localization in the kidney dataset. Percentage and total protein num-
bers are depicted. Categories: Plasma membrane, extracellular and secreted (red), mem-
brane associated (orange), internal side of plasma membrane (yellow), intracellular (grey),
no annotation information available (black). Data without one hit wonders for the com-
mercial reagents Sulfo-NHS-LC-biotin (LC) and NHS-PEG12-biotin (PEG), the peptide-
based reagents SMCC-Cys-(L-Asp)3-biotin (SMCC) and SM(PEG)6-Cys-(L-Asp)3-biotin
(SMPEG), the heparin-based reagents Biotin-Heparin-sNHS (Hep) and Biotin-Enoxapa-
rin-sNHS (Enox) and the PBS- (PBS) or non-perfused (no) negative control is shown.
associated proteins constitute a 40-45% fraction with the commercial and peptide-
based reagents. However, in terms of the numbers of identified proteins, no influence
of the decreased reactivity of the peptide-based reagents compared to the commer-
cial ones is observed. With the heparin-based reagents, a 35-37% enrichment of the
desired proteome fraction is achieved. In the in vivo setting, no co-enrichment of
nuclear proteins is detectable: The analysis of the subset Biotin-Heparin-sNHS vs.
commercial Sulfo-NHS-LC-biotin revealed, that only 7% of the proteins identified
with Biotin-Heparin-sNHS are exclusively identified within this group. An enrich-
ment analysis of those proteins did not point towards any specifically enriched sub-
cellular localization. Within the Biotin-Enoxaparin-sNHS vs. Sulfo-NHS-LC-biotin
subset, the same is true for a 10% fraction of the proteins identified with Biotin-
Enoxaparin-sNHS.
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The closer analysis of the plasma membrane and extracellular matrix annotated
fraction (see Table 4.5) revealed the comparability of the peptide-based reagents to
the commercial reagents in terms of identified protein numbers, whereas the heparin-
based reagents show reduced reactivity. Variability across different reagent groups
is reduced if proteins identified with only one proteotypic peptide are excluded from
analysis. Within the negative controls, the number of identified proteins annotated
to the plasma membrane is reduced, but the fraction is still surprisingly high. Rea-
sons are further discussed in chapter 4.4.4.2.
Subset Protein number LC & Sample LC only Sample only
LC & PEG 537 409 (76.2%) 116 (21.6%) 12 (2.2%)
LC & SMCC 577 433 (75.1%) 92 (15.9%) 52 (9.0%)
LC & SMPEG 586 439 (74.9%) 86 (14.7%) 61 (10.4%)
LC & Hep 561 328 (58.5%) 197 (35.1%) 36 (6.4%)
LC & Enox 594 376 (63.3%) 149 (25.1%) 69 (11.6%)
LC & PBS 550 245 (44.5%) 280 (50.9%) 25 (4.6%)
LC & no 531 176 (33.1%) 349 (65.7%) 6 (1.2%)
LC & PEG 436 375 (86.0%) 58 (13.3%) 3 (0.7%)
LC & SMCC 461 395 (85.7%) 38 (8.2%) 28 (6.1%)
LC & SMPEG 463 402 (86.8%) 31 (6.7%) 30 (6.5%)
LC & Hep 454 302 (66.5%) 131 (28.9%) 21 (4.6%)
LC & Enox 469 343 (73.1%) 90 (19.2%) 36 (7.7%)
LC & PBS 448 232 (51.8%) 201 (44.9%) 15 (3.3%)
LC & no 437 172 (39.4%) 261 (59.7%) 4 (0.9%)
Table 4.5.: Identification of proteins annotated to plasma membrane or extracellular ma-
trix. Upper panel: all proteins, lower panel: without one hit wonders. Protein number
and overlap of all sample groups against commercial Sulfo-NHS-LC-biotin (LC) in protein
numbers and percentage. Commercial reagent NHS-PEG12-biotin (PEG), peptide-based
reagents SMCC-Cys-(L-Asp)3-biotin (SMCC) and SM(PEG)6-Cys-(L-Asp)3-biotin (SM-
PEG), heparin-based reagents Biotin-Heparin-sNHS (Hep) and Biotin-Enoxaparin-sNHS
(Enox) and the PBS- (PBS) or non-perfused (no) negative controls.
Whereas in terms of identified protein numbers, the diversity among the different
biotinylation groups and the controls are smaller than expected, differences occur
at the level of the number of identified proteotypic peptides per protein (see Fig-
ure 4.36). High numbers of identified proteotypic peptides enable a more stable
identification and quantification of the corresponding proteins. With commercial
and peptide-based biotinylation reagents, the average number of identified proteo-
typic peptides per protein is significantly increased for the desired proteome fraction
(plasma membrane, extracellular, membrane annotated), whereas the intracellular
background proteins remain stable across the samples. Hereby, the highest aver-
age number of identified peptides per plasma membrane, extracellular or membrane
annotated protein were obtained with the peptide-based reagents SM(PEG)6-Cys-
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Figure 4.36.: Average number of proteotypic peptides per identified protein in the kidney
dataset with SEM. Proteins annotated to the categories plasma membrane, extracellular
and membrane in dark grey, intracellular proteins in light grey. Data includes all identified
proteins for the commercial reagents Sulfo-NHS-LC-biotin (LC) and NHS-PEG12-biotin
(PEG), the peptide-based reagents SMCC-Cys-(L-Asp)3-biotin (SMCC) and SM(PEG)6-
Cys-(L-Asp)3-biotin (SMPEG), the heparin-based reagents Biotin-Heparin-sNHS (Hep)
and Biotin-Enoxaparin-sNHS (Enox) and the PBS- (PBS) or non-perfused (no) negative
controls. Unpaired t-test with significance levels ** (P≤0.01), * (P≤0.05), ns (P>0.05).
(L-Asp)3-biotin and SMCC-Cys-(L-Asp)3-biotin.
Differences between the reagent and control groups, as well as between techni-
cal and biological replicates were further evaluated by relative quantification using
the in-house developed software MSQBAT.[282] The method is further described in
chapters 3.8.4 and 4.3.4.1. Data analysis included normalisation to internal standard
peptides, annotation, feature extraction and complexity reduction: On average, 42%
of the features per sample could be dismissed while keeping 99.5% of the identifica-
tions. Cross-alignments for propagation of annotations was performed as two-step
procedure: first within pairs of technical replicates, secondly within all biological
replicates belonging to the same reagent group. Variability between technical and
biological replicates was further examined via pair-wise alignment by a genetic algo-
rithm (GEAL alignment). For relative quantification, the eight samples belonging
to one biotinylation reagent (four biological replicates with two technical replicates
each) were combined to a super-sample by GEAL alignment, and quantified against
the Sulfo-NHS-LC-biotin super-sample (see Suppl. Table B.7).
Pairwise quantification of technical and biological replicates to visualize the vari-
ability show a narrow distribution for the technical replicates, that broadens if bio-
logical replicates are compared. (see Figures 4.37 and 4.38). Even for the biological
replicates 50% of all values are within a range of maximal 1.13-fold regulation.
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Figure 4.37.: Volcano plots of technical replicates (exemplary) for Sulfo-NHS-LC-biotin
(LC), NHS-PEG12-biotin (PEG), SMCC-Cys-(L-Asp)3-biotin (SMCC), SM(PEG)6-Cys-
(L-Asp)3-biotin (SMPEG), Biotin-Heparin-sNHS (Hep) and Biotin-Enoxaparin-sNHS
(Enox) and the PBS- (PBS) or non-perfused (no) negative controls. Proteins quantified
with at least two proteotypic peptides are depicted. No regulation (x = 0) and ±4-fold
regulation (x = ±2) shown as vertical lines, a p-value of 0.01 as horizontal line (y = 2).
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Figure 4.38.: Volcano plots of biological replicates (exemplary) for Sulfo-NHS-LC-biotin
(LC), NHS-PEG12-biotin (PEG), SMCC-Cys-(L-Asp)3-biotin (SMCC), SM(PEG)6-Cys-
(L-Asp)3-biotin (SMPEG), Biotin-Heparin-sNHS (Hep) and Biotin-Enoxaparin-sNHS
(Enox) and the PBS- (PBS) or non-perfused (no) negative controls. Proteins quantified
with at least two proteotypic peptides are depicted. No regulation (x = 0) and ±4-fold
regulation (x = ±2) shown as vertical lines, a p-value of 0.01 as horizontal line (y = 2).
To compensate for biological and technical variation, all samples belonging to one
reagent group were combined and relatively quantified to the Sulfo-NHS-LC-biotin
super-sample. Volcano plots for those quantifications are depicted in Figure 4.39.
Distributions are wide-spread and, especially in the negative controls, proteins are
heavily down-regulated compared to Sulfo-NHS-LC-biotin.
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Figure 4.39.: Volcano plots of super-samples from all reagents (NHS-PEG12-biotin (PEG),
SMCC-Cys-(L-Asp)3-biotin (SMCC), SM(PEG)6-Cys-(L-Asp)3-biotin (SMPEG), Biotin-
Heparin-sNHS (Hep) and Biotin-Enoxaparin-sNHS (Enox) and the PBS- (PBS) or non-
perfused (no) negative controls) against the Sulfo-NHS-LC-biotin (LC) super-sample. Pro-
teins quantified with at least two proteotypic peptides are depicted. No regulation (x = 0)
and ±4-fold regulation (x = ±2) shown as vertical lines, a p-value of 0.01 as horizontal
line (y = 2).
To sum up the findings about the variability between different samples, the quan-
tification of technical and biological replicates as well as of different reagent groups
against Sulfo-NHS-LC-biotin are shown in a direct comparison (see Figure 4.40).
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Figure 4.40.: Quantification of technical (tech) and biological replicates (bio) (exemplary)
and all biotinylation reagents (NHS-PEG12-biotin (PEG), SMCC-Cys-(L-Asp)3-biotin
(SMCC), SM(PEG)6-Cys-(L-Asp)3-biotin (SMPEG), Biotin-Heparin-sNHS (Hep), Bio-
tin-Enoxaparin-sNHS (Enox) and PBS- (PBS) or non-perfused (no) negative controls) vs.
Sulfo-NHS-LC-biotin (LC), all proteins. Box (median with 25th and 75th percentile) and
whiskers (5th to 95th percentile) plot, outliers in grey. Blue straight line (y = 0) indicates
no regulation, blue dotted lines (y = ±2) 4-fold regulation.
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In total, 1851 proteins could be quantified, thereof 1242 proteins with at least
two proteotypic peptides in one reagent group. Reactivity differences and down-
regulation in the negative controls were further analysed by visualizing the median
with the interquartile range (see Figure 4.41). Variation between both commer-
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Figure 4.41.: Quantification of all biotinylation reagents (NHS-PEG12-biotin (PEG),
SMCC-Cys-(L-Asp)3-biotin (SMCC), SM(PEG)6-Cys-(L-Asp)3-biotin (SMPEG), Biotin-
Heparin-sNHS (Hep), Biotin-Enoxaparin-sNHS (Enox) and PBS- (PBS) or non-perfused
(no) negative controls) vs. Sulfo-NHS-LC-biotin (LC), median with interquartile range.
Blue dotted line (y = 0) indicates no regulation between samples. All proteins (a) or
proteins quantified with at least two proteotypic peptides (b).
cial reagents NHS-PEG12-biotin and Sulfo-NHS-LC-biotin is low. No reactivity-
dependent shift is visible for the peptide-based reagents compared to Sulfo-NHS-LC-
biotin. The less-reactive Biotin-Heparin-sNHS and Biotin-Enoxaparin-sNHS exhibit
about two-fold down-regulation compared to commercial Sulfo-NHS-LC-biotin. If
one hit wonders are excluded from analysis, outliers are removed and the distri-
bution is narrowing. The non-perfused negative control is 7-fold down-regulated
compared to Sulfo-NHS-LC-biotin, the PBS-perfused control, which is less complex
due to blood removal, about 4-fold. Despite of the high background proteome iden-
tification in the negative controls, the proteins are clearly down-regulated compared
to the biotinylated samples. In total, differences among the reagents’ reactivity as
well as the negative controls’ down-regulation are less pronounced in the in vivo
dataset than in the in vitro dataset (see chapter 4.3.4.1). This effect is first of all
influenced by the higher background protein amount identified across all reagents in
the in vivo dataset. Secondly, the amount of biotinylation reagent used for perfu-
sion compensates better for reactivity differences than during in vitro biotinylation.
Limiting factor during the in vitro biotinylation was the negative effect of higher re-
agent concentrations on the cell viability. For perfusion of mice, the reagent amount
of commercial and peptide-based reagents was adapted to yield comparable results
in terms of signal intensity in CLSM analysis (see chapter 4.4.2.2) and in terms of
protein numbers in the proteomic dataset.
Cluster analysis of all proteins quantified against Sulfo-NHS-LC-biotin with at
least two peptides revealed, that the similarity is both reactivity- and reagent-type
dependent. In accordance with the previously determined decreased reactivity, the
heparin-based reagents cluster with the negative controls. Hereby, the non-perfused
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control is further apart than the PBS-perfused control, as the loss of blood compo-
nents is a common characteristic for all perfused mice. Commercial and peptide-
based reagents exhibit comparable reactivity in the in vivo dataset as shown before,
and also cluster together. According to structural similarity of the biotinylation
reagents, the peptide-based ones hereby form a sub-cluster.
Figure 4.42.: Cluster analysis kidney dataset using GENE-E.[285] Proteins quantified with
at least two peptides. City block distance and average linkage, 4-fold up-regulation (red),
4-fold down-regulation (blue). All biotinylation reagents (NHS-PEG12-biotin (PEG),
SMCC-Cys-(L-Asp)3-biotin (SMCC), SM(PEG)6-Cys-(L-Asp)3-biotin (SMPEG), Biotin-
Heparin-sNHS (BioHep), Biotin-Enoxaparin-sNHS (BioEnox)) and PBS- (PBS) or non-
perfused (no) negative controls vs. Sulfo-NHS-LC-biotin (LC).
Finally, the desired subset with plasma membrane or extracellular matrix an-
notation was analysed (see Figure 4.43). Commercial and peptide-based reagents
are comparable in terms of the quantified signal intensity of the desired proteome
fraction. For the heparin-based reagents, the plasma membrane/extracellular pro-
teome fraction is down-regulated. One reason is the introduction of a background
intensity value in a presence vs. absence situation, leading to an artificially high
ratio, rather then removal of this protein as non-quantifiable. Secondly, also for
the stably identified proteins, the signal intensity is lower with the heparin-based
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reagents due to their decreased reactivity. Negative control signal intensity is signif-
icantly decreased in the plasma membrane/extracellular fraction. Proteins are more
than ten-fold down-regulated within the negative controls, which is a ratio pointing
towards a presence vs. absence situation in the majority of the proteins.
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Figure 4.43.: Analysis of all proteins with plasma membrane or extracellular annotation
quantified with at least two peptides. Quantification of all samples (NHS-PEG12-biotin
(PEG), SMCC-Cys-(L-Asp)3-biotin (SMCC), SM(PEG)6-Cys-(L-Asp)3-biotin (SMPEG),
Biotin-Heparin-sNHS (Hep), Biotin-Enoxaparin-sNHS (Enox) and PBS- (PBS) or non-
perfused (no) negative controls vs. Sulfo-NHS-LC-biotin (LC). Median with SEM.
A detailed analysis of protein regulation within the subsets (see Figure 4.44)
shows the high similarity of both commercial reagents Sulfo-NHS-LC-biotin and
NHS-PEG12-biotin: 71% of all plasma membrane and extracellular matrix proteins
are within a range of ±2-fold regulation. Peptide-based reagents in comparison
to Sulfo-NHS-LC-biotin exhibit a larger variation: About 40% of the quantified
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Figure 4.44.: Detailed regulation analysis of all proteins with plasma membrane or ex-
tracellular annotation quantified with at least two peptides. Quantification of all sam-
ples (NHS-PEG12-biotin (PEG), SMCC-Cys-(L-Asp)3-biotin (SMCC), SM(PEG)6-Cys-
(L-Asp)3-biotin (SMPEG), Biotin-Heparin-sNHS (Hep), Biotin-Enoxaparin-sNHS (Enox)
and PBS- (PBS) or non-perfused (no) negative controls vs. Sulfo-NHS-LC-biotin (LC).
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proteins are more than 2-fold up- or down-regulated, about 20% more than 4-fold.
Within the heparin-based reagents Biotin-Heparin-sNHS and Biotin-Enoxaparin-
sNHS the reactivity shift is visible: 68% and 60% of the quantified proteins are
more than 2-fold up-regulated within the Sulfo-NHS-LC-biotin group, respectively.
The desired plasma membrane and extracellular matrix proteome fraction is severely
down-regulated within the negative controls.
The study of in vivo biotinylated kidney samples demonstrated comparability
in enrichment of the desired proteome fraction of commercial and peptide-based
reagents, both in terms of identified total protein numbers and in signal intensities
of the proteotypic peptides. Although a reduced reactivity of the peptide-based
reagents was shown previously, the quality of the enrichment of the desired proteome
fraction was not influenced in the in vivo setting. The enrichment of nuclear proteins
with the heparin-based reagents had no effect during in vivo perfusion of mice.
Nevertheless, the reactivity was decreased compared to other biotinylation reagents.
The high number of background proteins identified within the negative controls will
be further elucidated in the following chapter. The interplay between selectivity and
reactivity is the challenge for the work with novel biotinylation reagents.
4.4.4.2. Background Proteome in Negative Controls
As shown in chapter 4.4.4.1, most proteins within the PBS- or unperfused nega-
tive controls, are severely down-regulated in terms of signal intensity in comparison
to the Sulfo-NHS-LC-biotin sample. Nevertheless, 1008 (912) and 633 (597) pro-
teins have been identified in the PBS- and in the non-perfused control, respectively,
numbers, that are surprisingly high compared to the in vitro negative control (see
chapter 4.3.4.1).
To elucidate possible reasons for background protein binding, different sample
preparation strategies were examined: (i) Washing with high-salt buffer (2 M NaCl)
to disrupt non-covalent protein-protein interactions, (ii) pre-blocking of the strep-
tavidin-sepharose with BSA to exclude non-specific protein binding, (iii) Ultracen-
trifugation of the tissue homogenates to exclude the transfer of protein-containing
particles to the streptavidin-sepharose, that would be co-purified on the filter and
therefore be co-digested with the proteins on the beads and (iv) benzonase nuclease
treatment after protein precipitation to degrade nucleic acid and to release nuclear
proteins, that could be co-purified with the streptavidin-sepharose on the filter. All
sample preparation strategies included reduction of disulfide bridges with TCEP
and alkylation with IAA, as it is reported to improve tryptic digest, sequence cover-
age and the detection of cysteine-containing peptides in standard proteomic work-
flows.[348],[349] 2.5 mg of total protein were captured on 100 µl streptavidin-sepharose,
samples were processed as described above. Proteins derived from 2 mg total pro-
tein amount were examined per LC/MS run. Database searches and extraction of
proteotypic peptides were performed as described in chapter 4.4.4.1. To account
for mass spectrometric performance differences, annotations were propagated across
samples biotinylated with the same reagent with MSQBAT (see Suppl. Table B.8).
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No significant change of the fraction of identified intracellular proteins was ob-
tained with any strategy (see Table 4.6). The number of identified proteins was
reduced in precipitated, benzonase-treated samples, which however was first of all
an effect of non-complete protein resolubilisation.
Sample Preparation Protein number % intracellular
PBS reduction/alkylation 935 62.7%
PBS reduction/alkylation/high-salt 922 62.6%
PBS preblocking/reduction/alkylation 918 62.8%
PBS ultracentrifugation/reduction/alkylation 855 64.0%
PBS precipitation/benzonase/reduction/alkylation 670 63.1%
no reduction/alkylation 806 63.9%
no reduction/alkylation/high-salt 785 63.8%
no preblocking/reduction/alkylation 815 63.5%
no ultracentrifugation/reduction/alkylation 820 63.0%
no precipitation/benzonase/reduction/alkylation 745 64.1%
NHS-PEG12-biotin reduction/alkylation 1256 47.9%
NHS-PEG12-biotin reduction/alkylation/high-salt 1248 47.5%
NHS-PEG12-biotin preblocking/reduction/alkylation 1265 47.8%
NHS-PEG12-biotin ultracentrifugation/reduction/alkylation 1246 47.4%
NHS-PEG12-biotin precipitation/benzonase/reduction/alkylation 1151 46.2%
Table 4.6.: Sample preparation tests on kidney negative control samples. Perfusion with
PBS (PBS) or non-perfused (no), perfusion with NHS-PEG12-biotin as control. Number
of identified proteins (without one hit wonders) and percentage of the intracellular fraction
are shown. Sample preparation strategies are further described in the text.
Delipidation with organic solvents (1-butanol/diisopropylether) is a technique
reported for efficient release of plasma membrane proteins from the surrounding
lipids.[347] The delipidation step was included for both kidney and liver samples, as
it heavily facilitated sample preparation of tissue samples.
The identification of large background protein numbers may originate from a
combination of different sources. Compared to the in vitro biotinylated samples,
not only sample complexity, but also protein amount is increased: The total pro-
tein amount of the in vivo biotinylated samples loaded on the same amount of
streptavidin-sepharose is 2.5-fold (kidney dataset) or 5-fold (negative control tests
and liver dataset) higher compared to the capturing of the in vitro biotinylated
samples. Unspecific binding to the streptavidin-sepharose resin plays a minor role,
as only a small number of proteins was identified within the in vitro negative con-
trol and pre-blocking of the beads did not significantly influence the result. Still,
background proteome binding might be higher due to the extensive and highly-
concentrated total protein load in the in vivo situation. Furthermore, some strong
non-covalent protein-protein interactions might not be disrupted by extensive wash-
ing. As elucidated in chapter 4.3.4.1, protein localization annotation in the database
might be incomplete or wrong. The most influential explanation originates from an
experimental observation: Tissue samples contain a vast amount of lipids. Even
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after tissue homogenisation, sonication, heating in lysis buffer and centrifugation at
20 000×g, the lysate cannot be completely cleared from lipids. Without the delipi-
dation step, the separation of the streptavidin beads and the supernatant is hindered
as the filter is often blocked by a lipid layer. During delipidation, an extensive lipid
layer forms at the interface between the organic and the aqueous solvent. Although
a vast lipid amount is removed by the procedure, it is experimentally barely possible
to separate the streptavidin resin, the lipid layer and the solvents perfectly. Since
the desired protein fraction is also not in solution, but bound to the streptavidin
resin, some lipid structures are always subjected to tryptic digest with the beads.
Co-digestion of a vast amount of non-biotinylated proteins, that are non-covalently
bound to the lipid structures, is the result.
To further assess this hypothesis, the nature of the co-enriched background pro-
teins was examined. An enrichment analysis of the top-300 proteins (identification
with at least five proteotypic peptides) identified in the PBS-perfused negative con-
trol of the kidney dataset shows that most of those proteins belong to the severely
enriched categories membrane bounded organelle and mitochondrion and are heavily
involved in catabolic processes (see Figure 4.45). A pure protein abundance ef-
fect can be excluded, as no single protein of the 46 high-abundant intracellular
ribosome components or proteasome subunits, that have been identified across the
kidney dataset, are within the top-300 proteins of the PBS control. Therefore,
the co-digestion of top-300 proteins cannot only originate from the high abundance
of metabolic mitochondrial enzymes. Reason for the co-digestion of mitochondrial
membrane bound proteins is more likely rooted in their lipid-binding domains, lead-
ing to their co-purification with lipid impurities. Furthermore, the identified plasma
membrane annotated fraction within the negative controls was relatively high (18%),
also pointing towards non-specific co-enrichment by lipid-binding.
Despite the relatively high identified protein numbers, the background proteome
is significantly down-regulated in the kidney dataset as shown by relative quantifica-
tion based on MS1 signal intensites, and does not hinder successful enrichment of the
desired vascular accessible surface proteome fraction with the biotinylation reagents.
Nevertheless, the existence of a PBS-perfused negative control in biomarker discov-
ery studies might help to evaluate (by numbers of identified proteotypic peptides
or relatively quantified signal intensities) if potential biomarkers have been iden-
tified specifically by enrichment of vascular accessible proteins or by non-specific
co-purification.
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Figure 4.45.: Enrichment analysis of the cellular component of the top-300 proteins iden-
tified in PBS-perfused mouse kidney. Top-300 selection based on number of identified
proteotypic peptides. Visualisation as directed acyclic graph using Webgestalt.[283],[284]
Enriched GO categories are depicted in red, name of the GO category, number of included
genes and adjusted p-value are shown.
4.4.4.3. SRM-Analysis of High- and Low-Abundant Proteins
Protein candidates with intracellular, plasma membrane or extracellular localization
annotation were chosen based on the protein lists from the discovery experiment.
Proteotypic peptides were restricted to a mass range of 600-2000 Da, methionine
and cysteine containing peptides were excluded if possible. Peptide standards cor-
responding to the natural counterparts, but labelled with heavy isotopic lysine or
arginine were spiked into the peptide samples to enable relative quantification. For
the final experiment, the three most intense transitions (charge state +2 or +3) per
peptide were selected. SRM method optimisation and the quantification experiment
were performed on a QTRAP® 6500 system (AB SCIEX).
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Four biological replicates were measured per biotinylation reagent group (commer-
cial reagents Sulfo-NHS-LC-biotin and NHS-PEG12-biotin, peptide-based reagents
SMCC-Cys-(L-Asp)3-biotin and SM(PEG)6-Cys-(L-Asp)3-biotin, heparin-based re-
agents Biotin-Heparin-sNHS and Biotin-Enoxaparin-sNHS, negative control PBS-
or non-perfused). Samples were prepared by capturing biotinylated proteins out of
equal total protein amounts under reductive conditions, followed by alkylation, delip-
idation, tryptic digest and desalting, in accordance to the discovery experiment. To
assess if the proteins are comparably targetable by SRM-based quantification with
non-enriched full proteome samples, PBS- and non-perfused tissue homogenates
were reduced, alkylated and digested after protein precipitation. Hereby, the pro-
tein amount subjected to analysis was adapted to exploit the full capacity of the
LC/MS system.
To correct for mass spectrometric performance differences and ionization or spray
differences between runs, the quantification was based on the ratio of the background-
reduced peak areas from the light transitions and the background-reduced peak ar-
eas from the heavy transitions. Areas from three transitions per proteotypic peptide
were summed for analysis. Peptides with unfavorable elution profile or interfering
noise were excluded from analysis. The stability across the LC/MS runs was con-
firmed by a steady signal with low variation of the spiked heavy peptides (see Suppl.
Figure A.10a,b). To obtain a reliable quantification, peptides with an average peak
area less than four-fold up-regulated compared to the background signal were ex-
cluded from analysis. Enriched samples and full proteome samples were evaluated
separately. Peak areas were normalised to the maximal peak area achieved among
the enriched surface samples, mean and standard deviation were calculated across
four biological replicates (see Figure 4.46).
The precipitated full proteome samples are not directly comparable to the enriched
samples generated by capturing of the biotinylated proteins: The protein amount
subjected to analysis is not equal, as the amount of vascular labelled biotinylated
protein in the enriched samples is unknown and normalized to the same total protein
amount subjected to capturing. Moreover, different sample preparation strategies
come along with different percentages of sample loss. Yet, the full proteome analysis
provides the information, if the targeted proteins are also stably quantifiable without
prior enrichment.
Information about protein abundance in mouse kidney tissue was extracted from
PaxDB, a protein abundance database based on publicly available experimental
datasets.[286],[287] The integrated and re-processed kidney protein abundance infor-
mation from several publications was used.[280],[371],[372],[373]
To investigate, if the stable identification of highly abundant intracellular proteins
is decreased within the biotinylated samples compared to the full proteome samples,
four protein candidates were selected (see Figure 4.46a-d): Calreticulin, a calcium-
binding chaperone located in the endoplasmic reticulum lumen, as well as 60 kDa
heat shock protein involved in correct folding of imported proteins in the mitochon-
drion matrix and the multifunctional nucleolar phosphoprotein Nucleolin, reported
to play roles in chromatin structure regulation and the biogenesis of rRNA, all be-
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long to the top 5% kidney proteins in terms of protein abundance.[374],[375],[376],[377]
The fourth selected protein, the 40S ribosomal protein S8, a component of the 40S
ribosomal subunit, is reported to be amongst the top 25% abundant proteins.[378] All
intracellular proteins were very stably identified among the full proteome samples,
whereas the signals across the biotinylated samples are low - despite of the high
protein abundance.
Intracellular carboxylases are co-enriched with streptavidin-sepharose as biotin is
a covalently bound cofactor required in the enzymatic reaction. Three carboxylases,
all being at least amongst the top 25% abundant kidney proteins, have been selected
to demonstrate the stable identification across all biotinylation reagents (see Fig-
ure 4.46e-g): Acetyl-CoA carboxylase, involved in long-chain fatty acid synthesis,
Methylcrotonyl-CoA carboxylase, crucial for leucine and isovalerate catabolism, and
Propionyl-CoA carboxylase, which is essential for the catabolism of odd-numbered
fatty acid chains and of methyl-branched amino acids.[369] The latter two are amongst
the top 5% abundant kidney proteins, Acetyl-CoA carboxylase amongst the top
25%. Quantification works stably with the full proteome samples. As expected
from the stable identification within the mass spectrometric discovery dataset, the
biotin-dependent enzymes are severely enriched with the capturing approach.
Several cell surface or extracellular matrix proteins with different protein abun-
dances reaching from the top 25% to the bottom 5% of the kidney proteome have
been selected (see Figure 4.46h-o). The cell adhesion protein Cadherin-1, involved
in the formation of adherens junctions of epithelial cells, and one of the major
extracellular matrix components, the Collagen alpha-1(VI) chain, reported to be
deregulated in metastatic breast cancer, belong to the top 25% abundant kidney
proteins.[379],[380],[381] Quantification of both proteins out of full lysates is possible,
peptide-based reagents and Sulfo-NHS-LC-biotin exhibit comparable enrichment.
Next, three proteins with medium abundance levels are shown: the cell sur-
face proteoglycan Glypican-4 involved in the development of kidney tubules, the
immunoglobulin-like cell-cell adhesion molecule Nectin-3 as well as Integrin alpha-V,
an Integrin receptor subunit, which is interacting with extracellular matrix compo-
nents.[382],[383],[384] None of those proteins could be quantified within the full proteome
samples.
Finally, the detection of low-abundant proteins was examined: The cell adhesion
molecule Cadherin-2 is mostly expressed in the nervous system and belongs to the
bottom 25% proteins in terms of kidney protein abundance.[379] Integrin beta-5 is
among the bottom 5%. Receptor-type tyrosin phosphatase U regulating β-Catenin
function both in adhesion and signalling, was not identified in the kidney datasets
integrated into PaxDB, in terms of whole mouse body abundance it belongs to the
bottom 25%.[385] SRM-based quantification was possible with the biotinylated sam-
ples, but not with the full proteome samples. Proteins are down-regulated in the
heparin-based reagent samples in accordance to their low reactivity. Both com-
mercial and peptide-based reagents provide a stable technology platform for the
quantification of low-abundant surface or extracellular matrix annotated biomarker
candidates.
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Figure 4.46.: SRM analysis of kidney samples, mean with standard deviation of four bi-
ological replicates. Vascular accessible proteome enrichment with commercial reagents
Sulfo-NHS-LC-biotin (LC) and NHS-PEG12-biotin (PEG), peptide-based reagents SMCC-
Cys-(L-Asp)3-biotin (SMCC) and SM(PEG)6-Cys-(L-Asp)3-biotin (SMPEG), heparin-
based reagents Biotin-Heparin-sNHS (Hep) and Biotin-Enoxaparin-sNHS (Enox), negative
control PBS- (PBS) or non-perfused (no). Full proteome samples of precipitated proteins
from PBS- (Prec_PBS) or non-perfused (Prec_no) mice. Proteins with intracellular an-
notation (a-d), carboxylases (e-g), cell membrane or extracellular matrix annotation (h-o).
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4.4.5. Mass Spectrometric Analysis of Biotinylated Liver Tissue
4.4.5.1. Discovery Experiment Liver
For comparative proteomic analysis, capturing of biotinylated proteins was per-
formed with equal amounts of 2.55 mg total liver protein on 100 µL streptavidin-
sepharose. Samples were processed by reduction, alkylation, delipidation and tryp-
tic digest. As a lower biotinylation degree of liver tissue compared to kidney tissue
was detected by CLSM and ELISA, peptides derived from 1.25 mg total protein
amount (kidney: 750 µg) were examined per LC/MS run. Three biological replicates
per reagent group (commercial reagents: Sulfo-NHS-LC-biotin, NHS-PEG12-biotin,
peptide-based reagents: SMCC-Cys-(L-Asp)3-biotin, SM(PEG)6-Cys-(L-Asp)3-bio-
tin, heparin-based reagents: Biotin-Heparin-sNHS, Biotin-Enoxaparin-sNHS, nega-
tive controls: PBS- or non-perfused) were analysed.
Consistent chromatographic separation across the samples was visualised by 2D
peptide mapping (see Suppl. Figure A.9). The analysis of MS data based on pro-
teotypic peptide summaries was performed as already described in chapter 4.4.4.1.
In total, 1531 proteins were identified, thereof 1120 proteins with more than one
proteotypic peptide in at least one reagent group (without one hit wonders) (see
Suppl. Table B.9). 1102 (971) proteins were found with commercial Sulfo-NHS-LC-
biotin, 867 (804) with NHS-PEG12-biotin. With the novel peptide-based reagent
SMCC-Cys-(L-Asp)3-biotin 1281 (1034) proteins were obtained, 1097 (966) with
SM(PEG)6-Cys-(L-Asp)3-biotin. 945 (853) proteins were identified with Biotin-He-
parin-sNHS, 1000 (882) with Biotin-Enoxaparin-sNHS. 45% (51%) of all identified
proteins within the dataset were found with every biotinylation reagent. The over-
lap fraction between subsets of two sample groups is large and independent of the
nature of the biotinylation reagent, e.g. 76% (84%) between Sulfo-NHS-LC-biotin
and SMCC-Cys-(L-Asp)3-biotin, 74% (84%) between Sulfo-NHS-LC-biotin and Bio-
tin-Heparin-sNHS and 71% (79%) between both peptide-based reagents. Within the
PBS- or unperfused negative controls, 1003 (879) and 807 (740) proteins have been
identified respectively. The identified background proteome will be discussed later
in this chapter.
Differences in protein localization across the various biotinylation reagents was
analysed via extraction of subcellular localization information from the UniProt
website. The localization information was curated by screening for the categories
plasma membrane, extracellular and secreted, internal side of the plasma membrane,
membrane associated, intracellular and no information available (see Figure 4.47).
Compared to the kidney dataset, the surface/extracellular matrix fraction is re-
duced. Proteins annotated to plasma membrane, the extracellular matrix and mem-
brane constitute a 27-34% fraction with the commercial and peptide-based reagents,
heparin-based reagents and the negative controls exhibit both similar proteins num-
bers and fractions.
Also at the level of the number of identified proteotypic peptides per protein,
differences between samples and negative controls are small (see Figure 4.48). The
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Figure 4.47.: Protein localization in the liver dataset. Percentage and total protein num-
bers are depicted. Categories: Plasma membrane, extracellular and secreted (red), mem-
brane associated (orange), internal side of plasma membrane (yellow), intracellular (grey),
no annotation information available (black). Data without one hit wonders for the com-
mercial reagents Sulfo-NHS-LC-biotin (LC) and NHS-PEG12-biotin (PEG), the peptide-
based reagents SMCC-Cys-(L-Asp)3-biotin (SMCC) and SM(PEG)6-Cys-(L-Asp)3-biotin
(SMPEG), the heparin-based reagents Biotin-Heparin-sNHS (Hep) and Biotin-Enoxapa-
rin-sNHS (Enox) and the PBS- (PBS) or non-perfused (no) negative control is shown.
number of proteotypic peptides identified for the plasma membrane/extracellular
fraction is slightly, but non-significantly reduced within the negative controls (un-
paired t-test, 0.10≤P≤0.20 for the comparisons SMPEG vs. PBS and SMCC vs.
PBS).
Relative quantification was performed using the in-house developed software
MSQBAT.[282] The method is further described in chapters 3.8.4 and 4.3.4.1. Data
analysis included normalisation against internal standard peptides, annotation, fea-
ture extraction and complexity reduction: On average, 47% of the features per
sample could be dismissed while keeping 99.5% of the identifications. Annotations
were propagated after cross-alignment of all pairs of biological replicates belonging
to the same reagent group. For relative quantification, three biological replicates
belonging to one biotinylation reagent were combined to a super-sample by GEAL
alignment, and quantified against the Sulfo-NHS-LC-biotin super-sample (see Suppl.
Table B.10).
Variability between biological replicates was further examined via pair-wise GEAL
alignment. As expected, the variability between biological replicates is lower com-
pared to the variability between different reagents (see Figures 4.49, 4.50).
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Figure 4.48.: Average number of proteotypic peptides per identified protein in the liver
dataset with SEM. Proteins annotated to the categories plasma membrane, extracellular
and membrane in dark grey, intracellular proteins in light grey. Data includes all identified
proteins for the commercial reagents Sulfo-NHS-LC-biotin (LC) and NHS-PEG12-biotin
(PEG), the peptide-based reagents SMCC-Cys-(L-Asp)3-biotin (SMCC) and SM(PEG)6-
Cys-(L-Asp)3-biotin (SMPEG), the heparin-based reagents Biotin-Heparin-sNHS (Hep)
and Biotin-Enoxaparin-sNHS (Enox) and the PBS- (PBS) or non-perfused (no) negative
controls.
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Figure 4.49.: Volcano plots of biological replicates (exemplary) for Sulfo-NHS-LC-biotin
(LC), NHS-PEG12-biotin (PEG), SMCC-Cys-(L-Asp)3-biotin (SMCC), SM(PEG)6-Cys-
(L-Asp)3-biotin (SMPEG), Biotin-Heparin-sNHS (Hep) and Biotin-Enoxaparin-sNHS
(Enox) and the PBS- (PBS) or non-perfused (no) negative controls. Proteins quantified
with at least two proteotypic peptides are depicted. No regulation (x = 0) and ±4-fold
regulation (x = ±2) shown as vertical lines, a p-value of 0.01 as horizontal line (y = 2).
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Figure 4.50.: Volcano plots of super-samples from all reagents (NHS-PEG12-biotin (PEG),
SMCC-Cys-(L-Asp)3-biotin (SMCC), SM(PEG)6-Cys-(L-Asp)3-biotin (SMPEG), Biotin-
Heparin-sNHS (Hep) and Biotin-Enoxaparin-sNHS (Enox) and the PBS- (PBS) or non-
perfused (no) negative controls) against the Sulfo-NHS-LC-biotin (LC) super-sample. Pro-
teins quantified with at least two proteotypic peptides are depicted. No regulation (x = 0)
and ±4-fold regulation (x = ±2) shown as vertical lines, a p-value of 0.01 as horizontal
line (y = 2).
In total, 1458 proteins could be quantified, thereof 1026 proteins with at least
two proteotypic peptides in one reagent group. General differences in the signal
intensities were analysed by visualizing the median with the interquartile range (see
Figure 4.51). The distribution is narrowing, when only proteins quantified with at
least two proteptypic peptides are included. Compared to the kidney dataset, the
regulation between the different reagent groups is small. A maximum of 2.5-fold
down-regulation is visible in the heparin-based reagent group. Proteins quantified
within the non-perfused negative control are slightly down-regulated compared to
the PBS-perfused control as also seen in the kidney dataset. Reason is the reduced
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Figure 4.51.: Quantification of all biotinylation reagents (NHS-PEG12-biotin (PEG),
SMCC-Cys-(L-Asp)3-biotin (SMCC), SM(PEG)6-Cys-(L-Asp)3-biotin (SMPEG), Biotin-
Heparin-sNHS (Hep), Biotin-Enoxaparin-sNHS (Enox) and negative control (PBS)) vs.
Sulfo-NHS-LC-biotin (LC), median with interquartile range. Blue dotted line (y = 0)
indicates no regulation between samples. All proteins (a) or without one hit wonders (b).
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sample complexity due to the removal of blood components during perfusion. Nev-
ertheless, the negative controls, especially the PBS-perfused one, exhibit only small
differences to Sulfo-NHS-LC-biotin. Reasons will be discussed later in this chapter.
To reveal similarities among the reagent groups, cluster analysis was performed
based on all proteins quantified against Sulfo-NHS-LC-biotin with at least two pep-
tides (see Figure 4.52). Similar to the kidney dataset, structural similarity of the
biotinylation reagents determines proximity in the sub-clusters. Nevertheless, dif-
ferences to the negative controls are smaller than in the kidney dataset.
Figure 4.52.: Cluster analysis liver dataset using GENE-E.[285]. Proteins quantified with
at least two peptides. City block distance and average linkage, 4-fold up-regulation (red),
4-fold down-regulation (blue). All biotinylation reagents (NHS-PEG12-biotin (PEG),
SMCC-Cys-(L-Asp)3-biotin (SMCC), SM(PEG)6-Cys-(L-Asp)3-biotin (SMPEG), Biotin-
Heparin-sNHS (BioHep), Biotin-Enoxaparin-sNHS (BioEnox)) and PBS- (PBS) or non-
perfused (no) negative controls vs. Sulfo-NHS-LC-biotin (LC).
Liver samples exhibit a drastically reduced surface/extracellular matrix fraction
compared to the kidney samples. Across all analysis performed on the dataset, the
high similarity across all samples and the negative controls both in terms of protein
identification and in relative quantification is striking. In contrast to the kidney sam-
ples, the total protein amount loaded on the streptavidin-sepharose was higher, as
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liver tissue biotinylation is lower (shown by ELISA and CLSM analysis). One factor
for the identification of a large background proteome might be non-specific protein
binding to the streptavidin-sepharose. In fact, liver homogenates were even higher
concentrated than kidney homogenates, due to the reduced biotinylated proteome
fraction. Furthermore, the extremely high lipid content within the liver samples was
obvious during sample preparation. As elucidated in chapter 4.4.4.2, co-digestion
of lipid-bound proteins with the biotin-labelled and streptavidin-bound proteins is
likely to occur in tissue samples. To apply the hypothesis to the liver dataset, an
enrichment analysis of 605 proteins identified with all reagents and both negative
control groups was performed (see Figure 4.53). Membrane-bounded organelle is
heavily enriched as subcellular localization, pointing towards a co-enrichment of
high-abundant proteins with lipid-binding domains.
Figure 4.53.: Enrichment analysis of cellular component of 605 proteins identified in mouse
liver within all biotinylation reagent groups and the negative controls (without one hit
wonders). Visualisation as directed acyclic graph using Webgestalt.[283],[284] Enriched GO
categories are depicted in red, name of the GO category, number of included genes and
adjusted p-value are shown.
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The increased background proteome fraction in all samples reduces the detectable
variability: The regulation between different sample groups is low and reactivity-
dependent shifts are barely visible (see Figure 4.51). Proteins annotated to the
plasma membrane category do not exhibit any statistically significant regulation
between commercial or peptide-based reagents and the PBS-perfused negative con-
trol (unpaired t-test). This might be influenced by the non-specific co-purification of
proteins with lipid-binding domains in all samples. Furthermore, the highly abun-
dant background proteome might suppress the proper analysis of the labelled, but
still low-abundant target proteome: The total number of identified proteins with
plasma membrane or extracellular matrix annotation is not significantly increased
compared to the negative controls (see Figure 4.47).
To summarize, it can be stated, that the background proteome fraction identified
in the liver dataset severely interferes with the analysis: Differences among reagent
groups get superimposed by non-labelled, co-identified proteins, also leading to the
observed decrease in the surface proteome fraction. Hence, for a successful in vivo
biotinylation experiment, not only the vascularisation of the target tissue plays a
role: High lipid contents might interfere with sample preparation and hinder the
generation of a valuable mass spectrometric dataset.
4.4.5.2. SRM-Analysis of High- and Low-Abundant Proteins
SRM analysis of candidate proteins was performed as described in chapter 4.4.4.3
with three biological replicates per group. Integrated information about protein
abundance in mouse liver tissue was again extracted from PaxDB, based on several
publicly available liver datasets.[280],[372],[371],[386],[387],[388]
As shown before for mouse kidney tissue, the intracellular proteins Calreticulin,
60 kDa heat shock protein and Nucleolin also belong to the top 5% liver pro-
teins in terms of protein abundance. The mitochondrial transmembrane proteins
Sideroflexin-5 belongs to the top 25% of the liver proteome and is both a citrate
and also potentially an iron transporter.[389],[390],[391],[392] All of those highly abundant
intracellular proteins could be stably quantified within the full proteome samples,
and were down-regulated in the biotinylation approach (see Figure 4.54a-d).
The co-enriched biotin-carrying carboxylases are again heavily enriched by captur-
ing on the streptavidin-sepharose. Acetyl-CoA carboxylase as well as Propionyl-CoA
carboxylase belong to the top 5% in terms of protein abundance and could also be
quantified out of the full proteome. Methylcrotonyl-CoA carboxylase is among the
top 25%, but quantification out of the full proteome sample was already borderline
(see Figure 4.54e-g). As already seen within the kidney SRM dataset, the top 25%
line seems to be a good estimate about the measurability of protein candidates out
of the full proteome lysates.
Voltage-dependent anion-selective channel protein 1 belongs to the top 10% of
the mouse liver proteome in terms of protein abundance. The protein is reported
to be localised in the outer mitochondrial membrane and is involved in the reg-
ulation of apoptosis.[393] There is also high evidence that the protein is expressed
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in the plasma membrane, functions are still intensively discussed.[394] Not surpris-
ingly for the high protein abundance, the protein was reliably measurable out of
full cell lysates (see Figure 4.54h). The very stable quantification that was possi-
ble with the biotinylation samples might either emphasize the plasma membrane
localization of the protein or indicate the co-purification of the high-abundant mito-
chondrial protein bound to lipid impurities in the samples subjected to digest with
the streptavidin-sepharose-bound proteins. The latter hypothesis is supported by
the highly hydrophobic nature of the protein forming a β-barrel composed of 19
strands within the membrane.[394] Secondly, its enrichment is also observed in the
PBS- or unperfused negative controls. Thirdly, variability between biological repli-
cates is high, also suggesting differential amounts of co-purified lipid-bound proteins
during sample preparation.
Finally, some proteins annotated to the plasma membrane or the extracellular ma-
trix with medium to low abundance were examined (see Figure 4.54i-l). Again, the
cell adhesion protein Cadherin-2 and the extracellular matrix component Collagen
alpha-1(VI) chain were quantified. The latter belongs to the top 25% most abun-
dant liver proteins and could be quantified out of full proteome lysates. Cadherin-2
as well as the intercellular desmosome junction component Desmocollin-2 and the
plasma membrane localised or secreted Semaphorin-4G, interacting with Plexins es-
pecially in the nervous system, show medium to low protein abundances.[395],[396]
SRM analysis of those proteins was not possible with the full lysates. In accor-
dance to the results from the kidney SRM analysis, the heparin-based reagents were
down-regulated, whereas peptide-based and commercial reagents both enabled the
SRM-based quantification of low-abundant surface or extracellular matrix annotated
biomarker candidates.
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Figure 4.54.: SRM analysis of liver samples, mean with standard deviation of three bi-
ological replicates. Vascular accessible proteome enrichment with commercial reagents
Sulfo-NHS-LC-biotin (LC) and NHS-PEG12-biotin (PEG), peptide-based reagents SMCC-
Cys-(L-Asp)3-biotin (SMCC) and SM(PEG)6-Cys-(L-Asp)3-biotin (SMPEG), heparin-
based reagents Biotin-Heparin-sNHS (Hep) and Biotin-Enoxaparin-sNHS (Enox), negative
control PBS- (PBS) or non-perfused (no). Full proteome samples of precipitated proteins
from PBS- (Prec_PBS) or non-perfused (Prec_no) mice. Proteins with intracellular an-
notation (a-d), carboxylases (e-g), cell membrane or extracellular matrix annotation (h-l).
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5. Discussion
The aim of the work presented in this thesis was the development and validation
of novel reagents for the enrichment of vascular accessible proteins, which is a pre-
requisite for the identification of novel disease-specific biomarkers, targetable for
diagnostic or therapeutic purposes.
Potential biomarkers accessible for monoclonal antibodies are located on the cell
surface, on newly formed blood vessels and in the perivascular extracellular ma-
trix.[160] Proteomic discovery approaches have to deal with the high sample com-
plexity and a dynamic range of at least seven orders of magnitude in protein ex-
pression levels.[41] Cell membrane proteins are highly diverse in function, but mostly
expressed at low abundance levels, leading to their under-representation in full pro-
teome datasets.[132] Additional challenges in membrane proteomics are the decreased
solubility of membrane proteins due to their hydrophobic character as well as the
lack of polar cleavage sites for the standard proteolytic enzyme trypsin in trans-
membrane domains.[133],[119]
Classical fractionation techniques such as density gradient centrifugation cannot
provide a clear separation of plasma membrane and intracellular membrane sub-
proteomes (e.g. Golgi, endoplasmic reticulum, mitochondrium, nucleus).[133] Several
approaches have been developed to label the target proteins in the natural envi-
ronment for subsequent enrichment: Carbohydrate-based cell surface capturing ad-
dresses glycoproteins via chemical modification of the sugar residues.[172] Silica coat-
ing is based on vascular perfusion with colloidal silica followed by density-gradient-
based enrichment of silica-coated membranes.[174] The method of choice for covalent
labelling of all proteins on the cell surface and within an accessible radius around
the blood vessels in the perivascular matrix is the attachment of a derivative of
biotin, subsequently used for streptavidin-based enrichment.[160] The biotinylation
technique is applicable in vitro, but also in in vivo disease models or ex vivo with
surgically resected tissue material by vascular perfusion.[181],[184],[189],[190]
The different studies performed with commercial biotinylation reagents have shown
a substantial fraction of identified proteins with intracellular localization annotation,
despite the enrichment of plasma membrane proteins. One reason is the plasma
membrane crossing potential of the commonly used Sulfo-NHS-LC-biotin. In 2010,
the novel, triply charged and size increased reagent NHS-β-Ala-(L-Asp)3-biotin was
published.[12] The reagent was shown to up-regulate proteins with plasma membrane
or extracelluar matrix annotation compared to commercial Sulfo-NHS-LC-biotin.
Nevertheless, only 219 surface or extracellular matrix annotated proteins could be
identified in kidney tissue, originating in both the reduced reactivity of the reagent
and the use of a meanwhile outdated MS system.[12]
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Within this thesis, reactivity tests on BSA as model protein revealed the poor
reactivity of NHS-β-Ala-(L-Asp)3-biotin in comparison to commercial reagents (see
Figure 4.4). According to these results, two novel peptide-based reagents SMCC-
Cys-(L-Asp)3-biotin and SM(PEG)6-Cys-(L-Asp)3-biotin have been designed to im-
prove the reactivity while maintaining features such as the increased size and the
number of charges of the peptide linker. Additionally, two heparin-based reagents
with a large-scale and highly negatively charged linker have been created. Synthe-
sis was optimized for all compounds and the subsequent validation was performed
against commercial reagents using systems with increasing complexity: (i) Reac-
tivity was assessed on BSA as model protein. (ii) A proof-of-principle study was
performed on HeLa cells. (iii) In vivo biotinylation efficacy was determined via
perfusion of mice. Validation techniques included visualisation methods such as
CLSM, FACS, Western Blot and ELISA as well as mass spectrometric analysis of
the biotinylated proteome fraction of cells, mouse kidney and liver tissue enriched
on streptavidin-sepharose beads.
5.1. Design of Novel Enrichment Reagents
The common characteristic of all enrichment reagents designed and used within this
thesis is the activated carboxylic group for chemical derivatization of primary amino
groups from lysine side chains or the N-terminus of the target proteins. To ensure the
labelling of all accessible proteins, the targeted functional group has to be accessible
for the reagent: Aliphatic amino acids as well as thiol groups from cysteine residues
involved in disufide bridges are therefore excluded. Secondly, the targeted functional
group has to be reasonably abundant expressed: Lysine content in the total amino
acid composition of the human proteome is about 5%.[294],[397] Lastly, to minimize
effects on cell viability and plasma membrane integrity, the labelling reaction has to
be efficient and fast. The usage of activated carboxylic groups provides labelling in
a one-step reaction and was shown in an activity test on BSA to react with amino
groups within seconds (see Figure 4.3). Usage of NHS- or sNHS-activated carboxylic
groups is therefore the method of choice for the application.
Activated carboxylic groups are prone to hydrolytic deactivation. Reactivity tests
on BSA revealed the lowest hydrolysis rates at slightly acidic to physiological pH,
perfectly matching with in vitro or in vivo applications carried out in PBS (see
Figure 4.3). To prevent hydrolysis, the peptide-based reagents were synthesized in
dry solvents and diluted directly before use. Although it was shown, that storage
in dry DMSO under inert gas only leads to a slight reactivity decrease, all reagents
used within this thesis were freshly synthesized to ensure comparability. Batch-
to-batch variations detected by reactivity assessment on BSA most likely occur
due to slightly different storage or freeze-thaw conditions leading to varying water
content in the dried commercial reagents or in the peptide educt (see Figures 4.3
and 4.8). Moreover, different pH in the lyophilized peptide might occur, leading to
different hydrolysis rates. Four peptide synthesis batches have been used within this
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thesis. All individual batches were validated by reactivity assessment on BSA. For
in vivo validation experiments two different peptide educt batches had to be used to
synthesize the necessary reagent amounts. Heparin-based reagents are not soluble
in organic solvents, therefore activation was performed in aqueous buffer directly
before use.
The linker between the functional group for protein modification and the biotin
residue for enrichment is both a spacer minimizing steric hindrance during labelling
and capturing and determines the properties of the reagent.
The linkers of the novel peptide-based reagents SMCC-Cys-(L-Asp)3-biotin and
SM(PEG)6-Cys-(L-Asp)3-biotin exhibit an increase in charge and molecular weight
compared to the commonly used commercial Sulfo-NHS-LC-biotin with an aliphatic
linker. Those characteristics not only increase water solubility, but also minimize the
membrane crossing potential of the reagent. In contrast to the biotinylation reagent
NHS-β-Ala-(L-Asp)3-biotin published by Strassberger et al., the novel reagents can
be activated in a site-specific manner by a bifunctional crosslinker targeting the
reagent’s C-terminal cysteine residue, thus minimizing steric hindrance during the
labelling reaction on proteins. Hereby, reactivity was more than doubled in the
activity test on BSA as well as in FACS analysis on biotinylated HeLa cells (see
Figures 4.7, 4.14), while the linker structure with all its positive properties is kept.
Additionally to the peptide-based reagents, heparin chains were chosen as sec-
ond linker type (Biotin-Heparin-sNHS and low molecular weight Biotin-Enoxapa-
rin-sNHS). The large size, the high polarity with multiple charges, the extreme
hydrophilicity and the presence of a variety of functional groups for chemical deriva-
tization make the heparin structure a promising linker type. The reducing chain ends
were site-specifically derivatized with biotin hydrazide (exactly one biotin residue
per molecule) enabling direct comparisons of the biotin signal with the commercial
reagents via CLSM analysis of tissue sections or ELISA. Heparin chains contain one
carboxylic group per disaccharide subunit, which can be activated for protein cou-
pling. FACS analysis of labelled HeLa cells has shown that full NHS activation of
all carboxylic groups provides the best labelling rates possible. Chemical analysis of
the heparin-based reagents as well as reactivity assessment on BSA is complicated
due to its polymer nature with various heparin chain lengths and its extremely high
mass. Therefore, linear mass spectrometric analysis of labelled BSA to prove suc-
cessful labelling was only possible when using low molecular weight enoxaparin in
a reagent to protein ratio of 1:1 (see Figure 4.10). Successful activation of the car-
boxylic groups could additionally be shown in a mass spectrometric experiment of
labelled HeLa cells: Non-activated Biotin-Heparin yields a result comparable to the
negative control, while proteins are efficiently labelled and stably identified upon
NHS- or sNHS-activation of the heparin chains. Biotin signal could be proven by
CLSM analysis and ELISA of biotinylated tissue samples.
The biotin-streptavidin system is used for enrichment, as the interaction is one
of the strongest non-covalent interactions known (Kd ~ 10-15 M)[291], providing a
stable platform for affinity-based purification. As the captured proteins are directly
digested on the beads, also a covalent and bioorthogonal capturing strategy could
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in principle be developed. Circumventing the biotin system would also provide the
chance to avoid the co-purification of high-abundant intracellular proteins intrinsi-
cally carrying Biotin, such as carboxylases. Click chemistry capturing based on an
azide-alkyne system is such a bioorthogonal method. Therefore two alkyne-based
reagents based on the triply negatively charged peptide linker also used for the bi-
otinylation reagents have been synthesized. Reagents with terminal alkynes have to
be captured on azide-coupled beads under Cu(I) catalysis. As the labelling reaction
on cells or via the in vivo perfusion is still based on the reaction of the reagents’ ac-
tivated carboxylic group with a primary amino group, copper is hereby not applied
in living species, but in protein lysates. Nevertheless, some combinations of copper
and Cu(I) stabilizers have been found to favor protein precipitation. That’s way ad-
ditionally a reagent based on a dibenzylcyclooctyne was synthesized, a system that
is highly reactive due to the enormous ring strain and not copper-dependent. As
expected, reactivity of the alkyne-based reagents is comparable to the peptide-based
biotinylation reagents. Thiol-yne click coupling reported to occur as side-reaction
between thiol groups and alkyne residues in some systems seem to play a minor
role for this application.[398],[399] Click-mediated capturing on azide-modified beads
is currently set up. The low concentration of the modified proteins within the lysates
is one of the challenges for the approach.
5.2. Reactivity and Visualisation of Biotinylation
The site-specific activation of the novel peptide-based biotinylation reagents heavily
improves the reactivity compared to non-specifically activated NHS-β-Ala-(L-Asp)3-
biotin published by Strassberger et al. as shown by reactivity assessment on BSA
(see Figure 4.7).[12] Nevertheless it is not possible to achieve the same reactivity as
with the commercial Sulfo-NHS-LC-biotin: The peptide linker chosen to introduce
charges and an increase in size results in a structure sterically more hindered in
comparison to the aliphatic Sulfo-NHS-LC-biotin linker.
Besides the reactivity assessment on BSA, differential reactivity could also be
visualised by FACS analysis of HeLa cells labelled in different ratios with the re-
agents (see Figure 4.15). CLSM analysis provided spatial biotinylation information:
Plasma membrane labelling could be visualized with both commercial and peptide-
based reagents (see Figure 4.16). Hereby, the decreased reactivity of the novel
peptide-based biotinylation reagents was obvious, as the total signal intensity was
decreased. Consequently, samples biotinylated with peptide-based reagents had to
be acquired with higher laser intensities than the commercial reagents to ensure
consistent quality of the pictures. PBS-treated cell were taken as negative controls
in both cases. Based on the experience with the capacity of the LC/MS system,
the percentage of biotinylated proteins is about 1-2% of the total protein content of
the cell lysates. Analysis of biotinylation via Western blot was difficult: Vast total
protein amounts had to be loaded to get a biotin signal over the whole protein lane.
Without severe restriction of the quality of the Western Blot, this approach could
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only be performed with the higher reactive commercial reagents.
Within tissue samples of perfused mice it could be demonstrated that all biotiny-
lation reagents are capable to label accessible proteins within a few cell layers around
blood vessels and to enter highly capillarized regions, which nicely corresponds to the
tissue parts that can be targeted by a monoclonal antibody vascularly administered
for diagnosis or therapy (see Figure 4.30). With CLSM analysis, no significant dif-
ferences between commercial and peptide-based reagents could be detected. Within
liver tissue, staining mainly occurred around vascular structures, whereas in kidney
tissue the overall staining was stronger with an additional accumulation of the re-
agent around tubular structures and in the glomeruli. Stronger kidney biotinylation
was also proven by ELISA performed with the highly concentrated kidney and liver
homogenates. Western Blot analysis was only possible with the higher biotinylated
kidney lysates. Similar to the in vitro analysis, Western Blot lanes have to be over-
loaded to get signals from the peptide-based reagents (see Figure 4.34). Nonetheless,
there is no visible difference between commercial and peptide-based reagents in the
CLSM analysis (see Figure 4.31). Within ELISA analysis, SMCC-Cys-(L-Asp)3-
biotin turned out to be slightly more reactive than the sterically more hindered
SM(PEG)6-Cys-(L-Asp)3-biotin (see Figure 4.33), which was also confirmed in the
mass spectrometric analyses of cells or tissues.
The reactivity of heparin-based reagents was decreased compared to the commer-
cial and the peptide-based biotinylation reagents as shown in all analyses. FACS
analysis of HeLa cells biotinylated with different excess and differential NHS ac-
tivation grade of the heparin-based reagents showed the best results, when every
disaccharide unit contained an activated carboxylic group (see Figure 4.17). On
cells, no biotin signals could be detected via CLSM analysis or Western blot. CLSM
analysis of tissue sections of perfused mice revealed a comparable biotinylation pat-
tern to the commercial and peptide-based reagents, while overall signal intensity
was significantly decreased (see Figure 4.32). Therefore, pictures had to be taken
with higher laser intensity to ensure consistent quality preventing a direct compari-
son of the signal intensities across different reagent groups. PBS- and non-perfused
mice were taken as corresponding negative controls, pictures were hereby acquired
with all different laser properties used within the analyses. ELISA-based analysis
of the biotinylation rate could detect significantly increased biotin content in com-
parison to the PBS-perfused negative control (see Figure 4.33). Direct quantitative
comparison to the commercial reagents is not possible within the same experiment
to ensure a linear correlation of the ELISA biotin standard in the acquired range.
Western blot analysis was not possible on tissue homogenates biotinylated with the
heparin-based reagents.
Low biotin signals in all streptavidin detection-based tests might point towards
a decreased reactivity of the heparin-based reagents, but also leaves room for an
additional explanation: Due to the enormous tag size of the heparin-based linkers,
less biotinylated reagent molecules can be attached per surface area in comparison to
the small commercial or peptide-based reagents. This is why the maximal log-shift
achievable by FACS analysis of biotinylated HeLa cells is about two log-shifts less
161
than for commercial Sulfo-NHS-LC-biotin (see Figure 4.18). Hereby, no significant
difference between the heparin and the low molecular weight enoxaparin linker could
be detected. Mass spectrometric analysis of kidney tissue nevertheless revealed a
reactivity decrease of the heparin-based reagents.
For mass spectrometric-based validation, all cell samples or mice were biotinylated
with the same amount of biotinylation reagent allowing for a comparable analysis.
For the in vitro experiment, the amount was determined by FACS analysis, so that
maximal log-shift was achieved for all reagents. In vivo biotinylation was performed
with an amount yielding to comparable biotin signal intensities of commercial and
peptide-based reagents in CLSM analysis of tissue sections. Mass spectrometric
analysis of in vitro samples still revealed a down-regulation in signal intensity with
the peptide-based reagents corresponding to the decreased reactivity, whereas the
in vivo analysis was equivalent across the peptide-based and commercial reagent
groups. So, CLSM analysis might be the best way to evaluate optimal reagent
amounts for a valuable mass spectrometric analysis.
5.3. Aspects of Sample Preparation for Mass
Spectrometric Analysis
Differential FACS analysis of biotinylated HeLa cells for reactivity assessment was
performed on detached cells to ensure constant cell counts. Hereby, non-tryptic de-
tachment was achieved with 10 mM EDTA to preserve the cell surface proteins. The
slow detachment procedure decreases cell viability to below 80%. The consequence
is the biotinylation and mass spectrometric identification of a large fraction of intra-
cellular proteins (up to 85%) most likely derived from membrane permeable, necrotic
or apoptotic cells. Therefore, for successful mass spectrometric analysis of the cell
surface proteome, cells have to be biotinylated following a washing protocol, but still
adherent to the cell culture flask to ensure maximal viability. As the biotinylation
solution has to be applied in lower concentration on adherent cells in comparison
to biotinylation in solution, the total amount of biotinylation reagent had to be in-
creased about ten-fold to 1 µmol reagent per 1×106 cells. Hereby, optimization was
performed via FACS analysis to achieve maximal log-shift with all reagents. Cells
were seeded in cell culture flasks 24 h prior to biotinylation in constant cell density
to ensure stable cell counts for the validation experiments. Non-reacted reagent was
quenched with amine-containing buffer before proceeding with washing, detachment
and cell lysis, so that no further labelling non-specifically occurred in the following
workflow.
The novel peptide-based biotinylation reagents were synthesized in dry DMSO
to prevent hydrolysis. DMSO is one of the most polar organic solvents ensuring
the solubility of the peptide-based reagents in high concentrations, but difficult to
remove due to its high boiling point. The biotinylation reagent solution was diluted
in PBS before use resulting in a final DMSO concentration below 1%. No influence
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on the cell viability could be detected at the concentrations used.
Healthy NSG mice were perfused for in vivo validation of the novel biotinylation
reagents. All perfusion solutions contained 10% Dextran-40 000 MW to increase the
oncotic pressure and subsequently increase the flow within the blood vessels while
minimizing the risk of thrombosis, which would inhibit the flow through the blood
vessels.[185] Perfusion solutions and mice were kept at body temperature for maximal
perfusability. During perfusion, blood components were washed out. To ensure the
inactivation of non-reacted reagent, mice were sprinkled with amine containing solu-
tion during the procedure and perfusion with the reagent was followed by perfusion
with amine-containing quenching solution. CLSM and ELISA analyses have shown
differences in the degree of biotinylation between different organs, different reagents
as well as among biological replicates: Biotinylation success is dependent of the tis-
sue vascularisation, the reagent’s reactivity, reagent’s batch-to-batch variations, as
well as of the technical quality of the perfusion.
To solubilize membrane proteins from the surrounding lipid layers, different deter-
gents such as SDS and sodium deoxycholate were used in the solubilisation buffers
in about 2% total concentration. In such concentrations, these detergents are known
to negatively interfere with enzymatic digest and mass spectrometric analysis, which
led to the development of cleavable surfactants or other strategies such as gel fil-
tration in 8 M urea for full proteome samples.[120],[135] Due to the capturing of the
biotinylated proteins on the streptavidin resin followed by separation from the fil-
trate and extensive washing, the detergent containing protein extraction buffers are
compatible with the LC/MS analysis of the enriched surface proteins. Full proteome
samples have been prepared for SRM analysis out of the protein lysates from the
PBS- or non-perfused negative controls also used for the surface proteome enriched
sample, by using RapiGest™ (waters), an acid labile surfactant that is separated
before peptide desalting by centrifugation following cleavage of tridecan-2-on.
Reduction of disulfide bridges followed by alkylation of the free thiol residues
with iodoacetamide helps protein unfolding and prevents reformation of the disul-
fide bridges. Thus, tryptic digest and consequently sequence coverage are im-
proved.[348],[349] Capturing of the biotinylated proteins was carried out under re-
ductive conditions using TCEP, because TCEP is reported to be more efficient
than DTT and cannot react with the alkylating agent.[349],[400] As the proteins
are bound to the streptavidin resin, removal of excess alkylating agent in solu-
tion could be easily achieved to prevent over-alkylation or non-specific alkylation
of other amino acid side chains by long incubation times.[401] Delipidation of full
proteome samples is commonly carried out by chloroform/methanol- or acetone-
based protein precipitation, while lipids are kept in solution.[281],[402] For the tissue
lysates prepared, delipidation turned out to be crucial for efficient sample prepara-
tion and valuable mass spectrometric analysis. Since the target proteins are bound
to the resin, a precipitation-free method based on extraction in organic solvents
(1-butanol/diisopropylether solution) had to be applied.[347]
Tryptic digest is carried out directly on the streptavidin-sepharose bound pro-
teins. The modified trypsin (Promega) used provides high specificity as it was
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treated with TPCK, a chymotrypsin inhibitor: Autolytic products of native trypsin
have chymotrypsin-like activity, leading to the generation of peptide fragments with
non-tryptic cleavage sites interfering with database search.[403] Furthermore, the en-
zyme used contains methylated lysine residues to provide stability against autolytic
digestion.
The mass spectrometric detection of peptides is severely influenced by the pres-
ence of nonvolatile salt contaminants in the analyte: Decreased ionisation efficiency,
ion suppression, adduct formation and increase of noise in the spectra is the conse-
quence.[404],[405] Therefore, sample desalting is essential for mass spectrometric anal-
ysis, despite of a certain peptide loss: Most desalting methods are reported to have
98-99% desalting efficiency with peptide recovery rates above 70%, peptide binding
can hereby be increased by aspirating the sample in several cycles.[406] Within this
thesis, desalting tips as well as desalting plates with C18 material were applied for
sample desalting, material was loaded with respect to the reported binding capaci-
ties by twenty aspiration cycles (desalting tips) or in three loading steps (desalting
plate).
The peptide mixtures obtained from enzymatic digestion from full proteome or
plasma membrane proteome enriched samples are highly complex (diversity), and
highly variable in abundance (dynamic expression range). Powerful complexity re-
duction steps such as reversed-phase capillary liquid chromatography-based separa-
tion prior to mass spectrometric analysis are crucial to obtain valuable datasets.[407]
Small particles of 1.4-3 µm size in the packed column medium are reported to in-
crease the peak capacity during chromatographic separation, but the operating pres-
sure also has to be raised: The nanoACQUITY system (Waters) used is operated
with a C18 column with 1.7 µm particle size and 10 000 psi pressure limit.[200],[408]
For the discovery experiments, a MALDI/TOF system was used for analysis.
Chromatographic fractionation, MS and MS/MS analysis are uncoupled (off-line
process) providing the possibility to archive the sample plates and to intermedi-
ately evaluate sample quality after MS analysis (2D peptide maps). Compared to
an ESI system, analysis speed is decreased, but no peptide component is missed
during MS analysis due to measurement time aspects and MS/MS data is stably
collected from the maxima of the chromatographic elution peaks. Furthermore,
MALDI is described to be less sensitive to ion suppression by interfering contami-
nants.[409] Both ionisation by ESI and MALDI provide accurate data, the methods
are reported to be complementary with a significant overlap of above 60% in protein
identification.[410],[409] On peptide level, MALDI tends to an increased identification
of larger peptides with higher retention times on reversed-phase columns.[409],[411]
With the off-line system used, stable, label-free, relative quantification is enabled,
as several standard peptides covering the mass range were spiked into every fraction
for spectra normalisation.
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5.4. Presented Datasets and Aspects of Data
Analysis
Mass spectrometric validation of the novel peptide- and heparin-based biotinylation
reagents was performed against the commercial reagents Sulfo-NHS-LC-biotin and
NHS-PEG12-biotin. PBS-treated cells or PBS- and non-perfused mice were taken
as negative controls to investigate non-specific protein identification.
As shown previously, different biotinylation reagents have different structures,
characteristics and reactivities, leading to different amounts and also types of la-
belled proteins. Therefore, the amount of biotinylated protein in the lysates is not
a good basis for a comparative analysis. Furthermore, analysis of the biotin content
by ELISA would have to deal with technical challenges such as low total protein
concentrations in the cell lysates, differences in signal intensities inhibiting the anal-
ysis of all samples within the same linear standard range as well as with the excess
of activated carboxylic groups in the heparin-based reagents possibly leading to the
labelling of several proteins on the same singly-biotinylated heparin molecule. Thus,
the comparative analysis is performed based on biotinylation with the same reagent
amounts (5 µmol per cell culture flask with about 5×106 cells and 25 µmol per
mouse) followed by subjecting the same total protein amount to capturing on the
streptavidin-sepharose beads. The amount analysed per LC/MS runs always refers
to the total protein amount, which the captured and digested peptides were derived
from (dicovery experiments: in vitro: 500 µg, kidney: 750 ug, liver: 1.25 mg). The
amounts are chosen to use the full capacity of the LC/MS system with the highest
biotinylated samples, which could be easily visualized by 2D peptide map densities
of the MS1 runs. As the biotinylation rate of liver tissue is lower than for kidney
tissue (shown by CLSM analysis and ELISA), the total protein amount subjected
to analysis was higher than for kidney tissue.
In the following, the structure and the analysis strategy of the datasets pre-
sented in this thesis are elucidated. For in vitro validation of the peptide-based
reagents, technical triplicates of HeLa cells biotinylated with SMCC-Cys-(L-Asp)3-
biotin, SM(PEG)6-Cys-(L-Asp)3-biotin, Sulfo-NHS-LC-biotin, NHS-PEG12-biotin
or treated with PBS were analysed. The heparin-based reagents Biotin-Heparin-
sNHS and Biotin-Enoxaparin-sNHS were analysed against Sulfo-NHS-LC-biotin and
PBS treatment in technical duplicates. In vivo validation was performed via perfu-
sion of mice with Sulfo-NHS-LC-biotin, NHS-PEG12-biotin, SMCC-Cys-(L-Asp)3-
biotin, SM(PEG)6-Cys-(L-Asp)3-biotin, Biotin-Heparin-sNHS, Biotin-Enoxaparin-
sNHS, PBS or non-perfused as negative controls and analysis of kidney tissue with
four biological replicates per sample in technical duplicates each. As the variability
between technical replicates in kidney tissue could be shown to be low, liver tissue
was analysed in groups of biological triplicates only.
The proteotypicity of the identified peptides was determined with respect to a
given protein database of the organism. Only a proteotypic peptide can be clearly
mapped to its protein of origin, degenerated peptide would lead to ambiguities in
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protein identification and also interfere with protein quantification.[412] There are
several possibilities to deal with non-proteotypic peptides in data analysis. The
one applied for data analysis within this thesis is the most unambiguous one: All
non-proteotypic peptides as well as peptides identified below the 95% confidence
filter limit were excluded from analysis.[413] The disadvantage of the applied strat-
egy is the possible loss of valuable data. Another approach reported in literature
is the grouping of degenerated peptides based on the amino acid sequence to pro-
tein families (termed peptide-sharing closure groups) and the analysis of abundance
changes of whole protein families, which often share sequences as well as biological
functions.[414] Although all data is conserved, it is challenging to analyse differences
between proteins that share many peptides.[415] The third and most elaborated pos-
sibility is the assignment of the degenerated peptide entries to specific proteins
based on abundance criteria such as spectral counting determined with the non-
degenerated peptides.[416]
To evaluate differences in the identification of specific proteins with different bi-
otinylation reagents, the total number of identified proteins as well as the numbers
of proteotypic peptides identified per specific protein within a sample were analysed.
To obtain a stable dataset and to compensate for technical run-to-run variability or
variability among biological replicates, the information from all replicate runs be-
longing to one reagent group were hereby summed for analysis. For further analysis
of the datasets, so-called one hit wonders were excluded if not indicated differently:
Proteins analysed were identified with more than one proteotypic peptide in at least
one sample group.
Relative quantification on the validation datasets was performed based on MS1
signal intensities using the in-house developed software MSQBAT.[282] A fraction-
wise normalisation against four internal spike-in peptides in every MS1 spectrum
compensated for run-to-run differences. A more stable quantification can be achieved
by reduction of noise via exclusion of features below a given S/N filter and feature
length: Filter criteria were chosen in order to keep 99.5% of all identifications, while
about 40 - 50% of all features could be dismissed. Annotations were transferred
between technical and biological replicates under usage of narrow alignment param-
eters for fraction and mass delta to minimize the risk of false alignments.
Proteomic datasets are reported to exhibit a median overlap between technical
replicates of 75% in terms of protein identifications and 35 - 60% in terms of peptide
identifications.[417] With the data analysis strategies chosen it was possible to obtain
stable, valuable datasets: Main points hereby are the propagation of annotations
between technical and biological replicates as well as the combination of replicates to
super-samples. Quantification of all pairs of technical replicates within the in vitro
dataset shows a median regulation of 1.05 with more than 90% of all values below
a two-fold regulation (see Figure 4.25). Variability of technical replicates in kidney
samples was also shown to be low, median regulation across eight sample pairs
was 1.01 with 90% of all values below a 1.57-fold regulation. Biological replicates
exhibit a broader variability across eight exemplary sample pairs, but still 50% of
the values were below an 1.3-fold regulation and 90% below a 2.2-fold regulation (see
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Figure 4.40). Differences in biotinylation efficacy within the same reagent group can
lead to a slight up-regulation of the ratio towards the stronger biological replicates.
To compensate differences derived from technical variability in the biotinylation
workflow and the subsequent mass spectrometric analysis, all samples belonging to
the same reagent group were combined to super-samples via feature alignment by an
iterative process (genetic algorithm) based on a given fraction and m/z range and
the present annotations. Those super-samples were finally quantified against the
super-sample of the commercial Sulfo-NHS-LC-biotin reagent group. In a presence
vs. absence situation (e.g. the quantification of most of the proteins between Sulfo-
NHS-LC-biotin and the PBS-treated in vitro negative control), artificial background
values were introduced to enable relative quantification. Similar to the analysis of
the summaries of proteotypic peptides, variability was reduced if proteins quantified
with only one proteotypic peptide were excluded.
To further elucidate the nuclear protein enrichment with the heparin-based re-
agents in vitro as well as the identification of the background proteome in tissue
samples, additional datasets were generated based on single samples prepared with
different strategies. Hereby, all samples biotinylated with the same reagent within
an analysis were derived from the same cell lysate or the same tissue sample to
reduce biological variability. Whereas samples of the in vitro or in vivo validation
experiment described before were analysed consecutively, without any avoidable
instrumental variability, the background proteome investigation was performed in
several steps, over a long period of time, with large mass spectrometric performance
differences (determined by repeated measurements of an E. coli digest standard). To
account for those differences, MSQBAT was used to propagate annotations between
runs of sample within the same reagent group: Features from MS1 data were ex-
tracted and cross-alignments between all possible sample pairs were performed with
narrow alignment parameters for fraction and mass delta to minimize false positive
alignments. Annotation information was transferred, if no annotation of that feature
was present in one sample, but in the other. Data analysis was performed based on
identified protein numbers and their localization annotation.
To analyse the subcellular localization of the identified proteins, the annotation in-
formation was extracted from the UniProt database. The information was manually
curated by screening for different categories like plasma membrane, extracellular,
intracellular and membrane associated. As plasma membrane enrichment was used,
proteins exhibiting both plasma membrane and intracellular localization annotations
were assigned to the plasma membrane category. Proteins annotated with not fur-
ther specified membrane association (contain hydrophobic domains) are most likely
also associated with the plasma membrane, but are kept in an own category. In
some exceptional cases, the manual analysis might be ambiguous. Nevertheless, it
should be considered that biological systems are complex, for example proteins may
translocate upon different conditions or in malignant cells, leading to several con-
tradictory or incomplete annotations in the database.[16],[17],[18],[19] Still, automated
enrichment analyses of protein subsets using Webgestalt, supported the manual lo-
calization assignment and are also presented within this thesis.
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5.5. The Background Proteome
The aim of the biotinylation technique is the stable identification and quantification
of plasma membrane proteins in vitro or of vascular accessible proteins on the surface
of cells, on newly formed blood vessels or in the perivascular extracellular matrix in
an in vivo setting. Enrichment of the highly diverse and often low-abundant plasma
membrane proteome fraction is successful with the peptide-based reagents as it was
shown by a comparison of the in vitro data to a full proteome dataset by Nagaraj et
al. as well as by SRM analysis of full proteome samples. In full proteome samples, in
particular proteins with low or medium high abundance are either unstably identified
(i.e. low numbers of proteotypic peptides in the discovery dataset or signals within
the background in SRM analysis) or not found at all.[130] In contrast, identification of
high-abundant intracellular proteins such as proteasome subunits was significantly
decreased within the surface proteome enriched samples. Nevertheless, the fraction
of intracellular proteins identified within the surface proteome enriched samples is
still about 50 - 60% within the validation on HeLa cells as well as on kidney tissue
(see Figures 4.23, 4.35). Also in published datasets using commercial biotinylation
reagents, high intracellular fractions to up to 70% are reported, but even if the
high portions are mentioned, reasons are not further investigated in these biomarker
studies.[180],[186],[183],[295],[296] Within this thesis, the proteome fraction identified in
the negative controls as well as different sample preparation strategies were further
examined to elucidate reasons for the co-identification of intracellular proteins.
Only a small number of proteins was identified within the PBS-treated negative
control in the in vitro dataset, namely 65 proteins out of a triplicate analysis. Top
hits are different carboxylases carrying biotin as a cofactor, leading to their co-
enrichment on the streptavidin-sepharose. Those enzymes were also found within
the in vivo analysis and their biotin signal could additionally be detected via Western
Blot of the negative control protein lysates from kidney tissue.
As the protein fraction within the negative control is so low, non-specific binding
to the streptavidin-sepharose cannot be the main factor to explain the identification
of hundreds of intracellular proteins within the surface proteome enriched samples.
However, not all intracellular proteins identified have necessarily to be contamina-
tions. The analysis of localization based on database annotation entries was already
mentioned in the previous chapter: Entries might be not complete, as many exam-
ples for protein translocation from the intracellular part to the plasma membrane
are found under specific conditions such as in a pre-apoptotic state or in cancer
cell lines.[16],[17],[18],[19],[20] Plasma membrane crossing by biotin transporters or pas-
sive diffusion due to the high concentrations on the cells is unlikely with the novel
reagents, which are charged and increased in size, but might occur with the commer-
cial Sulfo-NHS-LC-biotin having a small and non-polar linker.[12] Co-purification of
intracellular proteins attached to plasma membrane proteins by non-covalent ionic
interactions can only play a minor role, as different washing strategies such as high
salt buffer did not significantly influence the outcome. Enrichment analysis of the
intracellular background proteome revealed the preferential identification of high-
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abundant intracellular proteins such as ribosomal subunits. Those proteins are most
likely identified due to covalent labelling with the biotinylation reagents. Thus, the
undesired labelling must occur during the biotinylation procedure due to a small
fraction of dying cells within the cell culture flask exhibiting permeable cell mem-
branes or releasing proteins. As the cells are still adherent during the biotinylation
procedure, cell viability could only be assessed after subsequent detachment and was
determined to be below 80% at that time, also within the negative control.
Within the in vitro samples biotinylated with the heparin-based reagents, the
intracellular fraction is increased to about 75% with a specific enrichment of the
nuclear proteome (see Figures 4.27, 4.28). Besides the considerations discussed
above, an additional factor not just depending on pure protein abundance must play
a role. Reason for the nuclear proteome enrichment can be found in the structural
similarity of the heparin chains to the DNA backbone.[350],[359] Two hypotheses based
on covalent binding of nuclear proteins from necrotic or apoptotic cells mediated by
covalent attachment or non-covalent interactions of nuclear proteins to the heparin
chains out of the cell lysate during sample preparation have been further discussed in
chapter 4.3.4.2. Although the mechanism of nuclear protein co-enrichment could not
yet be fully elucidated, it can be stated that the desired surface proteome enrichment
with the heparin-based reagents is heavily suffering from the increased background
proteome.
The fraction of intracellular proteins identified in the in vivo samples is comparable
to the in vitro samples with about 50 - 55% in the kidney samples and 63 - 69% in the
liver samples with peptide-based and commercial reagents. The fraction is slighly
increased to about 60% (kidney) and 72% (liver) with the heparin-based reagent
samples. Hereby, no significant nuclear proteome enrichment could be detected
in the in vivo setting. This finding might support the hypothesis of covalent co-
enrichment of nuclear proteins in the in vitro setting. Nevertheless, the main reason
is the reduced reactivity of the heparin-based reagents artificially increasing the
fraction of the background proteome detected within all samples.
In contrast to the in vitro negative control setting, hundreds of proteins were
identified within the PBS- or non-perfused kidney and liver tissue. In vivo lysates
are highly complex and larger total proteins amounts have to be subjected to cap-
turing and the sample preparation as well as on the LC/MS system: The protein
amount loaded on the same volume of streptavidin-sepharose is 2.5-fold (kidney)
and 5-fold (liver) increased compared to the in vitro setting. Furthermore, the
lysates are highly concentrated to enable comfortable sample handling with mini-
mal streptavidin-sepharose losses. Thus, more unspecific binding to the resin might
occur. However, introduction of washing steps with high salt buffer or pH gradi-
ents did not significantly change the result. Unspecific binding to the streptavidin-
sepharose cannot explain the extent of the background proteome identified within
the negative control samples. The most likely explanation is found within sample
preparation. The desired proteome fraction is bound to the streptavidin beads and
separated from the lysates by filtration. A non-soluble contamination within the
tissue homogenates would be co-purified with the resin and co-subjected to tryptic
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digest. To exclude the presence of solid particles or precipitated protein in the highly
concentrated tissue lysates, ultracentrifugation followed by capturing of proteins out
of the supernatant was examined, but did not change the result. Experimental ob-
servation of lipid structures within the homogenates blocking the filter tubes led to
the introduction of an essential delipidation step during sample preparation. Hereby,
the beads are incubated with a mixture of polar and non-polar solvents. Vast lipid
amounts are visible at the interphase between the solvents. Lipid removal works
well enough to not further interfere with the sample preparation, nevertheless, it is
barely possible to separate the beads, solvents and the lipid interphase perfectly. If
some of those non-soluble lipid structures are subjected to tryptic digest with the
streptavidin beads, all proteins that bind to the lipid structures via hydrophobic do-
mains would be co-digested. This hypothesis is supported by analysis of the proteins
identified within the negative controls as well as within the core-proteome identi-
fied with all biotinylation reagents and the negative controls: The enrichment of
proteins annotated to membrane bounded subcellular localization is striking. First
of all, high-abundant metabolic enzymes localised in the mitochondrial membrane
are identified. Although the mostly low-abundant plasma membrane fraction is sig-
nificantly down-regulated in the negative controls in terms of numbers of identified
proteotypic peptides as well as in quantified signal intensity in the kidney samples,
it is noticeable that the plasma membrane fraction identified is still surprisingly high
(up to 18% in kidney tissue), also supporting the hypothesis of lipid-bound protein
co-purification and co-digestion. The use of another type of streptavidin beads such
as magnetic beads might enable a more successful separation.
As the background proteome is high and both identified in the negative controls
and the biotinylated samples, the variability and the visible reactivity shift detected
by relative protein quantification across the samples is artificially decreased in the in
vivo setting compared to the in vitro setting. The comparison of the kidney and the
liver dataset reveals that the differences are even smaller among the liver samples:
The overlap in protein identification between different sample groups is high (about
80%) and no clear dependence of the reagent’s linker-type is visible. Relative quan-
tification between different reagent groups results in a very narrow ratio distribution
featuring similar characteristics as the quantification of pairs of biological replicates
within the kidney dataset. Pronounced reactivity differences (down-regulation of the
median) are barely visible and the similarity of the PBS-perfused and especially the
sample biotinylated with NHS-PEG12-biotin is obvious. The latter is probable an
effect of the small dataset: Within the kidney dataset, eight samples (four biological
replicates in two technical replicates each) were combined to super-samples, whereas
the liver groups are based on three biological replicates, as the variability between
technical replicates was low within the kidney set. The smaller dataset gives more
room to outliers, in this case either biological replicates with higher lipid content
and/or a less successful separation of lipid contaminants during sample preparation.
These findings correspond to the experimental observation that liver samples con-
tained more lipids than the kidney samples, complicating the sample preparation
and the LC/MS-based analysis. Furthermore, the liver samples are less biotinylated
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than the kidney samples as also shown by ELISA and CLSM analysis. Therefore,
the total protein amount subjected to analysis is higher and the tissue homogenates
even more concentrated than the kidney samples. The higher background may also
explain the increased fraction of intracellular proteins within the liver dataset.
In particular in the liver dataset, the identified background proteome fraction
severely interferes with the analysis. In summary, it can be stated that for a suc-
cessful biomarker identification experiment, not only the often reported tissue vas-
cularisation enabling the transport of the reagents to the site of interest plays a
role, but also an elaborated delipidation strategy adapted to the lipid content of the
respective tissue. Moreover, the preparation of PBS-perfused negative controls in
biomarker studies helps to evaluate, if proteins are accessible by the vasculature and
enriched or only co-purified.
5.6. Biotinylation Reagents: Reactivity vs. Selectivity
The in vitro dataset mirrors the reactivity differences among the commercial and
peptide-based reagents detected by CLSM and FACS analysis: Relative quantifi-
cation of all proteins against commercial Sulfo-NHS-LC-biotin revealed a two-fold
down-regulation of the median with SMCC-Cys-(L-Asp)3-biotin and a five-fold down-
regulation with SM(PEG)6-Cys-(L-Asp)3-biotin, which is increased in size and steri-
cally more hindered on the cell surface. 48% of the cell surface proteins (without one
hit wonders) were identified with all biotinylation reagents. The less reactive reagent
SM(PEG)6-Cys-(L-Asp)3-biotin does not stably identify a unique protein fraction,
whereas the uniquely identified fraction is 7% in Sulfo-NHS-LC-biotin and 6% in
SMCC-Cys-(L-Asp)3-biotin. In accordance with the reactivity, the total number of
identified plasma membrane proteins is slightly reduced with SMCC-Cys-(L-Asp)3-
biotin compared to Sulfo-NHS-LC-biotin. The reactivity differences result in de-
creased biotinylated protein amounts and subsequently also decreased signal inten-
sities in LC/MS analyses, preventing the detection of larger variations in protein
accessibility with the different reagents. As long as the cell viability is not affected,
an increase in peptide-based reagent amount for further experiments is discussable.
Nevertheless, the proof-of-principle study could show, that the novel peptide-based
reagents are capable to enrich and stably identify and quantify proteins annotated
to the cell surface.
Within the previous chapter is has been discussed that the ability of the large
and multiply charged heparin-based reagents for cell surface proteome enrichment
is suffering from the co-enrichment of nuclear proteins in the in vitro setting. The
analysis of biotinylated kidney and liver tissue first of all revealed the decreased
reactivity of the heparin-based reagents: Down-regulation of the median of all pro-
teins quantified against commercial Sulfo-NHS-LC-biotin is 2-fold in kidney tissue.
Comparison to the negative control down-regulation reveals the influence of the
identified background proteome: The PBS-perfused negative control exhibits a 4-
fold, and the more complex non-perfused control a 7-fold down-regulation, whereas
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the down-regulation in clear presence vs. absence situation as in the in vitro neg-
ative control was about 20-fold (see Figure 4.41). The absolute numbers obtained
by MSQBAT quantification might even be underestimated due to quantification
against an artificial background values in a presence vs. absence situation. The
increased background fraction in the kidney samples diminishes the median ratio
values. Within the liver samples, no clear trends in down-regulation are visible,
as the background fraction is heavily increased (further elucidated in the previous
chapter). Also the closer analysis of proteins annotated to the plasma membrane
and the extracellular matrix confirmed the decreased reactivity, as more than 60%
of the proteins were more than 2-fold up-regulated with commercial Sulfo-NHS-LC-
biotin (compared to 74% in the PBS-perfused and 85% in the non-perfused negative
control). The same trend was also visible in the SRM-based quantification of plasma
membrane annotated protein candidates (see Figures 4.46, 4.54). The fraction of
uniquely identified plasma membrane or extracellular matrix proteins in comparison
to commercial Sulfo-NHS-LC-biotin is low with 4%/8% with Biotin-Heparin-sNHS
and Biotin-Enoxaparin-sNHS, respectively, against 29%/19% with Sulfo-NHS-LC-
biotin, respectively (analysis without one hit wonders). Hereby, Biotin-Enoxapa-
rin-sNHS might be slightly more reactive compared to Biotin-Heparin-sNHS due to
the smaller size of the reagent. Besides, cluster-analysis of the quantified proteins
has shown the similarity of the samples biotinylated with Biotin-Heparin-sNHS or
Biotin-Enoxaparin-sNHS to the negative controls. Decreased reactivity leads to an
artificial overestimation of the identified intracellular background proteome fraction,
e.g. in the analysis of subcellular localization fractions, and to the high similarity to
the negative controls e.g. in cluster analysis.
Furthermore, with the peptide-based reagents, it was not possible to achieve the
full reactivity of commercial Sulfo-NHS-LC-biotin, which was shown earlier by reac-
tivity assessment on BSA and on HeLa cells. The effect is less pronounced in mass
spectrometric analysis of tissue samples, on the one hand due to the application of
a more favorable excess of the biotinylation reagents (25 µmol per mouse) and on
the other hand due to artificial variability reduction by the increased background
proteome fraction. The changes of the linker structure by increase in size and in-
troduction of charged groups to improve the reagents’ selectivity is at the same
time responsible for a reactivity decrease. Bulky side groups as well as reagents
with huge linkers are sterically more hindered during the labelling reaction. This
is why, in the mass spectrometric datasets, SMCC-Cys-(L-Asp)3-biotin is slightly
more reactive than the more spacious SM(PEG)6-Cys-(L-Asp)3-biotin. The same is
true for Biotin-Heparin-sNHS and Biotin-Enoxaparin-sNHS, and both large-scaled
heparin-based reagents exhibit a heavily decreased reactivity compared to all other
biotinylation reagents.
The tissue datasets have shown that both peptide-based and commercial reagents
identify comparable fractions in terms of total protein numbers and signal inten-
sities of the proteotypic peptides. Analysis of the identified plasma membrane or
extracellular matrix annotated fraction in the kidney dataset results in comparable
fractions uniquely identified with the different biotinylation reagents (6% to 8%,
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without one hit wonders). Also the quantification against commercial Sulfo-NHS-
LC-biotin proves no differences in terms of stability of target proteome identification.
About 40% of the quantified proteins are more than 2-fold up- or down-regulated,
but (unlike the heparin-based reagents) in comparable fractions with one or the other
reagent (see Figure 4.44). High numbers of identified peptides per protein increases
the stability of the quantification. The number of identified proteotypic peptides per
plasma membrane or extracellular matrix annotated protein is significantly increased
with both peptide-based and commercial reagents compared to intracellular proteins
(see Figure 4.36). Highest numbers were hereby obtained with the peptide-based re-
agents. Within the liver dataset, differences across the groups are small, also at the
level of the number of identified proteotypic peptides per protein. Only the number
of proteotypic peptides identified for the plasma membrane/extracellular fraction is
slightly, but non-significantly reduced within the negative controls. Reasons for the
artificial variability decrease by increased background proteome identification have
already been discussed. Despite the co-identified background proteome fraction, the
enrichment of vascular accessible surface and extracellular matrix proteins works re-
liably and successful with the peptide-based reagents, as additionally shown by SRM
analysis of kidney and liver samples. Most low- or medium-abundant plasma mem-
brane target proteins could not be quantified out of full proteome samples, whereas
preceding enrichment with peptide-based and commercial reagents provided a tech-
nology platform to enable their stable quantification.
Cluster analysis of all reagent and control groups first of all grouped samples ac-
cording to the reagent’s reactivity (based on the similarly identified background pro-
teome fractions), and secondly based on the reagent’s linker type (see Figures 4.42,
4.52). The interplay between selectivity and reactivity presents the main challenge
in the work with novel biotinylation reagents. A more selective biotinylation reagent
might not identify more plasma membrane proteins (or less intracellular proteins)
than a less selective one, if it exhibits a decreased reactivity. Also the dataset
published by Strassberger et al. suffers from the low reactivity of the NHS-β-Ala-
(L-Asp)3-biotin: Only 364 and 392 proteins in total could be identified in the kidney
and liver dataset, hereby the reported fraction of proteins with plasma membrane
or extracellular matrix annotation was 60% (219 proteins) and 42% (166 proteins)
respectively.[12] Within this thesis, the double amount of membrane or extracellular
matrix annotated proteins could be stably identified and quantified (without one hit
wonders) with the reactivity-improved peptide-based reagents.
To summarize the findings from the validation work with the novel biotinylation
reagents, it can be stated that an ideal reagent for biomarker discovery studies would
be site-specifically activated, not too big, with non-bulky side-groups and low steric
hindrance for high reactivity, but highly charged and not too small to prevent plasma
membrane crossing. In reality, every novel biotinylation reagent is a compromise of
those properties. Furthermore, it has been shown that optimized sample preparation
strategies are the basis for successful plasma membrane proteome enrichment. The
fraction of necrotic or apoptotic cells has to be minimized and delipidation is a
crucial step for the work with tissue samples.
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6. Conclusions and Outlook
Within this thesis, two novel peptide-based biotinylation reagents (SMCC-Cys-
(L-Asp)3-biotin and SM(PEG)6-Cys-(L-Asp)3-biotin) were developed, which signif-
icantly improved the reactivity of non-specifically activated NHS-β-Ala-(L-Asp)3-
biotin published by Strassberger et al.[12] Additionally, two novel biotinylation re-
agents based on a heparin linker (Biotin-Heparin-sNHS and Biotin-Enoxaparin-
sNHS) large in size and multiply charged were synthesized and validated. Further-
more, two alkyne-based reagents for bioorthogonal click-chemistry mediated cap-
turing, with comparable reactivity to the novel peptide-based reagents, have been
synthesised.
The mass spectrometric analyses performed within this thesis emphasize the im-
portance of an optimized sample preparation workflow for successful surface pro-
teome enrichment as well as the crucial interplay between selectivity and reactivity
for the design of novel biotinylation reagents. Heparin-based reagents exhibited a
significantly reduced reactivity, whereas the peptide-based reagents provide a sta-
ble technology platform for the identification and quantification of plasma mem-
brane or extracellular matrix proteins in mass spectrometric experiments. Even
low-abundant proteins, which cannot be identified out of full proteome lysate sam-
ples, are stably identified and quantified with many proteotypic peptides in discovery
experiments or can be targeted via SRM-based quantification. Maintenance of max-
imal cell viability as well as delipidation of tissue samples turned out to be crucial
for successful identification of a large fraction of plasma membrane or extracellular
matrix annotated proteins.
One of the challenges when working with plasma membrane proteins is the lack
of polar tryptic cleavages sites in the transmembrane domains.[290],[119] Sequence
coverage of the plasma membrane proteins could be further improved by combination
of tryptic digestion with another digestion enzyme or a chemical cleavage method.
Tryptic digest followed by cyanogen bromide cleavage (C-terminal of methionine
residues) has been shown to double the cleavage sites in hydrophobic transmembrane
domains.[142]
To further assess the differences in labelling with the peptide-based and com-
mercial biotinylation reagents, the application of higher reagent amounts have to
be evaluated. However, the applied amount must not interfere with cell viability.
Reactivity-dependent effects would be decreased, and therefore also the influence of
the identified background proteome fraction on the data analysis. To enable direct
comparison with commercial reagents, both in terms of reactivity and in the fraction
of identified plasma membrane proteins, the effects should be assessed with varying
reagent amounts of all biotinylation reagents.
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To identify differences in the chemical surroundings of the targeted primary amino
groups, it is necessary to analyse the labelled peptide fragment that remains bound
to the streptavidin-sepharose after tryptic digest. Differences in total protein size
or polarity are not meaningful enough as only a small protein part is accessible for
the biotinylation reagents on the cell surface. Furthermore, sequence coverage of
the labelled proteins is increased, if the labelled peptide fragments can be included
in the analysis. Two approaches are possible to release the biotinylated peptide
fragment from the streptavidin-sepharose. The first possibility is the disruption
of the non-covalent biotin-streptavidin interaction under harsh elution conditions
by competition with free Biotin.[418] The second possibility is the re-design of the
biotinylation reagents: Introduction of a cleavable linker (e.g. a vicinal diol group
cleavable by mild oxidative treatment) would provide the possibility of a chemical
release of the peptide fragments.[191]
The identification of robust, vascular-accessible biomarkers is a prerequisite for the
development of novel therapeutic or diagnostic tools. Vascular accessible targets can
be located on the surface of diseased cells, in the surrounding extracellular matrix or
on the surface of newly formed blood vessels: Angiogenic events in a healthy adult
are rare, but reported under various pathological conditions such as tumour forma-
tion, inflammatory diseases, atherosclerosis or upon transplantations.[14],[94] The tar-
geted delivery of bioactive molecules directly to the site of disease reduces side-effects
in healthy tissues. Diagnostic or therapeutic antibodies or antibody fragments can
hereby either interfere with a target on the diseased cells that is essential for growth
or survival or target a biomarker on the cell or in the cell surroundings while trans-
porting a therapeutic payload such as cytotoxic drugs, radionuclides or cytokines.[419]
The novel peptide-based reagents provide a reliable technology platform for the en-
richment, identification and quantification of surface or vascular accessible proteins.
Hereby, biotinylation can be performed in vitro by biotinylation of cells, via in vivo
perfusion of rodents or ex vivo with surgically resected tissue material. The success
of these biomarker studies is depending on the vascularisation of the target tissue
as well as on an optimized sample preparation protocol. Several delipidation steps
might improve the reduction of the intracellular background proteome identified in
mass spectrometric analyses of liver tissue. Novel plasma membrane or extracellular
matrix annotated targets can be identified by stable quantification of diseased vs.
healthy tissue based on many stably identified proteotypic peptides. Furthermore,
successful SRM-based quantification of potential medium- to low-abundant targets
is enabled by previous surface proteome enrichment.
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Figure A.1.: CLSM staining controls of mouse tissue perfused with commercial and
peptide-based reagents (corresponding to Figure 4.31) as well as with heparin-based re-
agents (corresponding to Figure 4.32). Scale bars: 50 µm. Sections from mouse tis-
sue perfused with Sulfo-NHS-LC-biotin (a), NHS-PEG12-biotin (b), SMCC-Cys-(L-Asp)3-
biotin (c), SM(PEG)6-Cys-(L-Asp)3-biotin (d), Biotin-Heparin-sNHS (e), Biotin-Enoxa-
parin-sNHS (f).
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Figure A.2.: CLSM of all mouse kidney samples perfused with commercial and peptide-
based reagents used for mass spectrometric in vivo validation. DAPI (blue), biotin (green),
endothelial marker CD31 (red), scale bars: 50 µm. Perfusion with Sulfo-NHS-LC-biotin
(a), NHS-PEG12-biotin (b), SMCC-Cys-(L-Asp)3-biotin (c), SM(PEG)6-Cys-(L-Asp)3-
biotin (d), PBS perfused controls (e), non-perfused controls (f). Corresponding staining
controls see Suppl. Figure A.4.
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Figure A.3.: CLSM of all mouse kidney samples perfused with heparin-based reagents used
for mass spectrometric in vivo validation. DAPI (blue), biotin (green), endothelial marker
CD31 (red), scale bars: 50 µm. Perfusion with Biotin-Heparin-sNHS (a), Biotin-Eno-
xaparin-sNHS (b), PBS perfused controls (c), non-perfused controls (d). Corresponding
staining controls see Suppl. Figure A.4.
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Figure A.4.: CLSM staining controls of kidney tissue perfused with commercial and
peptide-based reagents (corresponding to Suppl. Figure A.2) as well as with heparin-based
reagents (corresponding to Suppl. Figure A.3). Scale bars: 50 µm. Sections from mouse tis-
sue perfused with Sulfo-NHS-LC-biotin (a), NHS-PEG12-biotin (b), SMCC-Cys-(L-Asp)3-
biotin (c), SM(PEG)6-Cys-(L-Asp)3-biotin (d), Biotin-Heparin-sNHS (e), Biotin-Enoxa-
parin-sNHS (f).
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Figure A.5.: CLSM of all mouse liver samples perfused with commercial and peptide-based
reagents used for mass spectrometric in vivo validation. DAPI (blue), biotin (green), en-
dothelial marker CD31 (red), scale bars: 50 µm. Perfusion with Sulfo-NHS-LC-biotin (a),
NHS-PEG12-biotin (b), SMCC-Cys-(L-Asp)3-biotin (c), SM(PEG)6-Cys-(L-Asp)3-biotin
(d), PBS perfused controls (e), non-perfused controls (f). Corresponding staining controls
see Suppl. Figure A.7.
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Figure A.6.: CLSM of all mouse liver samples perfused with heparin-based reagents used
for mass spectrometric in vivo validation. DAPI (blue), biotin (green), endothelial marker
CD31 (red), scale bars: 50 µm. Perfusion with Biotin-Heparin-sNHS (a), Biotin-Eno-
xaparin-sNHS (b), PBS perfused controls (c), non-perfused controls (d). Corresponding
staining controls see Suppl. Figure A.7.
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Figure A.7.: CLSM staining controls of liver tissue perfused with commercial and peptide-
based reagents (corresponding to Suppl. Figure A.5) as well as with heparin-based reagents
(corresponding to Suppl. Figure A.6). Scale bars: 50 µm. Sections from mouse tis-
sue perfused with Sulfo-NHS-LC-biotin (a), NHS-PEG12-biotin (b), SMCC-Cys-(L-Asp)3-
biotin (c), SM(PEG)6-Cys-(L-Asp)3-biotin (d), Biotin-Heparin-sNHS (e), Biotin-Enoxa-
parin-sNHS (f).
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Figure A.8.: 2D peptide maps of in vivo biotinylated kidney samples (exemplary
maps). Biotinylation with Sulfo-NHS-LC-biotin (A), NHS-PEG12-biotin (B), SMCC-
Cys-(L-Asp)3-biotin (C), SM(PEG)6-Cys-(L-Asp)3-biotin (D), Biotin-Heparin-sNHS (E),
Biotin-Enoxaparin-sNHS (F), negative controls: PBS (G), non-perfused (H). m/z ratio
(x-axis), UPLC fractions (y-axis) and normalized signal intensity as grey scale. Normal-
ization to internal standard at m/z 1411 with standard peak height set to 1000, peak
height capping at 500.
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Figure A.9.: 2D peptide maps of in vivo biotinylated liver samples (exemplary maps). Bi-
otinylation with Sulfo-NHS-LC-biotin (A), NHS-PEG12-biotin (B), SMCC-Cys-(L-Asp)3-
biotin (C), SM(PEG)6-Cys-(L-Asp)3-biotin (D), Biotin-Heparin-sNHS (E), Biotin-Enoxa-
parin-sNHS (F), negative controls: PBS (G), non-perfused (H). m/z ratio (x-axis), UPLC
fractions (y-axis) and normalized signal intensity as grey scale. Normalization to internal
standard at m/z 1411 with standard peak height set to 1000, peak height capping at 500.
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Figure A.10.: Background-reduced peak areas of the heavy standards spiked into all sam-
ples, SRM analysis, median with interquartile range. Kidney samples: 32 vascular enriched
sample (a) and 8 full proteome samples (b). Liver samples: 24 vascular enriched sample
(c) and 6 full proteome samples (d).
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B. Supplementary Tables
The Supplementary Tables are enclosed in Microsoft’s Office Open XML format
(.xlsx) on a CD.
Table B.1.: Transition list SRM analysis, kidney tissue. Proteins, peptide sequences and
selected transitions are shown, including information about precursor and fragment m/z,
retention time, declustering potential and collision energy.
Table B.2.: Transition list SRM analysis, liver tissue. Proteins, peptide sequences and
selected transitions are shown, including information about precursor and fragment m/z,
retention time, declustering potential and collision energy.
Table B.3.: In vitro validation of peptide-based reagents, analysis of peptide summaries.
Numbers of identified proteotypic peptides per reagent group and protein, including local-
ization information (plasma membrane (pm), extracellular and secreted (ex), membrane
associated (mem), intracellular (int), no localization information (no)).
Table B.4.: In vitro validation of peptide-based reagents, relative quantification of all re-
agent groups against Sulfo-NHS-LC-biotin, performed with MSQBAT.
Table B.5.: In vitro validation of heparin-based reagents, analysis of peptide summaries.
Numbers of identified proteotypic peptides per protein, including localization information
(plasma membrane (pm), extracellular and secreted (ex), membrane associated (mem),
intracellular (int), no localization information (no)). Duplicate analysis in comparison to
Sulfo-NHS-LC-biotin (a), different sample preparation strategies (b), DNA blocking and
non-activated Biotin-Heparin (c).
Table B.6.: In vivo validation, kidney tissue, analysis of peptide summaries. Numbers of
identified proteotypic peptides per reagent group and protein, including localization in-
formation (plasma membrane (pm), extracellular and secreted (ex), membrane associated
(mem), cytoplasmic site of plasma membrane (ipm), intracellular (int), no localization
information (no)).
Table B.7.: In vivo validation, kidney tissue, relative quantification of all reagent groups
against Sulfo-NHS-LC-biotin, performed with MSQBAT. Including localization informa-
tion (plasma membrane (pm), extracellular and secreted (ex), membrane associated
(mem), cytoplasmic site of plasma membrane (ipm), intracellular (int), no localization
information (no)).
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Table B.8.: In vivo validation, kidney background proteome analysis, different sample
preparation strategies, analysis of peptide summaries. Numbers of identified proteotypic
peptides per reagent group and protein, including localization information (plasma mem-
brane (pm), extracellular and secreted (ex), membrane associated (mem), cytoplasmic site
of plasma membrane (ipm), intracellular (int), no localization information (no)).
Table B.9.: In vivo validation, liver tissue, analysis of peptide summaries. Numbers of
identified proteotypic peptides per reagent group and protein, including localization in-
formation (plasma membrane (pm), extracellular and secreted (ex), membrane associated
(mem), cytoplasmic site of plasma membrane (ipm), intracellular (int), no localization
information (no)).
Table B.10.: In vivo validation, liver tissue, relative quantification of all reagent groups
against Sulfo-NHS-LC-biotin, performed with MSQBAT. Including localization informa-
tion (plasma membrane (pm), extracellular and secreted (ex), membrane associated
(mem), cytoplasmic site of plasma membrane (ipm), intracellular (int), no localization
information (no)).
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